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B A C K G R O U N D
CHAPTER 1
G E N E R A L 
I N T R O D U C T I O N  A N D 
O U T L I N E  O F  T H I S 
T H E S I S
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Bart is a 9 year old boy diagnosed with Autism Spectrum Disorder. He is very curious and has a 
strong love for trains: his own miniature copy goes with him all the time. Routine activities are very 
important to Bart. As long as his schedule is not abruptly changed, he is doing fine. 
However, when something unexpected occurs, Bart gets heavily irritated. When, for example, 
he loses a game at school or the radio in the supermarket is playing too loud, he can get very 
frustrated. He then bangs his own head against the wall, or can kick or bite other children and his 
mother. This occurs several times a week, leading to serious injuries. 
The family has sought help from a social worker and a psychologist, who have intensively 
supported Bart, his family and school. Bart has received cognitive behavioral therapy and his 
parents have received parental training, but this has brought insufficient relief. His school has said 
that the situation is untenable and they can no longer handle Bart. Also his family is under severe 
pressure.
As illustrated in Bart’s story, emotional and behavioral problems associated with Autism Spectrum 
Disorder (ASD) can deeply affect a child and his environment. When supported ineffectively, 
these are likely to have profound and lifelong effects on psychosocial development, leading to 
school drop-out, social isolation, and decreased self-sustainability.1 Additional pharmacological 
treatment is deemed necessary when psychological and behavioral interventions are insufficient. 
Antipsychotic drugs are the first choice in the pharmacological treatment of severe behavioral 
problems associated with ASD in children and adolescents. But also for other psychiatric disorders 
in youths, such as Bipolar Disorder, Conduct Disorder or Psychotic Disorder, antipsychotic drugs 
play an important part in multimodal treatment. 
In this first chapter, the rationale and indications for antipsychotic use in children and adolescents 
are discussed, the pharmacokinetic and pharmacodynamic aspects are introduced, and the main 
aims of this thesis are presented.
A N T I P S Y C H O T I C  D R U G S  -  M E C H A N I S M  O F 
A C T I O N
Antipsychotic drugs, discovered in the 1950s, reduce dopaminergic neurotransmission in the 
brain. Dopamine plays an important role in several cerebral pathways, including the mesolimbic 
pathway which is believed to be associated with aggression, mania and psychosis. 
Atypical or second-generation antipsychotic drugs were introduced in the 1980s. Typically, these 
drugs additionally block a wide range of other neurotransmitter receptors, including serotonin, 
acetylcholine, histamine and noradrenaline receptors. The difference between typical and atypical 
antipsychotic drugs is however arbitrary, as their pharmacological properties largely overlap.2 The 
neuroreceptor affinities of three commonly used antipsychotic drugs in youths in the Netherlands 
(risperidone, aripiprazole and pipamperone) are shown in figure 1. 
E F F I C A C Y  A N D  I N D I C A T I O N S
Numerous randomized controlled trials support the efficacy of antipsychotic drugs in children and 
adolescents with ASD, schizophrenia, bipolar disorder, disruptive behavior disorders and Tourette’s 
disorder.4 As a result, antipsychotic drugs have been taken up widely in treatment recommendations 
of national and international guidelines and their use in children and adolescents is widespread.5-7 
The most common indication for antipsychotic drug prescriptions in children and adolescents in 
the Netherlands is behavioral problems associated with ASD, such as it is the case for Bart. ASD 
is characterized by impairments in social interaction, verbal and non-verbal communication, as 
well as by stereotypical patterns of behavior and interests.8 The disorder is quite common, with 
0.6 to 1 per 100 persons being diagnosed with ASD.9 Strikingly, more than half of children and 
adolescents with ASD have serious behavioral problems.10
The short-term efficacy for the treatment of behavioral problems associated with ASD is relatively well 
studied for risperidone and aripiprazole. The general number needed to treat for this indication is 
two for risperidone, and three for aripiprazole11, which reflects a very good efficacy. Pipamperone 
takes a special place as the evidence for its efficacy in children and adolescents is limited due 
to lack of research12, but there is extensive practical experience with pipamperone, especially in 
children and adolescents with cognitive impairment. Mainly because of the calming effects and 
the availability of oral liquid dosage formulation that enables flexible dosing, pipamperone is 
often prescribed to children in the Netherlands, Belgium and Germany.
Despite the growing evidence for efficacy, most antipsychotic drugs are used off-label in children 
and adolescents, thus outside the registered indication and duration of use.13 The registration status 
of risperidone, aripiprazole and pipamperone for children and adolescents in the Netherlands is 
shown in table 1.
Only the strongest receptor affinities are shown. Risperidone and aripiprazole are regarded as second-
generation antipsychotic drugs, and pipamperone as a first-generation antipsychotic drug. 
a aripiprazole is a partial agonist for the D2 and 5-HT2a receptor. This means aripiprazole does not block, but 



















Figure 1 Binding affinities to neuroreceptors of risperidone, aripiprazole and pipamperone. 
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Antipsychotic drug Registration 
Risperidone
Short-term treatment (up to 6 weeks) of persistent aggression in children with 
cognitive impairment (of at least 5 years) and young adults with a behavioral 
disorder.
Aripiprazole
Schizophrenia in young people aged 15 years and older.
Manic episodes in bipolar I disorder in adolescents aged 13 years and 
older, with a maximum prescription duration of 12 weeks.
Pipamperone Not registered for use in children and adolescents.
Table 1 Registrations of the three most commonly used antipsychotic drugs in children and 
adolescents in the Netherlands. 
A D V E R S E  E F F E C T S 
Along with an increased popularity of antipsychotic drugs in children and adolescents, concerns 
have been raised in past decades about the safety in this population. Children and adolescents 
appeared to be prone for serious side effects, including weight gain, metabolic abnormalities, 
prolactin elevation, extrapyramidal symptoms, sedation and cardiac abnormalities.3 These are the 
result of the broad receptor affinities of antipsychotic drugs, and involve serious short-term and 
long-term health risks. 
Weight gain 
The most important side effect concerns weight gain, with children gaining several kilograms 
during the first weeks of antipsychotic treatment. Antipsychotic-induced weight gain is more 
pronounced in youths than in adults14, and the propensity for weight gain differs among the 
different antipsychotics.  Olanzapine and clozapine cause most weight gain in youths, followed 
by risperidone, pipamperone and aripiprazole.15 Although weight gain is heterogeneous among 
children and adolescents starting antipsychotic drug treatment16, it is not well known which children 
and adolescents are particularly at risk.
Metabolic abnormalities 
Weight gain and obesity increase the risk for metabolic abnormalities, including lipid and 
glucose disturbances and insulin resistance.17 Additionally, antipsychotic drugs induce metabolic 
disturbances independently of weight gain.16 Lipid and metabolic parameters increase significantly 
within the first weeks of antipsychotic treatment18. After long-term risperidone treatment, 35% of 
children and adolescents have at least one criterion of the metabolic syndrome phenotype.19 
Diabetes and cardiovascular diseases 
Weight gain, glucose disturbances and insulin resistance lead to a threefold increased risk of 
diabetes mellitus during antipsychotic drug use in children and adolescents, even within the first 
year of use.20 Lipid disturbances also significantly increase the risk for cardiovascular diseases 
later in life, leading to significant morbidity.21
Extrapyramidal side effects 
Antipsychotic drugs induce extrapyramidal symptoms. During long term antipsychotic treatment, up 
to one in three youths experience mild to moderate EPS.22 Worldwide, extrapyramidal symptoms 
are the most reported adverse drug reaction of antipsychotic drugs in children and adolescents.23 
Prolactin
More than the other antipsychotic drugs, risperidone induces substantial prolactin elevations, 
possibly leading to gynecomastia, galactorrhea, sexual dysfunction and irregular menses.24 The 
long term risks of antipsychotic-induced prolactin elevations are not well studied, but may induce 
osteoporosis even in children and adolescents. 
Sedation
Sedation is common in children and adolescents, especially during the first weeks of antipsychotic 
treatment. Children and adolescents demonstrate more antipsychotic-induced sedation than 
adults.25 
Cardiac abnormalities 
Antipsychotic drugs can increase the corrected QT (QTc) interval, risking cardiac arrhythmias.26 
In children and adolescents, the risk of pathological QTc prolongation seems rare, but should be 
considered when other risk factors are present.27 
Retrieved from www.geneesmiddeleninformatiebank.nl
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Both the therapeutic and adverse effects of antipsychotic drugs are the result of pharmacokinetic 
and pharmacodynamic processes in the body. Pharmacokinetics determine the drug exposure 
in the body by absorption, distribution, metabolism and excretion after drug administration. 
Pharmacodynamics describe the subsequent drug effects through the interaction with the target 
receptors. Many factors can influence both processes, as is shown in figure 2. 
In childhood and adolescence, pharmacokinetics and pharmacodynamics alter rapidly. This 
is the result of changes in body composition, target receptor maturation and organ ripening 
during development28, leading to a large variability in antipsychotic drug concentrations29 and 
antipsychotic effects across the lifespan.25 This may cause relative overdosing or underdosing 
of antipsychotic drugs in children and adolescents when dosages are simply extrapolated from 
adults. 
P H A R M A C O K I N E T I C  A N D  P H A R M A C O D Y N A M I C 









































Figure 2 Pharmacokinetic and pharmacodynamic processes and influencing factors after an 
administered dose. 
T H E R A P E U T I C  D R U G  M O N I T O R I N G
The relationship between pharmacokinetics, reflected in drug concentrations, and 
pharmacodynamics, reflected in clinical outcomes, can be used to improve the safety and efficacy 
of drug therapy. Therapeutic Drug Monitoring (TDM) uses the measurement of a drug concentration 
to titrate dosages towards the concentration range that is associated with maximal efficacy and 
minimal side effects, known as the therapeutic reference range.30 TDM has proven to improve 
clinical outcomes of many psychotropic drugs, and is increasingly being used in adult psychiatry 
and other fields. The main reason for the increasing use of TDM, is that the relationship between 
the effects of a drug and its concentration in the blood is often better than between the dose of the 
drug and the observed effects. 
However, the relationship between antipsychotic drug blood concentrations and clinical outcomes 
in children and adolescents is currently unknown. As a result, no therapeutic reference ranges for 
antipsychotic drugs in this population exists, hampering the use of TDM as a tool to improve safety 
in this population. Several studies have shown that higher antipsychotic dosages increase the 
risk of side effects in children and adolescents including prolactin elevation31, weight gain32, 
extrapyramidal symptoms22 and diabetes mellitus20, suggesting that a higher antipsychotic 
exposure is associated with more side effects. However, within these studies, analyses with dosages 
adjusted for bodyweight are generally lacking, and therefore do not inform about the exposure-
response relationship. Only a few studies have assessed the relationship between risperidone 
blood concentrations and outcomes in children and adolescents, but these studies mainly focus on 
prolactin elevation and do not cover metabolic side effects.33-35 To our knowledge, no studies 
have been performed assessing the concentration-effect relationship in children and adolescents 
for aripiprazole and pipamperone. For these latter drugs, even the pediatric population 
pharmacokinetics are not well known. 
A L T E R N A T I V E  S A M P L I N G 
The pharmacokinetic and pharmacodynamic research that is needed to establish a therapeutic 
reference range is however challenging in children using antipsychotic drugs. Bart, the boy that 
was introduced earlier, is already overwhelmed by simple things, let alone by a venipuncture for a 
drug concentration measurement. Blood sampling is often complicated due to anxiety, restlessness 
or aggression in children with psychiatric disorders, and therefore, alternative, minimally invasive 
sampling methods are highly important. A well-established alternative sampling method concerns 
the Dried Blood Spot (DBS) method.36 This method can determine drug concentrations with only 
a fingerprick and a single drop of blood, which can be performed in the home-setting. DBS 
can overcome many sampling difficulties, and has therefore been suggested as a facilitator for 
pharmacokinetic research in pediatric populations.37 However, although numerous DBS methods 
have been developed for psychotropic drug quantification, little attention have been paid to the 
accuracy and feasibility of DBS in clinical practice.38 This hampers the implementation of these 
alternative sampling strategies for children and adolescents with psychiatric comorbidities. A 
 Adapted from: AGNP guidelines for TDM 2017, Hiemke et al..30 
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thorough clinically validated DBS method for the quantification of antipsychotic drugs in children 
and adolescents is therefore highly needed. 
W H A T ’ S  I N  A  D R O P  O F  B L O O D ?
Clarifying the relationship between pharmacokinetics and pharmacodynamics of antipsychotic 
drugs in children and adolescents is important, as it can provide an evidence-based basis for TDM 
in this population and allow us to individualize treatment to improve safety and efficacy.  
To  clarify this relationship, this thesis presents the results of the observational prospective cohort 
study SPACe, which has been performed in seven participating centers in the south-west region 
of the Netherlands between 2016 and 2019. Within this study, 89 children with ASD and severe 
behavioral problems who started with risperidone, aripiprazole or pipamperone, have been 
prospectively followed for 6 months. During the follow-up, both pharmacokinetic data obtained 
with DBS and pharmacodynamic data by measurements of side-effects and effectiveness were 
structurally collected (see figure 3).
Legend
questionnaires on effectiveness, 
medication adherence, sleepiness
anthropometric measurements 
including Body Mass Index (BMI
laboratory check-ups for metabolic abnormalities, 
renal and liver function, antipsychotic drug concentrations
electrocardiogram
DBS antipsychotic drug 
concentrations measurement
Start 4 weeks 12 weeks 24 weeks
Figure 3 Graphic illustration of study design of the SPACe study. 
R E S E A R C H  Q U E S T I O N S 
The aim of this thesis is to improve the safety and effectiveness of antipsychotic drugs in children and 
adolescents, by individualizing antipsychotic drug dosing and monitoring. The studies presented in 
this thesis address the following questions:
Part II   Current practice
 a What is the extent of antipsychotic drug use by children and adolescents in the Netherlands?
 a What are risk factors and what is the pattern of weight gain in children and adolescents 
starting with antipsychotic drugs?
Part III  Alternative sampling
 a Is the Dried Blood Spot method a suitable alternative sampling technique to measure 
antipsychotic drug blood concentrations in children and adolescents with severe 
behavioral problems?
Part IV  Antipsychotic drug concentrations and clinical outcomes
 a What is the relationship between antipsychotic drug blood concentrations, side effects 
and effectiveness in children and adolescents?
Participating centers were Erasmus MC, Curium-LUMC, GGZ Delfland, GGZ Breburg, Youz, Yulius and de 
Kroon kinderpsychiatrie. 
1
Part I :  Background - 2120 -  Chapter 1
O U T L I N E 
Part I provides a background on the effectiveness and safety of antipsychotic drugs in children 
and adolescents, and introduces pharmacokinetic and pharmacodynamic aspects that are 
relevant to improve its safety in this population. 
Part II describes the current practice of antipsychotic drug use in children and adolescents in the 
Netherlands. Chapter 2 reports on the Dutch trends in antipsychotic drug prescriptions in children 
and adolescents between 2005 and 2015. The risk factors and pattern of weight gain in children 
and adolescents starting with antipsychotic drug treatment are described in chapter 3.   
Part III investigates DBS as an alternative sampling method to measure antipsychotic drug blood 
concentrations by three consecutive studies. Chapter 4 describes the development of an Ultra–
High-Performance Liquid Chromatography–Mass Spectrometry method to measure risperidone, 
aripiprazole and pipamperone concentrations in DBS. In chapter 5, the accuracy of this DBS 
method is evaluated in a clinical setting. Subsequently, the feasibility of the DBS method in children 
and adolescents with behavioral problems is reported in chapter 6. 
Part IV focuses on the relationship between antipsychotic drug concentrations and clinical 
outcomes in children and adolescents. Chapter 7 presents a systematic review of the literature 
on this topic for all psychotropic drugs, including antipsychotic drugs. In chapters 8 and 9, the 
population pharmacokinetics in relation to clinical improvement and side effects is analyzed for 
pipamperone and risperidone in children and adolescents with behavioral problems. 
Part V gives and overall summary of the thesis and discusses the results in a broader clinical 
perspective. 
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A B S T R A C T
Objectives 
The use of antipsychotic drugs by youth is associated with serious side effects, especially when 
prescribed in higher dosages and for a longer period. Despite this, little is known about recent 
trends in the dosages and duration of use of antipsychotic drugs in children and adolescents. The 
aim of this study was to describe trends in prevalence, incidence, dosages, duration of use and 
preceding psychotropic medication in Dutch youth who had been prescribed antipsychotic drugs 
from 2005 to 2015. 
Methods 
We analyzed prescription data of 13.210 youths aged 0-19 years using antipsychotics between 
2005-2015, derived from a large Dutch community pharmacy-based prescription database 
(IADB.nl). 
Results 
Since a peak of 9.8 users per thousand youths in 2009, prevalence rates stabilized. Dosages 
in milligram per kilogram declined for the most frequently prescribed antipsychotic drugs during 
the study period. The median duration of use was 6.0 (95% CI 5.4-6.6) months. Boys used 
antipsychotic drugs significantly longer than girls, with a median of 6.9 (95% CI 6.1-7.7) vs 4.6 
(95% CI 3.9-5.3) months (p<0.01). Of the youths prescribed antipsychotics, 12.4% used them for 
at least 48 months. The majority of youths had used other psychotropic agents in the year prior to 
the start of an antipsychotic drug (62.4% in 2005 and 64.7% in 2015).
Conclusion 
Despite a stabilization of usage rates and decline in dosages an duration of use, one in eight youths 
still used antipsychotic drugs for 4 years or longer. A substantial share of youths may therefore be 
at high risk for serious side-effects.
I N T R O D U C T I O N
The use of antipsychotic drugs in children and adolescents has dramatically increased worldwide 
since the introduction of second-generation antipsychotics in the 1980s.1-3 Second-generation 
antipsychotics appeared promising for use in more vulnerable populations, such as children, as 
they originally had been marketed as having more favorable side effects than the first-generation 
agents. As a result, the number of trials supporting efficacy in youth grew, which led to numerous 
registered indications including schizophrenia, bipolar disorder and behavioral problems 
associated with autism spectrum disorder.4
However, in recent years concerns have been raised regarding the use of antipsychotic drugs 
in children. For instance, off-label prescriptions are very common, which involves particular 
risks as evidence for efficacy is often lacking.5 More importantly, few studies have adequately 
monitored long-term antipsychotic safety profiles in children. Indeed, second-generation 
antipsychotics appear to have major side effects, including weight gain, metabolic abnormalities 
and extrapyramidal symptoms.6 Moreover, it has been suggested that some side effects are more 
common in children than in adults.7 These might have a major impact later in life, as metabolic 
changes and tardive dyskinesia can be irreversible even upon drug discontinuation. Children 
receiving antipsychotic medication indeed show an increased risk of developing type 2 diabetes 
and metabolic syndrome, which significantly affects future quality of life and life expectancy. 8, 9
Given these concerns, pharmacoepidemiological research is crucial to monitor the extent of 
antipsychotic drug use in youth. Unfortunately, however, few studies have reported on the duration 
of use or the dosages of antipsychotics in children and adolescents 10-13, while especially high 
dosages and long duration of use might enhance the risk for serious side effects.8, 14 Furthermore, 
although comedication has been widely described, to our knowledge, no study has addressed 
the use of psychotropic medication preceding the start of an antipsychotic drug in children. Thus, 
it would be valuable to evaluate if the prescription of stimulants precedes antipsychotic treatment. 
Although aggressive, maladaptive behavior is an important indication for antipsychotic drug 
use in youths 15, stimulants have emerged as an alternative to antipsychotics to treat aggression 
associated with Attention Deficit Disorder (ADHD)16. Finally, as recent research showed that 
prevalence rates of antipsychotic use differ remarkably between countries17, it is of interest to know 
how trends on incidence and duration of therapy explain these differences. Since 2005, no such 
information concerning antipsychotic drug use in youth in the Netherlands is known.10
Therefore, the aim of this study is to examine antipsychotic drug prescription trends for children and 
adolescents in the Netherlands from 2005 to 2015, including the prevalence, incidence, dosages 
and duration of therapy. We provide, to our knowledge, the first descriptions of trends in dosages 
of antipsychotic drugs in youths in a Western population. 
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Data Analyses
First, prevalence and incidence rates of antipsychotic drug use per year per 1000 youths in the 
population were calculated. A new (incidental) user was defined as a youth being present in the 
database for at least 90 days and receiving an antipsychotic drug prescription for the first time. 
Prescription data from 2004 were used to identify starters in 2005. We stratified prevalence and 
incidence by gender, age group (0-6 years, 7-12 years, 13-19 years) and type of drug. Incidence 
rates were also stratified by type of prescriber (GP or specialist). Confidence intervals (CIs) were 
calculated using the Score method with continuity correction .20 Proportions were compared using 
the Chi square test.
Then we performed a dose analysis. Weight of the children was estimated using the Denekamp 
scale in order to provide milligram per kilogram dosages. 21 The Denekamp scale provides the 
median weight for boys and girls at different ages, based on anthropometric references of Dutch 
youth. Prescriptions of the four most prescribed antipsychotics were used for the dose analysis. Only 
prescriptions issued for at least seven days were selected in order to exclude rescue medication. 
Pipamperone was excluded from the dose analysis as this is often prescribed as a 40 mg/ml 
liquid formulation and daily dose was not consequently noted in the database as milliliters (ml) or 
milligrams (mg). The age on the first of January of the year of prescription was used. Means are 
presented as value ± the standard deviation (SD). 
We calculated duration of AP drug use by median and mean survival times using Kaplan Meier 
analyses. The start of an episode of AP drug use was defined as described above. An episode 
ceased if at least the amount of days for which medication was prescribed plus 90 days had 
passed and the youth could still be followed in the database. All other cases were considered 
censored. Duration of use was stratified by gender, age groups (at time of start of the antipsychotic 
drug), start year and type of drug. Subgroups were compared using the Logrank test. Starters from 
the year 2015 were excluded from the survival analysis, as the cohort could only be followed until 
the end of 2015 and in this year high rates of censoring would take place. Duration of AP use was 
presented in months, with 30 days being considered one month. 
An analysis on preceding psychotropic medication was also performed. Psychotropic prescriptions 
issued one year before the first antipsychotic drug prescription were considered as preceding 
psychotropic medication. Concurrent psychotropic treatment was defined as a psychotropic 
prescription being issued within the start- and stop date of an antipsychotic drug prescription. 
Prescriptions were stratified by year and gender.
Differences were considered significant at p<0.05. Statistical analyses were performed with SPSS 
for windows, version 21 and Microsoft Excel 2010.
M E T H O D S
Data source
This study was performed with pharmacy dispensing data from the population-based prescription 
database IADB.nl.18 The IADB database comprises prescription drug dispensing data from 
community pharmacies in the northern and eastern part of the Netherlands from 1994 onwards, 
covering a population of approximately 600,000 people. This population largely corresponds 
to the composition of the general Dutch population.18 It includes all prescriptions, irrespective of 
type of health insurance (also including people without insurance), prescriber and reimbursement 
status. Prescriptions during hospital stays are not included. 
The total population estimates were based on general population statistics from the Dutch Central 
Bureau for Statistics. Firstly, cities completely covered by IADB pharmacies were analyzed, 
to determine the proportion of the population visiting the pharmacy at least once a year. This 
proportion was used to estimate the coverage of IADB pharmacies in all other areas. 
The study database IADB.nl uses de-identified medical records which could not lead to individual 
patients. According to the Code of Conduct for Health Research by the Foundation Federation of 
Dutch Medical Scientific Societies (approved by Dutch data protection authority in 2004)19, no 
ethics committee approval is needed for research using anonymous medical records. This study 
was conducted in accordance with the Declaration of Helsinki.
Study sample and variables
Patients aged 0 through 19 years that used at least one antipsychotic drug between January 1, 
2005 and December 31, 2015 were selected. Antipsychotic drugs were defined as class N05A 
according to the World Health Organization’s Anatomical Therapeutic Chemical/Defined Daily 
Dose Classification System, except from N05AN (lithium). Clozapine, olanzapine, quetiapine, 
sulipiride, risperidone, aripiprazole, paliperidone, serindole and lurasidone were considered 
second-generation antipsychotics. The remaining drugs of class N05A were considered first-
generation antipsychotics. 
All other psychotropic drugs were defined as anxiolytics (class N05B), hypnotics and sedatives 
(class N05C), antidepressants (class N06A), psychostimulants (class N06B), lithium, clonidine, 
carbamazepine and valproic acid. 
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Incidence
The overall incidence rate was 2.0 (95% CI 1.8-2.3) per thousand minors both in 2005 and 2015. 
Incidence peaked in 2007 with 2.6 (95% CI 2.3-2.9) new users per thousand aged 0-19. The 
incidence rates, stratified for age, gender and year, are presented in Table 2. Risperidone was 
the preferred antipsychotic drug to start with for all age categories in all years. Antipsychotic drugs 
were mainly started by specialists (2005: 75.5%, 2015: 67.8%).
2005 (n= 131,980)a 2010 (n=138,251)b 2015 (n=126,666)c
per 1000 95% CI per 1000 95% CI per 1000 95% CI
Total
0-6 2.7 (2.3-3.2) 2.5 (2.1-3.0) 1.5* (1.2-1.9)
 7-12 10.1 (9.1-11.2) 13.5* (12.4-14.7) 10.8 (9.8-11.9)
13-19 9.5 (8.7-10.4) 12.5* (11.6-13.5) 13.8* (12.8-14.9)
Boys
0-6 4.1 (3.4-5.0) 3.8 (3.1-4.7) 2.0* (1.5-2.7)
 7-12 16.6 (14.8-18.5) 21.2* (19.3-23.3) 15.5 (13.8-17.4)
13-19 13.3 (11.9-14.9) 17.0* (15.5-18.7) 17.8* (16.2-19.5)
Girls
0-6 1.2 (0.8-1.8) 0.9 (0.6-1.4) 1.0 (0.6-1.6)
 7-12 3.3 (2.5-4.3) 5.3* (4.4-6.4) 5.7* (4.7-7.0)
13-19 5.7 (4.8-6.7) 8.1* (7.1-9.3) 9.9* (8.7-11.2)
an=66,430 boys,  n=65,550 girls
bn=70,255 boys,  n=67,996 girls
cn=64,777 boys,  n=61,889 girls
*p<0.05, significantly different compared to baseline ( 2005 )
R E S U L T S
The total population aged 0 to 19 years ranged from 131,980 persons in 2005 to 126,666 
persons in 2015. 
Prevalence
The overall prevalence of antipsychotic drug use ranged from 7.2 (95% CI 6.8-7.7) in 2005 to 9.0 
(95% CI 8.5-9.5) per thousand youths in 2015. The prevalence rates stratified for age, gender and 
year are presented in Table 1. The prevalence was highest in 2009 with 9.8 (95% CI 9.3-10.3) 
users per thousand youths (Figure 1). Boys were more likely to use antipsychotic drugs in all 
years and in all age groups. The most frequently prescribed antipsychotic drugs were risperidone 
(61.9% of all antipsychotic drug users), pipamperone (18.2%), aripiprazole (9.5%), quetiapine 
(9.3%) and olanzapine (3.7%). Trends of the three mostly prescribed antipsychotics are visualized 
in Figure 1. The prevalence of first-generation APs ranged from 2.2 (95% CI 2.0-2.5) in 2005 
to 2.3 (95% CI 2.1-2.6) in 2010 and 1.6 (95% CI 1.4-1.8) in 2015 per thousand youths. The 
prevalence of second-generation APs increased from 5.4 (95% CI 5.0-5.8) in 2005 to 7.8 (95% 
CI 7.3-8.3) in 2015 per thousand youths.
Figure 1 Prevalence of antipsychotic prescriptions in youth aged 0-19 years. 
Prevalence per 1000 youths. Prevalences of the unique agents add up to more than the total prevalence, as one 
patient can contribute to more than one line.
Table 1 Prevalence (per thousand) of antipsychotic prescriptions among children up to age 19 years.
Table 2 Incidence per thousand of antipsychotic prescriptions among children up to age 19 years
2005 (n= 131,980)a 2010 (n=138,251)b 2015 (n=126,666)c
per 1000 95% CI per 1000 95% CI per 1000 95% CI
Total
0-6 1.2 (0.9-1.6) 1.1 (0.8-1.5) 0.5* (0.3-0.8)
 7-12 2.0 (1.6-2.5) 3.4* (2.9-4.0) 2.2 (1.8-2.8)
13-19 2.8 (2.4-3.3) 3.0 (2.6-3.5) 3.1 (2.6-3.6)
Boys
0-6 1.9 (1.4-2.6) 1.6 (1.2-2.2) 0.7* (0.4-1.2)
 7-12 3.3 (2.6-4.3) 5.1* (4.2-6.2) 2.8* (2.1-3.7)
13-19 2.7 (2.1-3.5) 3.7 (3.0-4.6) 2.8 (2.2-3.6)
Girls
0-6 0.5 (0.3-0.9) 0.5 (0.3-0.9) 0.4 (0.2-0.8)
 7-12 0.8 (0.5-1.4) 1.6* (1.1-2.3) 1.6* (1.1-2.3)
13-19 2.8 (2.2-3.6) 2.3 (1.8-3.0) 3.3 (2.6-4.1)
an=66,430 boys,  n=65,550 girls
bn=70,255 boys,  n=67,996 girls
cn=64,777 boys,  n=61,889 girls
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D I S C U S S I O N
From 2005 to 2015 in the Netherlands, prevalence rates stabilized since a peak of 9.8 users per 
thousand youths in 2009. The duration of use decreased to a median of 6.8 months and a mean 
of 10.9 months in 2014. Also, dosages per kilogram for the mostly prescribed antipsychotic drugs 
in youth declined. Furthermore, first time antipsychotic prescriptions were preceded by the use of 
other psychotropic medication in the majority of cases. 
The major increase in antipsychotic drug use in youth that had been described in the Netherlands 
from 1997 to 200510, continued until 2009. The recent stabilization in usage is similar in other 
countries like the United States and Denmark.22-24 We found a decline of usage rates in the youngest 
age group aged 6 years or younger, which mirrors findings from other studies.15, 25 However, the 
prevalence of usage in adolescents increased. The overall plateauing of antipsychotic drug use 
in children might be attributed to more awareness of serious side effects in youth among health 
professionals following growing evidence from literature.6, 26 
Table 3 Duration of use (in months) of antipsychotic drugs among children up to age 19 years.
Dosages 
For 13,006 prescriptions analysis of the dosing (in milligram per kilogram) could be performed. 
For the five mostly used antipsychotics, the mean dosage decreased from 2005 to 2015, with 
the largest decrease for aripiprazole and quetiapine. The mean dosage (± standard deviation) 
for aripiprazole was 0.29 mg/kg (± 0.16) in 2005 and 0.11 mg/kg (±0.09) in 2015. The mean 
dosage for quetiapine decreased from 3.53 mg/kg (±3.00) in 2005 to 0.93 mg/kg (±1.09) 
in 2015. For risperidone the mean dosage was 0.03 mg/kg (±0.03) in 2005 and 0.02 mg/kg 
(±0.03) in 2015, for olanzapine 0.12 mg/kg (±0.09) in 2005 and 0.09 mg/kg (±0.06) in 2015. 
Duration of use
The overall median and mean duration of use of antipsychotic drugs were 6.0 months (95% CI 
5.4-6.6) and 19.1 months (95% CI 17.8-20.4) respectively, with considerable differences between 
subgroups (Table 3). 
The duration of use was longest for children aged 7-12 years with a median of 9.8 months (95% 
CI 8.1-11.4) and a mean of 25.5 months (95% CI 23.2-27.8) (Figure 2). Boys had a significantly 
longer duration of therapy than girls which was consistent over the years (p<0.01). Overall, 
risperidone was prescribed for the longest period. 
A large difference between the median and mean durations of therapy can be seen. This means 
that a small share of patients used antipsychotic drugs for a relatively long period. Overall 12.4% 
of the youths used antipsychotic drugs for at least 48 months. As is visualized in Figure 2, 19.4% 
of the children aged 7-12 years used an antipsychotic drug for 48 months or longer. 
Other psychotropic medication 
The majority of the population used other psychotropic medication in the year prior to the first 
start of an antipsychotic drug. This is consistent through the years; in 2005, 62.4% and in 2015 
64.7% of children starting with antipsychotic treatment used other psychotropic medication in the 
preceding year. Centrally acting sympaticomimetics, benzodiazepines and selective serotonin 
reuptake inhibitors were prescribed most often in every year, both as preceding and concomitant 
medication. In 2005, 32.5% of youths were prescribed a stimulant in the year preceding the first 
prescription of an antipsychotic drug, in 2015 this was 36.4%. Approximately half of the patients 
used psychotropic comedication during antipsychotic treatment from 2005-2015 (51.3%), peaking 
in 2009 with 55.6%. Boys used more comedication than girls (49.4% vs 47.1%), which was not 
statistically significant (p=0.10). 
Median 
(months)
95% CI Mean 
(months)
95% CI p-value
All users* 6.0 (5.4-6.6) 19.1 (17.8-20.4)
Age* <0.01
0-6 years 6.2 (4.5-7.9) 24.3 (20.0-28.6)
 7-12 years 9.8 (8.1-11.4) 25.5 (23.2-27.8)
13-19 years 4.3 (3.7-4.8) 10.7 (9.8-11.7)
Gender* <0.01
Boys 6.9 (6.1-7.7) 21.6 (19.9-23.3)
Girls 4.6 (3.9-5.3) 13.9 (12.0-15.7)
Start year 0.12
2005 7.3 (5.1-9.5) 20.7 (16.5-24.9)
2010 4.1 (2.8-5.4) 15.4 (12.9-17.8)
2014 6.8 (4.7-8.9) 10.9 (9.6-12.2)
Agent** <0.01
Risperidone 11.7 (9.5-13.9) 21.1 (19.0-23.3)
Aripiprazole 6.5 (5.3-7.8) 14.3 (10.3-18.3)
Pipamperone 1.0 (0.6-1.4) 7.9 (4.5-11.3)
*  Analysis was performed for the years 2005-2014
**  Analysis for the years 2011-2013, as in these years aripiprazole was prescribed to a considerable 
share of the total population
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Despite the relatively high prevalence, the duration of use decreased from a median of 1.9 years in 
1997-2005 10, to a median of 6.0 months in 2005-2015. Although, a sizable share of children and 
adolescents used antipsychotic drugs for a long time. For example 19.4% of children treated with 
an antipsychotic drug aged 7 to 12 years used antipsychotics for 4 years or longer. These children 
might benefit substantially from such treatment. However, simultaneously, a longer duration of use 
might incur a greater risk to develop side effects, like dyskinetic movements, metabolic changes 
and the development of diabetes.8, 14 Remarkably, few studies describe duration of antipsychotic 
drug use in youth. Verdoux et al reported a median duration of only 1 month in a French 
community based study which suggests this concerns mainly rescue medication for managing 
acute behavioral problems. 11 Burcu et al described a median duration of use of 180 days in a 
population of Medicaid-insured youth, similar to our findings.13 
Consistent with earlier findings10, 13, boys showed a significantly longer duration of use than girls. 
As mentioned, other studies have shown that antipsychotics in children are mainly prescribed to 
treat aggressive, impulsive and hyperkinetic behavior associated with ADHD, autism and mental 
retardation.3, 15, 32 We might speculate that this explains the longer duration of use in boys, as 
physical aggressive behavior is more prevalent among boys than girls 33, and might exist for a 
longer time. However, as boys differ in a lot of ways from girls, also other factors might contribute 
to the difference in duration of use. 
For both stimulants and antipsychotic drugs there is evidence for efficacy in aggressive and 
impulsive behavior associated with ADHD16. These agents are often found to be used concomitantly 
3, 34, 35, which is also confirmed in this study. Interestingly in our study we found that most first time 
antipsychotic prescriptions in youth were not preceded by a stimulant prescription, although the 
latter agents are known to have a more favorable side effect profile. However, overall, most 
antipsychotic prescriptions were preceded by any type of other psychotropic medication. This 
is different from an earlier study conducted in adolescents with new onset psychotic symptoms, 
where most antipsychotics were not preceded by another psychotropic like antidepressants or 
benzodiazepines.36 This finding might be explained by the sudden onset of psychotic symptoms 
and limited pharmacological treatment options other than antipsychotic drugs. This also might 
suggest that in our cohort, antipsychotics were mainly used to treat aggressive behavior rather 
than psychosis. 
In our study, we found a trend towards lower dosages of antipsychotic drugs per kilogram from 
2005 to 2015. A decrease in dosing in children has also been observed in a Japanese study.12 
This trend might be the result of the growing number of trials investigating antipsychotic drug use 
in children, generating new information on specific dosing schemes. For example in aripiprazole, 
after its introduction on the market, adult dosing schemes were advised as no specific information 
for children was available. For both aripiprazole and risperidone, formal dose recommendations 
were only available from 2009 in the Netherlands. Besides these guideline changes, also other 
factors might have influenced the dose changes over time. These include gender and age of the 
patients in the cohort, being moderators of weight and therefore influencing dosing. In this study, 
Nevertheless, the usage rates of antipsychotic drugs in Dutch youth remain fairly high compared 
to other European countries.17 For example, a German study carried out between 2004 and 2011 
found a prevalence between 2.0 and 2.6 per thousand minors and a French study conducted 
between 2006 and 2013 reported usage rates between 4.6 and 4.9 per thousand youths.11, 15 
Several factors might contribute to these differences. Firstly, prevalence of psychiatric disorders 
may vary between countries, which can be partly due to differences in diagnosing patterns.27 The 
most important registered psychiatric disorders that may warrant antipsychotic drug use by children 
and adolescents in the Netherlands include behavioral problems associated with autism spectrum 
disorder, bipolar disorder and schizophrenia. However, for example for pervasive developmental 
disorders like autism, differences in prevalence by geographical region are not supported by 
current literature.28 Secondly, access to healthcare, child- and adolescent psychiatrists and 
prescription medicine might influence usage rates of antipsychotic drugs as well . In a densely 
populated country like the Netherlands, the access to healthcare is more easily guaranteed than in 
a country with great regional differences like France.29 Furthermore, the number of psychiatrists per 
persons in the Netherlands is one of the highest in Europe 30, which is reflected by the high rate of 
first prescriptions being issued by specialists in this study. Also, access to prescription medicine for 
children in the Netherlands is guaranteed, as health insurance is compulsory and antipsychotics 
are fully reimbursed. Thirdly, prescription behavior of child- and adolescent psychiatrists might be 
influenced by cultural factors or differences in training. For example French psychiatrists are known 
to have a more psychoanalytical basis and might thus be more reluctant to prescribe psychotropic 
drugs.31 
Kaplan-Meier survival curve; plus signs indicate censored data. Analysis was performed for the 
years 2005-2014
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C O N C L U S I O N S
In the Netherlands, overall antipsychotic drug prescription rates among children and adolescents 
stabilized and dosages per kilogram declined from 2005 to 2015. Although overall duration of 
use decreased, one in eight youths used antipsychotic drugs for at least four years.
C L I N I C A L  S I G N I F I C A N C E 
Youths with severe behavioral problems might substantially benefit from long term antipsychotic 
treatment and high dosages. However, longer duration of use and higher dosages may also 
increase the risk for side-effects of antipsychotics. Our study shows that a substantial share of Dutch 
youths who use antipsychotics use them for a considerable long time. Therefore we recommend 
adequate screening for side-effects in chronic users. Furthermore, health care providers should 
assess whether an attempt to discontinue antipsychotic drugs in chronic users is indicated. 
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we corrected for these factors using estimates of weight normalized for age and gender. Also, 
patients’ ethnicities and socio-economic statuses might impact dosing over time. Although these 
latter variables were not known in our cohort, we expect these factors to be fairly constant during 
the study period, as the area covered by the pharmacies that delivered the prescription data did 
not significantly change.
Implications for future research include further investigation of international trends in duration of 
therapy and dosages of antipsychotic treatment in youths. In this way, country-specific exposure 
of antipsychotic medication to children and adolescents can be better quantified. Furthermore, by 
identifying specific populations at risk, tailored interventions to prevent serious side effects can be 
made. 
This study has several limitations. Firstly, prescription rates do not represent actual usage rates, as 
medication might be taken in other dosages or not be taken at all. Secondly, the IADB database 
only includes pharmacies in the Northern and Eastern part of the Netherlands, which might not be 
representative for the whole country as these regions consist of more rural areas compared to the 
western part of the country. Some literature suggests antipsychotic drug prescribing might increase 
with density of population for young children 11, which might have led to an underestimation of 
usage rates. Nevertheless, other studies do not show such an association.34 However, the IADB 
database has previously proven to be representative for the whole Dutch population.18 Thirdly, by 
our definition of a new incidental users, also patients on ongoing treatment with a discontinuation 
of at least 3 months are defined as a new user. Also, as no inpatient prescriptions are included in 
the database, children that were hospitalized for a longer period of time might have been defined 
as a new incidental user upon discharge as well. This might have been resulted in an overestimation 
of incidence rates and an underestimation of duration of use. However, hospitalization in child- 
and adolescence psychiatry is rather rare. Moreover, a more strict definition of new users might 
have led to more children falsely being not identified as new users, for example when they moved 
into an area being covered by the database in the past months. Fourthly, no information on 
diagnoses was available. Lastly, the analysis of dosages per kilogram was based on median 
weight reference values of Dutch youth. As antipsychotics are known to induce weight gain, the 
weight of the children in our cohort might be above average. Therefore our analysis of dosages 
per kilogram might be an overestimation. 
Strengths of this study are the use of a large dataset that was not limited to type of health insurance 
or health provider, in a country that is representative for the Western developed world. We provide 
an unique analysis of trends in dosages, duration of therapy and used preceding psychotropic 
medication which is of great importance to address the health risks of use of antipsychotics in 
youths. 
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A B S T R A C T
Introduction
Antipsychotic-induced weight gain is a major health concern in children and adolescents. The 
aim of this study was to identify risk factors for weight gain during short-, middle- and long-term 
treatment with antipsychotic drugs in this young population. 
Methods
We analyzed a combined prospective and a retrospective observational cohort of Dutch children 
and adolescents, starting with risperidone, aripiprazole or pipamperone treatment. Linear mixed 
models were used to test whether sex, age, baseline body-mass-index (BMI) z-score, type of 
antipsychotic, dose equivalent/kg, duration of use, previous antipsychotic use, ethnicity, physical 
exercise, IQ, concomitant medication, and psychiatric classification predicted the BMI z-score for 
a follow-up of <15 weeks, 15-52 weeks or >52 weeks. 
Results
A total of 144 patients were included with a median (interquartile range [IQR]) age of 9 ( 4) years 
and median follow-up of 30 (73) weeks. During the complete follow-up, the median (IQR) weight 
gain was 0.37 (0.95) BMI z-score points. Antipsychotic-induced weight gain was found to be 
most pronounced during the first 15 weeks of use (BMI z-score increase per week β=0.02, 95% 
C.I.0.01-0.03, p=0.002). A higher baseline BMI z-score and the absence of stimulant use was 
associated with a higher BMI z-score during the entire follow-up and after 15 weeks respectively. 
Previous treatment with an antipsychotic drug was associated with less weight gain during the first 
15 weeks of treatment. 
Conclusion
Our findings underscore the importance of close patient monitoring during the first weeks of 
antipsychotic treatment with a focus on patients with a high baseline BMI z-score. 
I N T R O D U C T I O N
Antipsychotic-induced weight gain has been recognized as a major health concern in children 
and adolescents.1 Although the magnitude of weight gain differs across type of antipsychotics 
and individuals, on average 1 in 7 minors gains 7% or more weight within the first 6-8 weeks 
of treatment.2 This is not only highly stigmatizing, but also involves serious long-term health risks. 
Weight gain is associated with glucose and lipid abnormalities, thereby increasing the risk for 
diabetes and cardiovascular morbidity in children and adolescents using antipsychotics.3, 4 It has 
been suggested that this leads to higher rates of unexpected death in this population, even at 
young age.5
The observed weight gain in youths starting antipsychotic treatment is highly heterogeneous, with 
some youths gaining a lot of weight, while others don’t.This heterogeneity suggests that certain 
patient-related factors underlie the risk for antipsychotic-induced weight gain. The identification 
of these risk factors is an important target in the prevention of obesity, as it can facilitate early 
recognition and interventions for children and adolescents at risk. Such interventions can include 
both behavioral and pharmacological interventions, which are proven to be effective at least to 
some extent in the management of antipsychotic-related weight gain in this population.6, 7
To date, literature is inconclusive about which children and adolescents are particularly at risk for 
weight gain during antipsychotic treatment. While it has been suggested that girls are at higher 
risk than boys 4, other studies have found the opposite 8, or did not find an influence of gender at 
all.9 Likewise, some studies showed that a young age is associated with more weight gain 10, 11, 
while others found older age increases the risk for obesity 4. Data on clinical predictors is generally 
limited, although several studies found that a low baseline body mass index (BMI) is associated 
with more weight gain 8, 12, and the concomitant use of stimulants would not be of significant 
influence. 12, 13
It can be hypothesized that, amongst other factors, different follow-up durations might have 
contributed to these mixed findings. Weight gain in children and adolescents has been reported to 
be most pronounced during the first weeks of antipsychotic use and to stabilize during continued 
treatment, although long-term data are limited.14, 15 In these different phases of weight acceleration, 
several mechanisms that are involved in antipsychotic-related weight gain are likely to contribute 
differently. Although these mechanisms are only poorly understood, several neurotransmitter and 
endocrine systems, such as serotonergic, dopaminergic and histaminergic receptors and leptin 
have been implicated. 16, 17 As different patient-related factors, such as sex or comedication, might 
influence these mechanisms individually, the influence of risk factors might be time-dependent as 
well. 
Therefore, the aim of this study is to describe risk factors for weight gain in children and adolescents 
using antipsychotic drugs with a short-, middle- and long-term duration of use.  
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Predictors
Date of birth, sex, IQ and psychiatric classification according to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) IV or V were retrieved from the medical files. Physical exercise, 
country of birth of mother, father and child were collected based on questionnaires that were part 
of routine clinical care. For the antipsychotic drugs the following data was collected: type, dose, 
start date, stop date and previous use of antipsychotics. Dose equivalent/kg was calculated based 
on defined daily doses from the WHO which were multiplied by 100.21 The dose equivalents were 
5 mg for risperidone, 15 mg for aripiprazole and 200 mg for pipamperone. IQ was treated as a 
binary variable, defined as intellectual disability (IQ <70) or not (IQ >70). If IQ-scores were not 
available, medical records were screened for the diagnosis of intellectual disability. Ethnicity was 
considered a binary variable, and scored as either both parents were born in the Netherlands, 
or not. Concomitant stimulant use was defined as the use of methylphenidate or amphetamines at 
time of bodyweight and height measurement. 
Statistical analysis 
First, the course of weight gain within the sample was visually inspected. As the slope of the BMI 
z-score gain differed during the first 15 weeks of treatment (short-term), after 15 weeks (medium 
term) and after 52 weeks (long term), three separate analyses were performed for these time 
frames as described below. These timeframes were considered clinically relevant, as randomized 
controlled trials have shown that weight gain is significant during the first weeks of use2 and many 
children use antipsychotic drugs only for a short period of time, but at the same time, a considerable 
proportion of children use antipsychotic drugs for more than a year.18
The data was analyzed per timeframe using linear mixed models with visits clustered within patients. 
The BMI z-score values at different time points during follow-up were used as dependent variable. 
Multiple imputation was used to replace missing values for IQ (4 % missing), physical exercise 
(15% missing) and ethnicity (10% missing). Imputation was based on the baseline data, as these 
variables did not change over time, and data were imputed on the individual level only. The fully 
conditional specification procedure in SPSS was used to impute five datasets for the analyses22. 
The imputed datasets were augmented with the repeated measurements to conduct the linear 
mixed models. The validity of the imputed variables was checked by computing the observed and 
imputed frequencies of the scores; there were no large differences between these frequencies. 
Subsequently, the assumptions of the linear mixed model were checked with visual inspection 
for the three timeframes separately, and were all met 23.   First, all predictors were analyzed in a 
univariate model as fixed effect with random intercept together with baseline BMI z-score (model 
1). For the predictors with p<0.15 in the univariate model, interaction terms with time were added 
(model 2) to test whether they also predicted the BMI z-score increase per week (rather than 
for the whole timeframe). The predictors and interaction terms that were statistically significant 
(p<0.05) in one or more timeframes were combined in a multivariate model per timeframe (model 
3). Variables with a p-value <0.05 in one or more timeframes were selected for the final model. 
SPSS Version 25 (SPSS Inc.,Chicago, IL, USA) was used for the analyses.
M E T H O D S
Population
The study population consisted of children and adolescents treated with risperidone, aripiprazole, 
or pipamperone in the south-west region of the Netherlands. These three antipsychotics are the 
most frequently prescribed antipsychotics in this population in the Netherlands. 18
The study population consisted of a prospective and a retrospective observational cohort. The 
prospective cohort included children and adolescents that were enrolled in an observational 
Dutch multicenter trial (NTR 6050) with a follow-up of 6 months. These patients were treated in 
an inpatient or outpatient setting in the Erasmus Medical Center, or one of 6 other participating 
centers in the south-west region of the Netherlands (1 other academic tertiary care center and 5 
psychiatric secondary care centers) between August 2016 and November 2018. All patients and/
or their legal representatives gave written informed consent before entering the study. The study 
was approved by the medical ethical committee of the Erasmus Medical Centre, the Netherlands 
(number MEC-2016-124). The retrospective cohort consisted of children and adolescents being 
treated in the Erasmus medical center between  1 January 2012 and 31 December 2017. The 
medical ethical committee of the Erasmus Medical Centre waived informed consent for this study 
(MEC-2018-1613).  
Patients were included based on the following criteria: 1. Treatment with risperidone, aripiprazole 
or pipamperone, 2. No simultaneous use of other antipsychotics, 3. Bodyweight known at least 
2 weeks before or after the start of antipsychotic, 4. Minimally 1 other bodyweight known during 
use of antipsychotic, 5. Age up to 18 years, 6. No concomitant condition with direct influence 
on bodyweight (e.g. eating disorder, Prader-Willi syndrome). Patients who had used more than 
one antipsychotic during the study periods, were only included with the first antipsychotic that met the 
inclusion criteria. 
Outcome
The outcome was age- and gender specific BMI z-score. To calculate the BMI z-score, BMI 
values were transformed into BMI z-scores based on the World Health Organization (WHO) 
BMI-for age reference values (5–19 years).19 According to the WHO, a BMI z-score >1 is 
considered overweight, and a BMI z-score >2 is considered obesity. In the prospective cohort, 
weight and height were measured at baseline and at 6 months, and for a subset of patients that 
initiated antipsychotic treatment at start of the study, also at 1 month and at 3 months. In the 
retrospective cohort, weight and height were measured at variable time points during visits as part 
of routine clinical care. When a height measurement was missing but weight was known, a height 
measurement of the same patient that was performed within 5 weeks from that time point could be 
used. An average  child or adolescent grows 6 cm per year, so 5 weeks would amount to maximal 
±0,6cm difference in height which was considered insignificant.20  
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BMI z-score
During the complete follow-up, the median (interquartile range, IQR) weight gain was 0.37 (0.95) 
BMI z-score points. The increase in BMI z-score was most pronounced during the first 15 weeks 
of treatment, followed by a slower increase up to 52 weeks and a slight decrease after 52 weeks, 
which is shown in figure 1. Analyses were separately done for the timeframes <15 weeks (short-
term, n=144 patients), 15-52 weeks (middle-term, n=111 patients) and >52 weeks (long-term, 
n=58 patients) duration of use.  
When predictors were individually tested together with only baseline BMI z-score as a covariate, 
dose equivalent/kg, duration of use, sex, no previous antipsychotic use, and stimulant use were 
significantly correlated with BMI z-score during one or more follow-up time frames (see table 
2, model 1). With addition of interaction terms with time to these models, only a higher dose-
equivalent/kg (β=0.02, 95% C.I. 0.01-0.04, p=0.011), a lower baseline BMI z-score (β=-0.01, 
95% C.I. -0.02- -0.01, p<0.001) and no previous antipsychotic treatment (β=0.02, 95% C.I> 
0.00-0.03, p=0.01) were found to significantly predict the BMI z-score increase per week, 
during the first 15 weeks of use (table 2, model 2). The absence of stimulant use was significantly 
associated with a higher mean BMI z-score during the first 15 weeks, as was a higher baseline 
BMI z-score during all time frames. 
These variables were combined in the final multivariate model per timeframe. The mean BMI 
z-score gain per week was higher in the first 15 weeks (duration of use β=0.02, 95% C.I. 0.01-
0.03, p=0.002) than between 15 and 52 weeks (β=0.01, 95% C.I. -0.01-0.02, p=0.378) and 
after 52 weeks (β=0.00, 95% C.I. 0.00-0.00, p=0.01). During the first 15 weeks of follow-up, 
previous antipsychotic treatment was associated with less weight gain per week. A higher baseline 
BMI z-score was found to be strongly predictive for a higher BMI z-score during all times frames 
of follow-up, as was the absence of stimulant use after 15 weeks. Removal of dose equivalent and 
its interaction term did not remarkably change the findings of the final model. The results of the final 
model are shown in table 3. 
Figure 1 Pattern of weight gain
R E S U L T S
Sample
A total of 289 unique patients was screened for inclusion in the retrospective cohort, of which 90 
patients were included. The main reasons for exclusion were: no use of risperidone, aripiprazole 
or pipamperone (n=57), no bodyweight known at baseline (n=66), simultaneous use of other 
antipsychotics (n=15), and no bodyweight measurements at follow-up (n=15). An additional 
number of 54 patients was included in the prospective cohort, resulting in a total study sample of 
144 unique patients. Within this sample, 18.8% of patients were overweight and 11.8% of patients 
were obese at start of antipsychotic treatment. The patient characteristics can be found in table 1. 
Table 1 Patient characteristics
Legend: Total n=144 children and adolescents. All variables are presented as medians (interquartile range, 
IQR) unless otherwise stated. *available data: nationality n=129 (90% complete), IQ n=138 (96% complete), 







Baseline BMI z-score 0.23 (1.91)
Age, years 9 (4)
Male, n (%) 109 (76)
Dutch nationality*, n (%) 90 (70)
Follow-up, weeks 30 (72.5)
No. of visits 4 (4)




Previous antipsychotic use, n (%) 60 (42)




Comorbidities, n (%)    
Epilepsy 11 (8)
Other 78 (54)
IQ <70*, n (%) 45 (33)
Physical exercise*, n (%) 57 (47)
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Model 2 <15 weeks follow-upα 15-52 weeks follow-upα >52 weeks follow-upα
 β p-value S.E. 95% 
C.I.
β p-value S.E. 95% 
C.I.
β p-value S.E. 95% 
C.I.









   * duration of use 
(weeks)






Baseline BMI z-score 1.00 <0.001 0.02 0.96 -1.04 0.85 <0.001 0.11
0.63-
1.06 0.68 <0.001 0.07
0.53-
0.82 
   * duration of use 
(weeks)





































   * duration of use 
(weeks)

























Legend: α <15 weeks: n= 144 patients, 15-52 weeks 111 patients, >52 weeks: 58 patients. Antipsych = 
antipsychotic. Class=classification. S.E.= standard error. 95% C.I. = 95% confidence interval
Table 3 Predictors of BMI z-score in children and adolescents during antipsychotic treatment – 
final model
Model 3 <15 weeks follow-upα 15-52 weeks follow-upα >52 weeks follow-upα
 β p-value S.E. 95% 
C.I.
 β p-value S.E. 95% 
C.I.
 β p-value S.E. 95% 
C.I.




















Baseline BMI z-score 0.99 <0.001 0.02 0.95-1.03 0.83 <0.001 0.11
0.61-
1.04 0.65 <0.001 0.08
0.50-
0.80
   * duration of use 
(weeks)

















   * duration of use 
(weeks)






No stimulant 0.10 0.074 0.06
-0.01-
0.21
0.38 0.009 0.15 0.09-0.67 0.35 <0.001 0.10
0.16-
0.55
Duration of use (weeks) 0.02 0.002 0.01 0.01-0.03 0.01 0.378 0.01
-0.01-
0.02
0.00 0.010 0.00 0.00-0.00
Legend: α <15 weeks: n= 144 patients, 15-52 weeks 111 patients, >52 weeks: 58 patients
Table 2 Predictors of BMI z-score in children and adolescents during antipsychotic treatment 
Model 1  <15 weeks follow-upα 15-52 weeks follow-upα > 52 weeks follow-upα
    β               
p-value 




β p-value S.E. 95% 
C.I.
β p-value S.E. 95% 
C.I.






Duration of use (weeks) 0.03 <0.001 0.00 0.03-0.04 0.01 0.088 0.00
0.00-
0.02 0.00 <0.001 0.00
0.00-
0.00
Baseline BMI z-score 0.92 <0.001 0.02 0.90-0.96 0.80 <0.001 0.05
0.7-
0.9 0.69 <0.001 0.07
0.56-
0.83









Sex (male) 0.10 0.076 0.06 -0.01 - 0.22 0.27 0.096 0.16
-0.05- 































No previous antipsych. 
treatment






















































  No stimulant 0.13 0.040 0.06 0.00-0.25 0.38 0.007 0.14
-0.11-
0.66 0.43 <0.001 0.10
0.24-
0.62
  No other medication 0.09 0.267 0.08
-0.07 
-0.25
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values are naturally expected to grow closer to the population mean during follow-up. 26 Also, 
a low baseline BMI as predictor is easily confounded by stage of illness, as younger and thus 
lighter children are likely to have less prior antipsychotic exposure.16 These children may gain more 
weight, as was found in our study. 
Regardless of the change in weight, the finding that overweight children and adolescents are 
likely to remain overweight during antipsychotic treatment has important implications. Apart from 
the evident risk of lipid and glucose disturbances with obesity, an additional, distinct mechanism 
inducing metabolic abnormalities independently of weight gain is suggested for antipsychotic 
drugs.17 This results in an increased prevalence of metabolic abnormalities in overweight children 
using antipsychotics 12, which calls for a close monitoring of overweight children at start of 
antipsychotic treatment. However, not all monitoring guidelines for children and adolescents on 
antipsychotic treatment provide such a standardized intensified monitoring schedule for overweight 
children.1  
Most antipsychotic-induced side-effects monitoring guidelines, developed as a result of the growing 
awareness of cardiometabolic adverse effects of antipsychotic drugs in children and adolescents, 
recommend a first visit at 3 months after start.1, 27 Given our findings that the most accelerated 
weight gain occurs in the first 15 weeks, it should be considered to bring this visit forward to 1 
month after start of treatment. It has been shown previously that the weight gain at 1 month is 
predictive of problematic weight gain after 3 months in adolescents using antipsychotics, further 
confirming the added value of an early monitoring visit. 28 In addition, bodyweight controlling 
strategies are expected to be most beneficial when offered at an early stage, as childhood obesity 
is likely to persist in adulthood. 29
Stimulant use was associated with lower BMI z-scores from 15 weeks of follow-up. It is well-
known that decreased appetite is a common-side effect of stimulants,30 thereby often leading 
to weight loss in children using this type of drugs. It seems obvious that concomitant stimulant 
use can attenuate antipsychotic-induced weight gain, although this has not been consistently 
demonstrated in previous studies.12, 13 Possibly, children in our study received higher dosages of 
stimulant drugs, but this could not be analyzed. However, although concomitant stimulant use 
can possibly lower weight gain in children and adolescents using antipsychotic drugs, the risk for 
adverse cardiovascular adverse events remains unclear. While stimulants have been associated 
with an increased blood pressure and heart rate, and antipsychotics with cardiac arrhythmias, little 
is known about the combined cardiac risks in children and adolescents.31 32  
Children receiving a higher dose equivalent experienced more weight gain during the first 
weeks of use, although this finding did not remain significant in combination with other variables. 
A higher dosage has been described previously as a risk factor for short-term weight gain in 
children and adolescents using risperidone, although findings in adults have been conflicting. 10, 33, 
34 Furthermore, in this study, no difference in weight-inducing potency between different types of 
antipsychotic drugs was found. In randomized controlled settings however, these differences have 
D I S C U S S I O N
We found that antipsychotic-induced weight gain in children and adolescents was most 
pronounced during the first 15 weeks of use. A higher baseline BMI z-score predicted a higher 
BMI z-score during follow up, while the use of stimulants was associated with lower BMI z-scores 
after 15 weeks. Previous antipsychotic treatment was associated with less weight gain during the 
first 15 weeks of treatment.
Although significant weight gain in children and adolescents on antipsychotic treatment has been 
widely recognized, the time course of this weight gain is only poorly documented.2 A previous 
study has found that BMI z-score gain is most pronounced during the first month of treatment, 
while in our cohort a longer period of accelerated weight gain of almost 4 months was found.14 
Furthermore, although long-term data is generally lacking, several studies have described a slight 
decrease in BMI z-score after 6 months.9, 24 This plateauing was also observed in our study, but 
considerably later. Despite this, the BMI z-score generally does not return to the baseline value 
during long-term antipsychotic use. Limited data however has shown that after antipsychotic 
discontinuation, baseline BMI z-score values might recover.25  
The mechanisms behind this course of antipsychotic-induced weight gain in youths are complex 
and only partly understood. Both increased appetite, increased food intake and an altered 
metabolism contribute to an imbalance between energy intake and energy expenditure, regulated 
by both neurotransmitter systems and hormonal changes. Within the neurotransmitter systems, the 
interaction of antipsychotic drugs with both dopamine, histamine and serotonin receptors has been 
suggested to moderate weight gain. 17  These neurotransmitter receptor interactions are expected 
to happen directly, as neurotransmitter-induced side-effects like extrapyramidal symptoms and 
sedation can arise in several hours after initiation of antipsychotic treatment. As such, the weight-
moderating effect too might start immediately. Conversely, the effects of dysregulation of the 
hormonal system is likely to take longer. Antipsychotic drugs affects leptin, also known as the 
satiety hormone. 16, 17 As this hormone is secreted by adipose tissue, the effects on appetite might 
only become apparent after an increase in adipocytes, and thus might need more time. Although 
both mechanisms are likely to reach a new homeostasis after a while, the different time courses of 
the induction of these two mechanisms might partly explain the non-linear development of weight 
gain in children and adolescents using antipsychotics. Nevertheless, numerous other mechanisms, 
including gene-environment interactions and neuropeptides, play a role and have not yet been 
clarified, especially in children and adolescents.  
This study found that patients with higher BMI z-score at baseline also had higher BMI z-scores 
during antipsychotic treatment. However, the interaction with time suggests a faster increase in 
bodyweight during the first 15 weeks of treatment in children with lower bodyweight. This resembles 
the findings from previous, mostly short-term studies, identifying lower baseline BMI as risk factor 
for weight gain in children and adolescents using antipsychotics.8, 11, 12 Nevertheless, this effect 
can be overestimated by the phenomenon of ‘regression to the mean’, indicating that extreme BMI 
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This study has been approved by the ethics committee and has therefore been performed in 
accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later 
amendments. All persons and/or their legal representatives gave their informed consent prior to 
their inclusion in the prospective study; in the retrospective study, informed consent was waived by 
the ethics committee. 
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been clearly shown, with risperidone inducing more weight gain than aripiprazole.35 Although the 
relative weight-inducing properties of pipamperone have only been limitedly described, it is likely 
that this antipsychotic also contributes significantly to weight gain due to its strong anti-serotonergic 
properties. The differences between antipsychotics can diminish in an observational settings with 
limited sample sized like this study, as heavier children are more likely to start treatment with 
antipsychotics that are associated with less weight gain, such as aripiprazole. Similarly, another 
relatively small retrospective study performed in Dutch children and adolescents did not show a 
difference in weight gain between children using risperidone or aripiprazole, while based on the 
literature this could have been expected.9
The results of this study should be interpreted in the light of its limitations. Firstly, due to the merely 
retrospective design, no causal relationship between patient-related factors and BMI z-score gain 
could be established. Also, data was collected in a real-life, clinical setting, thereby allowing 
changes in antipsychotic regimens upon the physician’s discretion or patient preferences. This 
might have influenced the results, as dosages could be lowered or the antipsychotic drug could 
be stopped when a child gained too much weight or had other side-effects. Moreover, drug 
adherence was not analyzed. Lastly, the sample size of this study was relatively small and only 
a limited proportion of patients could be followed for several years, thereby possibly missing risk 
factors with a low effect size. 
However, this is the first study that describes risk factors for antipsychotic-induced weight gain 
in children and adolescents by distinguishing between short-, middle- and long-term use. Also, 
the follow-up duration in our cohort was considerably longer than in previous studies. By using 
advanced mixed-modelling techniques, we could use all weight assessments instead of only 
studying endpoint differences, which is especially important as weight gain was non-linear. The 
findings of this study can guide further, targeted monitoring of children at risk for antipsychotic-
induced weight gain, thereby increasing safety of antipsychotic use in the young. 
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A B S T R A C T 
Background
Risperidone, aripiprazole and pipamperone are antipsychotic drugs frequently prescribed for 
the treatment of comorbid behavioral problems in children with autism spectrum disorders (ASD). 
Therapeutic drug monitoring (TDM) could be useful to decrease side effects and to improve patient 
outcome. Dried blood spot (DBS) sample collection appears to be an attractive technique to 
develop TDM of these drugs in a pediatric population. The aim of this work was to develop and 
validate a DBS assay suitable for TDM and home sampling.
Methods
Risperidone, 9-OH risperidone, aripiprazole, dehydroaripiprazole and pipamperone were 
extracted from DBS and analyzed by UHPLC-MS/MS using a C18 reversed phase column with a 
mobile phase consisting of ammonium acetate/formic acid in water or methanol. The suitability of 
DBS for TDM was assessed by studying the influence of specific parameters: extraction solution, 
EDTA, carryover, hematocrit, punching location, spot volume, hemolysis. The assay was validated 
with respect to conventional guidelines for bioanalytical methods.
Results
The method was linear, specific without any critical matrix effect and with a mean recovery around 
90%. Accuracy and precision were within the acceptance criteria in samples with hematocrit values 
from 30% to 45%. EDTA or hemolysis did not skew the results and no punching carryover was 
observed. No significant influence of the spot volume neither the punch location was observed. 
The antipsychotics were all stable in DBS stored 10 days at room temperature and 1 month at 
4°C or -80°C. The method was successfully applied to quantify the three antipsychotics and their 
metabolites in patient samples.
Conclusions
An UHPLC-MS/MS method has been successfully validated for the simultaneous quantification 
of risperidone, 9-OH risperidone, aripiprazole, dehydroaripiprazole and pipamperone in DBS. 
The assay provided good analytical performances for therapeutic drug monitoring and clinical 
research applications. 
I N T R O D U C T I O N
Antipsychotic drugs play an important role in the treatment of comorbid behavioral problems 
in children with autism spectrum disorders (ASD). Risperidone, aripiprazole and pipamperone 
are antipsychotic drugs frequently prescribed in these patients.1-4 Unfortunately, metabolic 
abnormalities, diabetes, extrapyramidal symptoms and cardiovascular disorders, as well as 
irreversible extrapyramidal symptoms, are major side effects of these drugs.5-8It is recognized 
that therapeutic drug monitoring (TDM) might be useful to improve treatment efficacy, to control 
compliance and to avoid adverse effects in adults using antipsychotics.9-16 Some data suggest that 
in children as well TDM might enhance therapeutic results while lowering risk of toxicity.17,18 
In the last few years, dried blood spot (DBS) sampling has experienced renewed interest in 
bioanalysis. DBS collection requires only a simple finger prick and less blood than a venipuncture. 
Consequently, this is less painful and stressful for the patient than conventional blood sampling. 
Additionally, patient samples can be collected in a home environment.19-21 Thus, this type of 
sampling is particularly interesting to develop a less invasive sampling method for TDM in a 
pediatric population. 
Several analytical methods using DBS to monitor drugs levels have been reported in the 
literature.22 Although quantitative methods measuring antipsychotics levels in plasma are 
widespread23-29, analytical procedures able to quantify antipsychotics in DBS are sparse. To the 
best of our knowledge, only Patteet et al.30 have described a DBS method to quantify risperidone, 
pipamperone, aripiprazole and their major metabolites. However, their assay requires to collect 
an accurate volume of blood in order to analyze the whole DBS. Such a strategy cannot be 
implemented if home sampling is intended. Besides, the extraction procedure chosen by Patteet 
et al. requires a time consuming step to evaporate extraction solvent because the authors aimed 
at quantifying simultaneously more than ten antipsychotics in a high throughput method. The 
approach of the present work is different. The scope of the assay is defined for an application 
in a specific population. Hence, less analytes are included in the method that allows a simplified 
analytical workflow. 
When developing a quantitative DBS method, the impact of critical analytical parameters should 
be investigated. Although specific guidelines for DBS method validation are not yet available from 
regulatory agencies, recommendations are proposed by several authors31-34 who highlight the 
importance to perform a thorough analytical validation before considering replacement of plasma 
sampling by DBS sampling. 
The aim of this study was to validate a DBS assay by means of ultra-high-performance liquid 
chromatography tandem mass-spectrometry (UHPLC-MS/MS), allowing an easy finger prick 
sample at patient’s home, and suitable applications on TDM of risperidone, aripiprazole, 
pipamperone and their major active metabolites 9-OH-risperidone and dehydroaripiprazole. 
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Material and methods
Chemicals and material
Risperidone, Aripiprazole, Dehydroaripiprazole and Haloperidol-d4 were purchased from 
Sigma-Aldrich (Zwijndrecht, The Netherlands). 9-OH-Risperidone was purchased from 
Bioconnect life sciences (Huissen, The Netherlands) and Pipamperone was purchased from Santa 
Cruz Biotechnology (Huissen, the Netherlands). Methanol and acetonitrile were purchased from 
Biosolve BV (Valkenswaard, the Netherlands). Ammonium acetate and formic acid were obtained 
from Sigma-Aldrich (Zwijndrecht, The Netherlands). All reagents were of UHPLC-MS grade. Water 
was purified using a Milli-Q® Ultrapure Water System (Merck Millipore, Darmstadt, Germany). 
Whatman® 903 proteinsaver DBS cards were purchased from Sigma-Aldrich (Zwijndrecht, 
The Netherlands). A regular puncher (Fiskars, Helsinki, Finland) was used for punching the DBS 
discs out of the spotting cards. Drug free human whole blood was obtained from the Dutch 
blood donating centre (Sanquin, the Nederlands). Blood samples were gently mixed using the 
HulaMixer™ sample mixer (Thermo Scientific, Waltham, USA).
UHPLC-MS-MS equipment and conditions
Instrumental
Analysis was carried out on a Thermo TSQ Vantage UHPLC-MS/MS system consisted of a 
Dionex Ultimate UHPLC system, connected to a triple Quadrupole mass spectrometer Thermo TSQ 
Vantage (Thermo Scientific, Waltham, USA). The UHPLC system consisted of an Ultimate 3000 RS 
UHPLC-pump, an autosampler and a column oven. XcaliburTM (2.1 SP1 w/foundation 1.0.2. 
SP2, Thermo Scientific), and ChromeleonTM (Dionex, Thermo Scientific) were used to acquire 
the data. LCquanTM (version 2.6.1.32, Thermo Scientific), was the software used for the analytes 
quantification process.
Chromatographic conditions
Chromatographic separation was achieved using an Acquity UPLC BEH C18 reversed phase 
column (2.1 x 50 mm, 1.7 µm) (Waters, Milford, USA). Gradient elution was performed with a 
mobile phase composed of a mixture of 0.1% formic acid and 2mM ammonium acetate in water 
(eluent A) or methanol (eluent B). A multistep gradient was used at a flow rate of 0.5 ml/min and 
was programmed as follows: equilibration at initial conditions with 15% of B, increase to 50% of B 
from 0 min to 0.6 min, increase to 60% of B from 0.6 min to 1.5 min, increase to 100% of B from 
1.5 min to 1.8 min, stabilization at 100% of B from 1.8 min to 3.0 min, reversion to the starting 
conditions at 15% of B from 3.0 min to 3.3 min and re-equilibration with the initial composition 
from 3.3 min to 4.4. The total run time was 5.4 min. The autosampler temperature was set at 10°C 
and the column oven was set at 50°C.
Mass spectrometry conditions 
The MS settings and conditions were as follows: sheath and auxiliary nitrogen nebulizer gas 
pressure were set to 50 and 20 (arbitrary units) respectively. The collision gas pressure (argon) 
was 1.5 mTorr. Electrospray ionization in the positive mode was applied for all compounds. The 
MS run time was 3.5 min performed in the selective reaction monitoring (SRM) scanning mode. 
Capillary temperature was 250oC, vaporizer temperature was 375oC and spray voltage was 
3000 Volt. The optimized settings of each analyte are summed up in table 1. The most abundant 
SRM transition was used as quantifier ion for all analytes except for 9-OH-Risperidone. For this 
analyte, an interferent matrix product appeared at the same transition as the quantifier ion so the 
second most abundant transition ion (qualifier ion) was used.
Table 1 Mass spectrometry settings used in the DBS assay. 




Rt (min) CE (V) S-lens (V)
Pipamperone 376.2 165.1 1.63 26 113
123.0 43
291.1 17
9-OH-Risperidone 427.2 207.1 1.79 26 126
110.0 39
69.0 46
Risperidone 411.2 191.1 1.86 27 126
110.0 46
82.0 49
Aripiprazole 448.2 285.1 2.39 25 138
176.0 30
98.0 34
Dehydroaripiprazole 446.1 285.1 2.34 22 114
98.0 36
84.0 46
Haloperidol-d4 380.2 127.0 2.15 37 114
SRM transitions, retention time (Rt), collision energy (CE) and S-lens amplitude voltage for all analytes. The bolt 
daughter ions are used as quantifiers for the quantitative analysis, the other ions are qualifier used for analytes 
identification and detection selectivity. SRM: Single reaction monitoring
Preparation of standards (Std) and quality control (QC) samples
Individual stock solutions of each analyte were prepared in methanol at a concentration of 100 mg/L. 
These stock solutions were combined and diluted with methanol to obtain an intermediate mixture 
solution containing the five analytes together at 20 mg/L for aripiprazole, dehydroaripiprazole, 
pipamperone and 4 mg/L for risperidone and 9-OH risperidone. The mixture solution was stored 
at -20°C in a brown bottle. Working solutions of each calibration standard and each QC level 
were daily prepared by dilution of the mixture solution in methanol. 
Two batches of stock solutions per analyte were made to independently prepare two batches 
of mixture solutions (one for QC and one for Standard) in order to detect mistake in solutions 
preparation. The stock solution of Haloperidol-d4 (Internal Standard) was prepared at a 
concentration of 1 mg/L using methanol. 
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Aliquots of 950 µL of drug free human blood were spiked with 50 µL of the corresponding working 
solution. Thus, the percentage of organic solvent in blood was only 5%. Concentrations obtained 
in calibration standards and QC samples are presented in table 2. Tubes were gently mixed for 
10 min and 15 min of stabilization time were waited before spotting blood on a DBS card. 
Table 2 DBS concentrations of calibration standards and quality control
Analyte Calibrations standards (μg/l)
 
Internal quality control 
samples (μg/l)







9-OH-Risperidone 2 4 10 20 50 100 150 200 2 6 80 140
Risperidone 2 4 10 20 50 100 150 200 2 6 80 140
Aripiprazole 10 20 50 100 250 500 750 1000 10 30 400 700
Dehydroaripiprazole 10 20 50 100 250 500 750 1000 10 30 400 700
Pipamperone 10 20 50 100 250 500 750 1000 10 30 400 700
Blood hematocrit adjustment 
For the method validation, adjustment of drug-free whole blood hematocrit was needed. The way 
to proceed was chosen in the light of Koster et al. findings.35 The hematocrit value used to prepare 
blood samples of calibration standards and QCs, was adjusted and normalized to 35%. This 
is assumed to be the median normal hematocrit value of the studied population (children with 
ASD).36 For the assessment of the hematocrit effect, blood samples of increasing hematocrits had to 
be prepared. The first step of the procedure consisted in measuring the hematocrit of the collected 
drug-free blood with a flux cytometer (Sysmex, Kobe, Japan). Blood was then centrifuged for 
6 min at 3000 g and the appropriate amount of plasma was removed or added to obtain the 
target hematocrit. The proportion of red blood cells was checked again after adjustment by the 
automated analyzer. 
Sample preparation
Quality control and calibration standard samples were prepared by pipetting 50µL of spiked 
blood onto a Whatman 903 paper and leaving them to dry at room temperature for 4 to 24 hours. 
DBS discs were punched out using a 6 mm mechanical puncher and the discs were pushed into 
a polypropylene microtube (Sarstedt, Germany). To prevent carryover, the puncher was cleaned 
with ethanol between a high and a low concentration sample and spots were punched out in 
increasing concentration order. 200 µL of the extraction solution was added (ACN/MeOH/
eluent A  1.5:1.5:1 v/v/v) with IS (haloperidol-d4 5 µg/L in sample preparation solution) or 
without IS to make a blank sample. Tubes were vortexed for 1 min and sonicated in an ultrasonic 
bath at 40°C for 20 min. After 1 min vortexing, samples were centrifuged (5min, 16000 g) and 
50 µL of the supernatant were transferred to 200 µL of eluent A in an auto sampler vial. Solvents 
proportions in the vial matched the starting conditions of the mobile phase in the LC as good as 
possible to avoid chromatographic changes for early eluting analytes. Only 10 µL of the final 
extract was injected into the UHPLC-MS/MS apparatus.
Method development and validation
Method development and optimization
The process to quantify simultaneously analytes of interest in DBS was adapted from an in house 
method previously developed in plasma.37 In order to transfer the method to whole blood and 
DBS, some elements were investigated. 
The developed method was carried out with blood from the Dutch blood donating center (Sanquin). 
In order to prevent blood coagulation, the blood was dispensed into tubes coated with ethylene 
–diamine- tetra -acetic acid (EDTA). Whether EDTA has any influence on the analytical results was 
investigated. Fresh blood (directly obtained from the blood center) or blood kept for three days in 
an EDTA coated tube, were spiked with analytes at low and high concentrations. Samples (n=2 
for each kind of blood and concentration level) were applied on DBS paper and analyzed. The 
response obtained in blood containing EDTA was compared to the one measured in fresh blood.
In order to find the best procedure to extract the antipsychotics and their metabolites from DBS, 
several processes based on protein precipitation were investigated. Various mixtures of precipitant 
agents such as methanol, acetonitrile, zinc sulphate, and trichloro-acetic acid were prepared. A 
liquid extraction with ethyl acetate was also tested. The optimal procedure was selected based on 
visual criteria and signal response. In addition, optical density at 280 nm was measured by UV-
spectrophotometry in the final extract to estimate and compare efficacy of the extraction solutions 
regarding protein components removal.38 Optical densities of neat solutions were controlled 
beforehand to avoid any bias due to the solvent intrinsic absorbance.
Method validation
Validation was performed according to international guidelines for bio-analytical method 
validation.39,40 These guidelines contain no specific items for the validations of DBS. Nevertheless, 
based on common practice reported in the literature, the influence of specific critical parameters 
was also investigated. Validation was performed using whole blood with a standardized hematocrit 
value at 35% to be representative of the population of interest.
Selectivity, sensitivity
Selectivity was investigated using six independent sources of human blood. DBS samples were 
prepared from drug free blood and from blood spiked with the antipsychotic drugs and metabolites 
of interest at the expected lower limit of quantification (LLOQ). The lack of endogenous interferences 
was checked by carefully examining the chromatograms of blank samples in the retention window 
containing the peaks of the analyte(s) or the IS. Signal in blank should be less than 20% of the 
LLOQ area. The LLOQ was defined as the lowest amount of an analyte in a sample determined 
with precision and accuracy within ± 20%. It was identical with the concentration of the lowest 
calibration standard. 
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of sample B/ peak area of sample C x100. IS corrected MF was calculated by dividing the MF 
of the analyte by the MF of the IS. The CV of the IS-normalized MF calculated from the 6 lots of 
matrix should not be greater than 15 %.
Hematocrit effect
To investigate the influence of the hematocrit on the method performances, drug-free blood 
samples were prepared with adjusted hematocrit values of 25, 30, 35, 40, 45, 50, 55 %. At 
each hematocrit level, DBS QC samples were prepared in triplicate at low, medium and high drug 
concentration. Samples were analyzed against a calibration curve prepared in blood with an 
hematocrit value normalized at 35%. The hematocrit effect was assessed by calculating analytical 
bias of the measurements in samples of different hematocrits versus samples made in blood with a 
normalized hematocrit at 35% at the corresponding concentration. A difference within ±15% was 
considered acceptable.
Impact of the spot volume
The influence of the spot volume on the assay must be assessed to allow self-sampling by the 
patient without any tool to deliver an accurate volume of blood onto the paper. DBS samples were 
prepared using increasing volumes of blood spiked with the analyte at three QC concentrations 
levels. Each QC sample made with a defined volume was analyzed in triplicate. Responses 
measured in QC samples made with different spot volumes were normalized to the responses 
obtained in DBS made with a standard volume of 50µL. A bias within ±15% was considered 
acceptable. 
Impact of the punching location
In order to evaluate the influence of the punching position or chromatographic effect, QCs DBS 
samples at low and high concentrations were prepared in five-fold and punched out at the center 
and at the edge of the spot. Homogeneity of the spot was estimated through the bias of the 
response measured in spots from the edge with respect to the signal measured in spots punched 
at the center.
Influence of hemolysis
The influence of hemolysis on analyte determination was investigated because a small amount of 
hemolysis can occur during drug-free blood storage, and when it is spiked with working solution 
containing the analytes in methanol during preparation of QCs and calibration standards.
Blood samples spiked at the concentration of QC low, medium and high were stored 4 h at -80°C 
in order to fully hemolyze the blood. DBS samples were created in four replicates for each QC and 
were analyzed as described above. DBS QCs prepared with fresh non-hemolyzed blood were 
analyzed as well. The bias of QCs prepared in hemolyzed blood with respect to QCs prepared in 
fresh blood was calculated to assess the impact of hemolysis on the assay.
Linearity  
The linearity of the methods was assessed by analyzing calibration samples spiked with the analytes 
at 8 concentration levels. Calibration standards analysis was performed over three different days. 
Calibration curves were established by plotting peak area ratio of the target compounds to the 
internal standard (IS) versus the nominal concentrations. The homoscedasticity assumption for 
each linear regression analysis was tested using the F-test. A minimum of 75% of the standard 
calibration samples had to be in the ±15% range (LLOQ:±20%) of the nominal value. 
Accuracy and precision
Accuracy and precision were determined by replicate analysis of samples containing known 
amounts of the analytes. Quality control DBS samples were daily prepared at each concentration 
level (LLOQ, Low, Medium, High). Within day accuracy and precision were determined by 
analyzing QCs in six replicates in a single validation batch. At the LLOQ, between-day accuracy 
and precision were determined by repeating analysis of six replicates over three different days. 
For the highest QC levels, between-day accuracy and precision were determined by quantifying 
analytes at each concentration in duplicate over six different days. Precision was expressed by 
the coefficient of variation (CV). Between-day precision data were calculated using a one-way 
ANOVA analysis. Accuracy was reported as the relative error (RE) or bias to the theoretical value. 
The acceptance criteria for precision and accuracy were ±15 % except for LLOQ which should not 
deviate by more than 20%.
Carry over
Carry-over was evaluated by sequentially injecting an upper limit of quantification (ULOQ) 
sample immediately followed by two extracted blank DBS samples. The response in the first blank 
matrix injection at the retention time region of the analytes should be less than 20% of their mean 
response at the LLOQ. To avoid any additional interfering carry over from the puncher, two spots 
of paper soaked with methanol were punched and discarded after the highest calibrator and QC.
Extraction recovery and matrix effect
Recoveries and matrix effects were assessed with the post extraction addition technique adapted 
from Matuszewski41 and using blood from six different donors. QC samples at low and high 
concentrations were created with 10 µL of blood spiked with analytes and precisely spotted on a 
DBS card in duplicate for each source. The whole DBS containing a known amount of each analyte 
were punched and analyzed according to the sample preparation procedure (samples A).  Blank 
DBS were created in duplicate for each source with 10 µL of drug free blood. They were extracted 
and post fortified with the analytes at the same concentrations than in the QC extracts (samples 
B). Neat solutions (samples C) were prepared in five replicates with the extraction solution spiked 
with the analytes at the same concentrations than in the extracts A and B. Each extract was diluted 
in eluent A before injection as describe above. Recoveries were calculated as follow: recovery 
(%)= peak area of sample A/ peak area of sample B x100. Absolute matrix effects of each source 
were estimated for all analytes and the IS by matrix factors (MF) determined as MF= peak area 
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Stability
In order to study the stability of the analytes in DBS samples, QCs DBS samples at low and high 
concentrations were prepared and stored under several conditions. All QC’s were analyzed in 
triplicate with fresh QC and along a freshly prepared calibration curve. Concentrations measured 
for each analyte were compared to the nominal value. Bias within ±15% of the nominal values was 
acceptable to conclude that the analyte was stable in DBS samples under the studied condition. 
Samples were stored with a desiccant in a sealed plastic bag.  Stability of the analytes was 
investigated in the following conditions of storage: room temperature for 24h, 72h, 1 week, 10 
days and 1 month; refrigerator (+2 to +8°C) for 72h, 1 week, 10 days, 1 month; -80°C for 20 
days and 1 month. In order to mimic high temperature or humid conditions which can occur during 
the sample shipment by regular mail, some DBS samples were kept 36h in an oven at 60°C and, 
while some other samples were placed in a Dutch mail box outdoor during an April rainy week 
for 24h and 6 days. Stability of the extracts was also evaluated by re-injecting QC low and high 
kept 24 h at 10°C in the auto-sampler. 
Clinical application
Before any implementation of DBS in clinical practice, a comparison of patient’s paired DBS and 
plasma samples has to be performed. It allows establishing the correlation relationship between 
plasma and DBS concentrations in order to interpret results according to the appropriate therapeutic 
ranges. Therefore, a thorough clinical validation comparing DBS and plasma concentrations is 
currently started in our center. Nevertheless, as a proof of concept of the ability of the analytical 
method to be applied to real patients samples, the results of the first nine paired patient’s samples 
(three per compound) are reported. Paired DBS and plasma samples were collected from patients 
treated by one of the antipsychotics under study, and being hospitalized in the Erasmus Medical 
Center, a tertiary center, or living in Middin, an institution for disabled persons in the Netherlands. 
Sampling occurred at a random time at steady state. Before DBS sampling, the finger was cleaned 
using water (no ethanol was used as this might influence the results). A single-use automatic lancet 
was used to prick the finger. One blood spot was collected on the DBS paper without pressuring the 
finger. Plasma samples were obtained by a venipuncture. Each patient’s hematocrit was measured 
using the venous blood sample. DBS samples were analyzed according to the method described 
above and plasma samples were analyzed by UHPLC-MS/MS with our already developed and 
validated method.37 The DBS to plasma ratio was calculated for each compound. The Medical 
Ethical Committee of the Erasmus MC approved the protocol of the clinical validation study. 
R E S U L T S
Method development
There was no significant difference between response of the analytes quantified in fresh blood or 
in blood containing EDTA. Bias due to EDTA calculated for all analytes and concentrations were 
lower than 10% and ranged from -4.7% to 8.9% with an overall mean value of 1.3%. The effect 
of EDTA on the determination of the antipsychotics is negligible and batches of drug-free blood 
used to prepare QCs and calibration standards can be stored in EDTA coated tubes. Extraction 


















LLOQ 15.1 12.2 13.1 15.1
QC low 11.6 9.3 4.4 4.6
QC medium 4.9 4.4 2.8 1.9
QC high 3.8 4.2 8.9 2.9
Risperidone
LLOQ 10.1 16.0 14.7 19.8
QC low 4.1 8.4 6.4 2.7
QC medium 4.1 4.1 4.6 4.1
QC high 5.1 5.0 2.0 -0.7
Aripiprazole
LLOQ 12.5 10.2 -11.4 -8.5
QC low 8.1 6.5 -2.0 -3.0
QC medium 4.3 5.6 1.2 -0.2
QC high 4.2 3.5 9.8 2.1
Dehydroaripiprazole
LLOQ 11.1 18.1 -11.4 -6.5
QC low 4.2 8.9 0.3 -1.4
QC medium 4.9 6.7 2.5 1.0
QC high 4.2 3.8 9.4 1.7
Pipamperone
LLOQ 6.7 18.1 -1.8 1.2
QC low 5.8 9.8 -3.8 -6.5
QC medium 2.9 3.2 -0.7 1.6
QC high 5.5 6.0 3.6 2.3
LLOQ: Lower limit of quantification;  QC: quality control; CV: coefficient of variation
Table 4 Matrix effect and Recovery of analytes in DBS. 
Analyte
Matrix effect IS corrected matrix effect Recovery

























9-OH risperidone 94.3 9.9 110.1 6.1 102.7 3.6 99.4 1.7 90.2 3.9 90.3 6.0
Risperidone 140.3 12.1 123.4 8.7 154.7 6.0 125.7 5.2 92.7 6.6 86.3 5.7
Aripiprazole 89.1 12.2 95.8 6.0 96.5 3.9 100.0 1.7 89.6 7.1 91.1 4.8
Dehydroaripiprazole 90.8 9.7 94.7 6.1 98.9 2.4 98.9 2.3 88.2 5.3 90.7 5.8
Pipamperone 100.7 10.5 100.6 5.5 109.5 2.2 105.1 2.3 90.2 7.5 89.4 4.4
LLOQ: Lower limit of quantification; QC: quality control; CV: coefficient of variation. 
Matrix samples from 6 different sources were investigated. Results express means and CV of matrix factors and 
recoveries determined in the different sources.
with precipitant solvents mixture was preferred for its simplicity. Regarding the signal response, 
the highest areas were observed using an equal ratio of methanol and acetonitrile. The addition 
of a strong precipitant as zinc sulphate (10%) did not increase the signal response. Addition 
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Figure 1 Influence of the hematocrit on analytical bias at each QC level.
Linearity  
The linearity of the method was obtained for all analytes over the calibration range detailed 
in table 2. Heteroscedasticity was found for all compounds. The best fit was obtained with a 
weighing factor of 1/x. The back calculated concentrations of the calibration standards were 
within the acceptance criteria (± 15%) and the coefficient of correlation was > 0.99 for every 
validation analysis.
Accuracy and precision
Results of within day and between day precision and accuracy determined at four concentrations 
are detailed in table 3. They fulfilled the acceptance criteria since bias and CV did not exceed 
20% for LLOQ and 15% for other QC concentrations.
Carry over
No carry-over was observed in the validation experiments for all analytes as the responses of the 
blank sample after injecting an ULOQ sample were less than 20% of the response of the LLOQ 
samples.  A maximum percentage of 10% was observed for aripiprazole with a trend to increase 
over the time. To prevent accumulation and release of the compound in the system, two blank 
samples were injected after a ULOQ in analytical sequence and column was rinsed with eluent B 
after each run.
Extraction recovery and matrix effect
Recoveries and matrix effects determined from 6 different sources are presented in table 4. 
Recoveries were high and around 90% for all analytes at low and high concentrations. We 
did not observe any absolute matrix effect beyond 15% except for risperidone. Indeed, for this 
analyte matrix interference caused a significant positive bias since mean matrix factor was higher 
than 20% for both concentrations. The enhancement remained stable without variability among 
samples from different sources since coefficients of variation of matrix factors were less than 
15%. The lack of relative matrix effect was also observed for 9-OH risperidone, aripiprazole, 
dehydroaripiprazole and pipamperone.
Hematocrit effect
The effect of hematocrit was investigated at low, medium and high concentration for hematocrits 
ranging from 25% to 55%. Results are presented in figure 1. It appears that hematocrit influences 
the accuracy of the measurement. The same pattern is observed for all analytes. Except for QC 
medium with a hematocrit of 25%, the bias from the standard hematocrit level (35%) tends to be 
negative for samples with low hematocrit and positive for those with a high hematocrit. However, 
deviations from the standardized QCs with a hematocrit of 35% were within +/-15% for all 
analytes when the hematocrit ranged between 30% and 45%. Considering analytes individually, 
the acceptable hematocrit range was found wider for 9-OH risperidone and pipamperone since 
bias was lower than 15% in samples with hematocrit ranging from 30% to 50%. 
of trichloroacetic acid resulted in the paper dissolution. Addition of eluent A (acidic aqueous 
solution) in the mixture was needed to avoid new precipitation of proteins and opacity in the 
vial to inject after final dilution of the extract in the mobile phase. The efficacy of this ternary 
mixture was confirmed by a low value of optical density of the final extract at the absorption length 
of proteins (0.08 versus 0.23 for the binary mixture ACN/MeOH). Liquid extraction with ethyl 
acetate was very time consuming due to the solvent evaporation step and was unable to extract 




There were no interferences at the retention times of the analytes and IS in the six human 
bloods. Areas in blank samples were less than 20% of the areas in spiked samples at the LLOQ 








































































































































expressed as mean bias ± CV, n = 3
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Table 5 Impact of the punching location. 
Analyte
Bias edge/centre (%) 






Results are reported as bias between the mean response of DBS punched at the peripheral part (of a 100μL 
blood drop) versus at the centre (n=5 per location) QC: quality control
Influence of hemolysis
The deviation of the response between non-hemolyzed and hemolyzed was less than 5% for all 
analytes at the three concentration levels (Table 6). It means that the slight hemolyzation which 
can occur in the blood used to prepare QC and calibration standards does not affect the analysis.
Table 6 Influence of hemolysis
Analyte
Bias hemolyzed blood/fresh blood (%)
QC Low QC Medium QC High
Risperidone -3.4 -0.8 -5.0
9-OH-Risperidone 3.0 -0.8 -3.8
Aripiprazole -0.7 3.4 -1.2
Dehydroaripiprazole -4.4 2.4 -3.3
Pipamperone -4.3 1.5 -2.6
Results are reported as bias between the mean response of DBS samples made with hemolyzed blood (stored 
12h at -80°C before spot) versus non hemolyzed blood  (n=5 per type of blood)
QC: quality control
Stability
Analytes were found to be stable in an autosampler for 24h. As shown in table 7, at room 
temperature they were stable over 10 days of storage.  After 1 month, a significant degradation 
was observed for aripiprazole at low concentration and dehydroaripiprazole at high concentration 
(-17.2 % and -15.3% respectively).  Samples were stable after storage at 4°C and -80°C for 
1 month. Degradation of the analytes in samples stored outside in a moist atmosphere for 24h 
did not result in a loss higher than 15%. Except for Aripiprazole and dehydroaripiprazole, the 
antipsychotics could handle these conditions of storage for 1 week. Only risperidone was found 
stable in DBS kept 36h at 60°C.
Impact of the spot volume
The spot size had a minor impact on the quantification of the antipsychotics and their metabolites. 
Results are presented in figure 2. A maximum bias of 12.8% was observed for 9-OH risperidone 
at low concentration for a spot of 60µL. The lack of influence of the spot volume suggests a 
homogeneous distribution of the blood through the paper. 
Impact of the punching location
Concentrations measured in DBS punched at the edge of the spot were not substantially different 
from those measured in DBS punched at the center, as presented in table 5. Bias was less than 
10% at low and high concentration. This indicates that diffusion of the blood is uniform through 
the paper.
Figure 2 Influence of spotting volume on analytical bias (n=3). 
Expressed as mean bias ± CV, n = 3 at low (A), medium (B) and high (C) concentration levels. Nominal 
concentrations are respectively 3, 15 and 100 μg/l for risperidone and 9-OH risperidone and 70, 350, 500 
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Clinical application
The method was successfully applied to the analysis of DBS samples obtained from three subjects 
per drug (4 females and 5 males) between June and December 2016. Delay between last drug 
intake and sampling ranged from 10 hours to 21 hours. Samples median hematocrit was 41%. 
Antipsychotics and their corresponding metabolites were detected in DBS and plasma for every 
patients treated. Concentrations measured in DBS and plasma and mean blood to plasma ratios 
are reported in table 8.
Table 8 DBS and plasma concentrations of the antipsychotics and their metabolites determined in 




























13.2 24.3 0.57 ± 0.10
7.1 14.4
14.5 21.0




























20°C 24h -4.8 11.4 -7.0 7.7 -6.1 9.1 -9.8 3.7 -4.1 5.6
72h 15.2 -3.3 2.0 0.5 -2.5 -5.5 4.7 3.3 12.9 1.7
1 week -2.2 -6.1 -3.3 -2.9 -1.6 -4.1 -7.8 -2.3 -10.5 -7.9
10 days -7.5 2.8 -14.3 -5.9 -10.6 -4.0 -9.9 -5.8 3.1 -11.1
  1 month -12 -7.2 -17.2 -10.8 -13.7 -15.3 -13.4 -8.9 -6.1 2.7
4°C 72h 18.2 -6.1 6.8 -2.4 0.8 -6.4 8.2 -1.7 12.3 0.8
1 week -4.8 -5.3 -6.3 -1.9 -4.4 -1.3 -7.5 -4.6 -12.2 -12.3
10 days 4.5 10.1 -11.9 3.0 -9.0 5.6 -9.0 4.2 4.0 0.3
  1 month -2.8 -2.7 -11.2 -4.1 -6.8 -10.3 -11.3 -9.9 -5.2 1.7
-80°C 20 days 6.8 6.3 -6.6 8.6 -2.2 2.9 -4.2 6.3 -17.5 5.5
  1 month 7.3 -13.5 -14.6 -11.9 -16.5 -17.6 -8.1 -13.3 1.4 -2.0
Humidity* 24h 5.9 -12.8 -12.1 -13.4 -10.4 -12.3 -4.9 -14.3 -2.6 -14.7
  1 week -10.9 -10.5 -14.1 -17.1 -15.5 -13.2 -13.0 -9.4 -3.4 -13.0
60°C 36h -8.6 -17.4 -17.6 -18.5 -17.1 -19.7 -18.4 -21.9 -7.2 -11.9
* humidity conditions: to mimic real conditions, DBS card were placed in a zip bag with desiccant bag in a 
plastic box (non hermetic) outdoor during a rainy week QC: quality control
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blood is required. An alternative strategy has been proposed by Capiau et al.42 The authors 
estimated hematocrit through potassium measurement in DBS since both parameters were found 
well correlated. In the case of patients treated for autism, somatic comorbidities are not likely to 
affect the hematocrit which should remain stable over the time.43 Thus, a single determination of 
the patient hematocrit in a venous blood sample could be performed before a TDM follow up with 
DBS in order to identify patients whom antipsychotics concentrations would need to be corrected 
for the hematocrit.
Along method development common strategies reported in the literature to cope with the hematocrit 
effect aimed at suppressing it, were investigated. To soak the punched DBS with water before 
extraction tended to increase bias observed with extreme hematocrit levels. The increase of positive 
bias in sample with high hematocrit suggests that this approach is beneficial to improve analytes 
recoveries only when they are in blood of high viscosity. On the contrary, Li et al.44 succeeded 
in decreasing hematocrit effect in lansoprazole determination using pre-soaking, however they 
used this strategy combined with the analysis of the whole spot of a pre-perforated DBS. This 
approach was also assessed to decrease bias in the antipsychotics determination due to varying 
hematocrits. As explained by Fan et al.45, whole spot analysis avoids bias due to inhomogeneity 
of the blood spreading on the filter paper. The major drawback of this strategy is the need for an 
accurate volume of blood which is difficult to consider in the case of patient self-sampling. Results 
of the experiment showed a lower bias in samples with low hematocrit when analyzing the entire 
spot but an important negative bias was observed with increasing hematocrit values and high 
concentrations (data not shown). This highlights that hematocrit does not only impact spot size and 
spreading but also analytes recoveries from the paper. Nevertheless, reduction of the hematocrit 
effect by analyzing the whole spot was achieved by several authors when they associated specific 
systems or devices.46-50 
During the stability study, all analytes were found stable in DBS for at least 10 days at room 
temperature or 4°C. This is relevant for TDM application. In addition, the impacts of high 
temperature (60°C) and wet atmosphere were investigated to mimic extreme conditions which 
can occur during sample shipment by regular mail. The effect of a moist atmosphere was not 
found critical up to 1 week for all the analytes but one. Except for risperidone, high temperature 
exposition leads to analyte degradation after 36h, therefore analysis of DBS samples received by 
regular mail in such hot climatic condition must be discussed.
The relation between plasma or venous blood and capillary DBS concentrations is another crucial 
point to take into account to implement a DBS method in clinical practice.22,34 Current therapeutic 
ranges of antipsychotics were determined in plasma. Therefore, threshold concentrations might 
differ if the measurement comes from a whole blood sample like DBS. The results obtained from the 
analysis of incurred patient’s DBS and plasma samples confirm these expectations. Indeed, whole 
blood concentrations determined in DBS were lower than plasma concentrations. This might be 
explained by the high level of plasma protein binding of antipsychotics drugs and thus less partition 
into blood cells.51 In this way, blood cells act like a diluent, leading to a lower concentration in 
D I S C U S S I O N
The analytical procedure for simultaneous determination of three antipsychotics and their major 
metabolites in DBS was extensively validated according to EMA and FDA requirements. In order 
to take into account specific issues due to the DBS sampling strategy, additional parameters were 
thoroughly investigated according to literature recommendations.31-34  
The developed method is based on an effective and simple extraction by a precipitant mixture 
as demonstrated by the high recoveries and the low matrix effects observed. Interestingly, 
haloperidol-d4 was chosen as single IS based on the development of another method measuring 
the same analytes in plasma.37 Indeed, it was found that performances of the method was good 
enough using only one deuterated IS instead of the deuterated form corresponding to each analyte. 
In DBS as well, the use of haloperidol-d4 appeared suitable to quantify every compounds with 
accuracy and precision. In addition, haloperidol-d4 could correct for a relative matrix effect since 
inter-individual CV of matrix factors from blood of six different sources were lower when IS was 
taken into account. Although a signal enhancement was observed for risperidone, it remained 
constant between matrix sources. Moreover the use of this single IS for a multiplex quantification 
presented obvious practical advantages. 
Repeatability and accuracy were within the acceptance criteria for all analytes. However between 
days accuracy of risperidone at the LLOQ revealed a positive bias close to the acceptable limit 
(19.8%). The bias observed at low concentration might be explained by the ion enhancement 
suggested for risperidone in the experiments determining matrix factors. Considering the therapeutic 
range of the drug is largely higher than the LLOQ value (risperidone+9-OH-risperidone: 20-60 
µg/L), clinical consequences of this variability may be limited and should not be an issue for 
dose adjustment. The European Bioanalysis Forum DBS microsampling consortium conclusions33 
support this idea by considering that acceptance criteria of a DBS method could be widened if 
patient safety is not impacted. 
Interestingly, the current assay is the only one able to provide a reliable measurement of 
pipamperone in DBS since in the study by Patteet et al., accuracy requirements were not met for 
pipamperone at low concentrations.30
The hematocrit effect is known to be the most important hurdle to the implementation of a DBS 
method since variation in hematocrit level leads to variations in the viscosity of the blood spot 
and consequently alters diffusion of the blood on paper. In the current method based on partial 
punch of the DBS, variations of hematocrit within 30% to 45 % did not produce any concerning 
bias. Thus, for TDM purposes it seems appropriate to analyse patients samples against calibration 
curves prepared using blood with hematocrit of 35%, since hematocrit values outside the validated 
range (30-45%) are not expected in children with autism.36 However, it would be optimal to know 
the hematocrit of each sample prior to analysis. This appears challenging when home sampling 
is intended. The blood parameter cannot be directly determined from DBS sample since liquid 
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fluid that comes with the fingerprick could also occur.  Interestingly, despite the small number of 
subject analyzed, our results are comparable with those reported by Patteet et al.52 in a clinical 
validation study of capillary DBS. Indeed, these authors found whole blood to serum ratios of 
0.6, 0.7 and 0.7 for risperidone, 9-OH risperidone and aripiprazole respectively. We observed 
that DBS to plasma concentrations ratio were considerably different between drugs. This might be 
attributed to each drug specific distribution or binding to the blood components. For instance, for 
pipamperone we found a DBS to plasma ratio significantly lower than the other antipsychotics. The 
reason of this difference is unclear. Nevertheless, one can make the hypothesis that this is due to 
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less likely distributed in red blood cells. Unfortunately, although pipamperone was launched 
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C O N C L U S I O N
An UHPLC-MS/MS method has been successfully validated for the simultaneous quantification 
of risperidone, 9-OH risperidone, aripiprazole, dehydroaripiprazole and pipamperone in DBS. 
Based on a quick and simple sample preparation procedure, the assay demonstrated good 
analytical performances and was applied on patient samples analysis. Because no volumetric 
device is required to collect blood, home sampling can be considered. An extensive clinical 
validation, establishing the correlation relationship between plasma and DBS concentrations, is 
now required to rely on DBS as an alternative to collect samples for TDM of pediatric patients with 
ASD in an easy, stressless and painless way. 
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A B S T R A C T
Background 
Dried Blood Spot (DBS) sampling offers a minimally invasive sampling method for therapeutic 
drug monitoring of antipsychotics. To facilitate implementation in clinical practice, the aim of this 
study was to perform a clinical validation study of a DBS method for quantification of risperidone, 
aripiprazole, pipamperone and its major metabolites 9-OH risperidone and dehydro-aripiprazole 
in a real-life, clinical setting.
Methods 
Paired DBS and venous plasma samples were analyzed (n=35 for risperidone, n=21 for 
aripiprazole, n=21 for pipamperone). Estimated plasma concentrations were calculated from 
DBS concentrations based on hematocrit and/or Deming regression formulas. Deming regression 
and Bland Altman analyses were used to determine the agreement between the calculated and 
measured plasma concentrations. For Bland Altman analysis, the following acceptance limit was 
used: for a minimum of 67% of the samples, the difference of the two measurements should be 
within 20% of their mean.
Results
The median venous plasma levels were 0.9 µg/l for risperidone, 14.8 µg/l for 9-OH risperidone, 
135.4 µg/l for aripiprazole, 54.9 µg/l for dehydro-aripiprazole, and 56.4 µg/l for pipamperone. 
All antipsychotics required different correction formulas of DBS concentrations for best agreement. 
Subsequently, no constant or proportional bias was observed using Deming regression analysis. 
With Bland Altman analyses, for risperidone, 48% of the samples were within the 20% limits; 
for 9-OH risperidone, 36%; for aripiprazole, 40%; for dehydro-aripiprazole, 40%; and for 
pipamperone, 33%.
Conclusions
 The DBS method to quantify risperidone, aripiprazole, pipamperone, and their major metabolites 
did not meet the acceptance criteria in the Bland Altman analyses. Therefore, this DBS method was 
not clinically valid. This study shows the importance of a clinical validation study with use of Bland 
Altman plots prior to clinical implementation. 
I N T R O D U C T I O N
Antipsychotic (AP) drugs are widely used. Second-generation APs have become increasingly 
popular due to the belief of having more favorable side effects than the first-generation APs. This 
has led to an increased use of second-generation APs worldwide.1, 2 Indications for use of APs 
include, among others, schizophrenia, bipolar disorder, psychosis, and behavioral problems 
associated with autism and/or mental retardation.
Unfortunately, both second- and first-generation APs are associated with major adverse effects. 
First-generation APs like haloperidol may cause extrapyramidal symptoms, while second-
generation APs mainly induce metabolic changes including weight gain and the metabolic 
syndrome.3 Furthermore, these side effects might have serious long-term consequences. 
Extrapyramidal symptoms might continue even after drug discontinuation, while the metabolic 
syndrome significantly increases the risk of developing diabetes and cardiovascular problems in 
the long term. In this way, APs might have a major negative impact on morbidity and mortality.4
There is evidence that therapeutic drug monitoring (TDM) can help in maximizing clinical efficacy 
while minimizing the risk of side effects of APs.5 For example, for the second-generation APs 
risperidone and aripiprazole, a relationship is shown between plasma levels and both efficacy 
and safety.6-8 TDM might thus help to find adequate dosages to reduce the incidence of the serious 
long-term side effects.
However, blood sampling may be challenging in populations that use antipsychotics. These 
include psychotic patients, mentally disabled persons, and children with autism, who may be more 
anxious or difficult to reach. Therefore, new sampling techniques have been explored, including 
the Dried Blood Spot (DBS) method.9 DBS uses a simple fingerprick to collect a small amount of 
blood on filter paper. The minimally invasive technique, sample stability, and allowance for home-
sampling appear to be advantageous compared to the conventional phlebotomy, especially for 
more vulnerable populations.
For this reason, several analytical methods for the determination of APs with DBS have been 
developed and reported in the literature. Patteet et al. published a clinical study of a DBS method 
to determine 16 APs and 8 metabolites.10 However, blood was obtained by a capillary. Others 
published DBS assays to quantify clozapine and ziprasidone.11 Recently, Tron et al. published a 
bioanalytical validation of a DBS method to determine the three most used APs in children in the 
Netherlands in this journal.12 An advantage of the latter method is that no capillary is needed for 
sampling, which facilitates self-sampling in a home environment.
It is generally accepted that a thorough clinical validation is needed before implementation 
of a DBS method in routine care.13, 14 Therefore, in the continuity of the work of Tron et al., we 
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performed a clinical validation study of the DBS method to determine risperidone, aripiprazole, 
and pipamperone, and their major metabolites 9-OH risperidone and dehydro-aripiprazole in a 
real-life clinical setting.
M A T E R I A L S  A N D  M E T H O D S
Patients
81 patients aged 18 years or older who used either risperidone, paliperidone (the active metabolite 
of risperidone), aripiprazole, or pipamperone were included. Patients were recruited in the 
Erasmus Medical Center, an academic tertiary center, and Middin, a residence for mentally and/
or physically disabled persons, both located in the Netherlands. All patients and/or their legal 
representatives gave written informed consent before entering the study. Patients were recruited 
between June 2016 and May 2017. The study was approved by the medical ethical committee of 
the Erasmus Medical Center and is registered in the Dutch Trial Register with number 6655.
Sampling
DBS samples were collected by SMK and LAH. Before sampling, the fingers of the patients were 
cleaned with water and regular soap or, if that was not possible, by wiping with a wet gauze. No 
alcohol was used as this might bias the biochemical analysis. Both a fingerprick and a venous 
blood sample were obtained simultaneously with a mean sampling time difference of 3 minutes. 
During DBS sampling, 1 to 4 falling drops were separately collected (including the first drop). After 
drying for several minutes, samples were stored at room temperature in an envelope containing 
silica desiccant. Upon arrival at the laboratory, DBS samples were stored in a desiccator at room 
temperature until analysis. Venous samples were centrifuged, and plasma was subsequently stored 
at −80 °C until analysis. Hematocrit was determined in the venous sample within 24 hours.
Analysis
DBS samples were prepared for bioanalytical analysis as described previously.12 Concentrations 
of risperidone, 9-OH risperidone, aripiprazole, dehydro-aripiprazole, and pipamperone in both 
DBS and plasma samples were determined using ultra-high-pressure liquid chromatography-
tandem mass spectrometry (UPLC-MS/MS), which was fully validated according to EMA and FDA 
guidelines.12, 15 The Lower Limit of Quantification (LLOQ) was established as follows: for risperidone, 
1.0 µg/l; 9-OH risperidone, 0.7 µg/l; aripiprazole, 10.0 µg/l; dehydro-aripiprazole, 10.0 µg/l; 
and pipamperone, 1.5 µg/l.
Calculation of estimated plasma concentrations
Estimated antipsychotic plasma concentrations (EPC) were calculated from DBS concentrations 
using two converting formulas.
Formula 1: Plasma estimated concentration = DBS concentration /(1-hematocrit)
This previously described formula corrects for the influence of hematocrit.16 The fraction bound 
to red blood cells could be ignored in formula 1, as the blood:serum ratio of the investigated 
antipsychotics is around 0.6, which means only a small fraction partitions into blood cells.10 
Furthermore, the antipsychotics are characterized by high protein binding. The unbound fraction, 
which is the fraction that can partition into blood cells, can thus be concerned negligible.
For the second converting formula, the plasma and DBS concentrations were plotted with plasma 
levels on the x-axis and DBS levels on the y-axis. Then, a Deming regression analysis was 
performed. The slope and the intercept of the regression formula were used to convert DBS to 
estimated plasma concentrations as described in formula 2.
Formula 2: Plasmaestimated concentration = (DBS concentration – intercept Deming regression) / slope Deming regression 
Additionally, the agreement was checked with formula 3: 
Formula 3: Plasmaestimated concentration = DBS concentration / slope Deming regression 
All converting formulas were used separately and combined to determine the formula with the best 
agreement between the two methods.
Statistics
Agreement between the DBS and plasma samples was determined using Deming regression 
analysis and Bland Altman plots. Deming regression was used to test for a proportional and 
constant bias. When the 95% CI of the slope of the regression formula includes 1, no proportional 
bias is observed. When the 95% CI of the y-intercept includes 0, no constant bias is observed. 
Bland Altman plots were used to test the agreement between the two methods. According to the 
guideline Bioanalytical Method Validation of the European Medicines Agency,17 the difference 
between DBS and plasma concentrations should be within 20% of the mean of the concentrations 
for at least 67% of the samples.
Stratification based on patients’ department type was made to see if agreement between the 
two methods differed for somatically and non-somatically ill patients. Non-somatic departments 
included the psychiatric departments of the Erasmus MC and the residence for mentally and 
physically disabled persons. Somatic departments included all other departments, concerning all 
non-psychiatric departments of the Erasmus MC.
If an analyte did not meet the Bland Altman acceptance criteria, we calculated the percentage of 
variance (>20%), which shows an agreement for 67% of the samples.
Analyses were performed with Excel 2010 (Microsoft Corp., Redmond, WA, United States), IBM 
SPSS Statistics version 21 for windows (IBM Corp.,Armonk, NY, Untited States) and Graphpad 
Prism 5 (GraphPad Software, La Jolla California, United States).
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R E S U L T S
A total of 82 paired samples were taken from 81 unique patients. For 4 patients, DBS sampling 
yielded not enough blood volume for analysis. This was due to cold extremities in bedridden 
patients with impaired peripheral circulation, or motoric restlessness in patients with severe mental 
retardation. One patient was excluded as the samples were taken directly after intake of the 
antipsychotic (within the distribution phase), which caused a large difference in concentrations 
between capillary and venous taken blood. A total of 35 samples of patients using risperidone, 
21 using aripiprazole, and 21 using pipamperone could be analyzed. The baseline characteristics 
of the patients are presented in table 1.






Age (y) 49 (29-59) 45 (25-61) 54 (37-66)
Female (n) 14 (44%) 13 (68%) 10 (48%)
Length (cm) 175 (169-182) 170 (165-185) 170 (160-176)
Weight (kg) 76 (65-89) 83 (78-99) 78 (58-95)
Daily dosage (mg) 2.0 (1.6-4.0) 10 (5-20) 40 (20-70)
HtO (L/L) 0.39 (0.34-0.43) 0.43 (0.35-0.45) 0.41 (0.36-0.44)
Department* (n)
Somatic 15 (47%) 10 (53%) 6 (29%)
Non-somatic 17 (53%) 9 (47%) 15 (71%)
Indication (n)
Psychosis 14 (44%) 6 (32%) 1 (5%)
Behavioral problems 5 (16%) 1 (5%) 12 (57%)
Schizophrenia 4 (13%) 4 (21%) 0 (0%)
Delirium 3 (9%) 3 (16%) 0 (0%)
Bipolar disorder 1 (3%) 3 (16%) 1 (5%)
Other 5 (16%) 2 (11%) 7 (33%)
Values are presented as median (25th-75th percentile) unless stated otherwise
∆ 3 patients using risperidone and 2 patients using aripiprazole gave consent for 2 times DBS-venous sampling 
on 2 different days.
O Hematocrit missing for n=2 for risperidone, n=1 for aripiprazole, n=1 for pipamperone
* Non-somatic departments include the psychiatric departments of the Erasmus MC and all departments of 
the residence for mentally and physically disabled persons, somatic departments include all non-psychiatric 
departments of the Erasmus MC.
The median plasma levels (25th – 75th percentile) measured in the venous samples were 0.9 
(0.4-7.2) µg/l for risperidone, 14.8 (8.7-32.3) µg/l for 9-OH risperidone, 135.4 (74.2-226.9) 
µg/l for aripiprazole, 54.9 (28.7-73.0) µg/l for dehydro-aripiprazole, and 56.4 (30.3-119.7) 
µg/l for pipamperone. For risperidone, 18 (51%) of the samples were below the LLOQ, as well 
for DBS as venous samples. For 9-OH risperidone, none of the DBS or venous samples were 
below the LLOQ. For aripiprazole, 1 (5%) of the DBS samples was below the LLOQ, and for 
dehydro-aripiprazole, 2 (10%) samples of both DBS and venous samples were below the LLOQ. 
For pipamperone, 2 (10%) of the DBS samples were below the LLOQ.
Deming regression
Deming regression analysis showed a constant bias for all analytes. Therefore, corrections of DBS 
values according to formulas 1,2 and 3 were applied to derive estimated plasma concentrations 
(EPCs). For risperidone, aripiprazole, and their metabolites, correction based on the hematocrit 
using formula 1 improved agreement, while for pipamperone, hematocrit correction did not improve 
results. For aripiprazole, dehydro-aripiprazole, and pipamperone, (subsequent) correction based 
on Deming regression (formula 3) showed better agreement. The final EPC correction formulas 
are shown in table 2. The Deming regression analysis with these EPCs showed no proportional 
or constant bias for all analytes. The results of Deming regression analyses are shown in table 2.





















































Ht, hematocrit; EPC, estimated plasma concentration. *For formula 1, only cases with known hematocrit were 
used. Hematocrit missing for n=2 for risperidone, n=1 for aripiprazole
Bland Altman analysis
Bland Altman analysis was applied to all analytes using the plasma concentrations and EPCs. 
Results are presented in table 3. The plots of risperidone, aripiprazole, and pipamperone are 
shown in figures 1, 2, and 3, respectively. None of the analytes meet the acceptance limits. 
When neglecting the acceptance limits, for 67% of the risperidone samples, the difference between 
plasma and EPC levels lay within 30% of the mean of the samples. For 9-OH risperidone this was 
35%. For aripiprazole and its metabolite, this was 47% and 52%, respectively. For pipamperone, 
for 67% of the samples, the difference lay within 40% of the mean. 
The results of the Bland Altman analysis did not improve when only patients from non-somatic 
departments were analyzed. Therefore, somatic illness did not influence the agreement between 
DBS and venous sampling.
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Table 3 Results of Bland Altman analysis of DBS versus Estimated Plasma Concentrations
Analyte n* Mean bias 95% limits of 
agreement
∆ within 20% 
of average 
(%)
∆ within 25% 
of average 
(%)














Pipamperone 21 18.204 -103.599-
140.006
33 52
For formulas of estimated plasma concentrations, see table 2.
*For risperidone, aripiprazole, and their metabolites, only cases with known hematocrit were analyzed. 
Hematocrit missing for n=2 for risperidone, n=1 for aripiprazole.
Acceptable bias (20%)
----- Mean bias
Figure 1 Bland Altman plot for Risperidone Figure 2 Bland Altman plot for Aripiprazole
EPC: Estimated Plasma Concentration
Figure 3 Bland Altman plot for Pipamperone
D I S C U S S I O N
The present clinical validation study shows that DBS and plasma concentrations of risperidone, 
aripiprazole, pipamperone, and their major metabolites have good agreement based on Deming 
regression analysis, but do not fulfill Bland Altman acceptance limits. Therefore, not all criteria for 
a completely successful clinical validation have been met.
The Bland Altman analysis is a simple way to evaluate the bias between two quantitative methods 
of drug measurement. Bland Altman analysis, in addition to weighted Deming or Passing Bablok 
regression analysis, is generally recommended for clinical validation of DBS assays.13, 14 Despite 
this, Bland Altman analysis is often absent in clinical validation studies.14 For instance, Patteet et al. 
performed a clinical study to determine 16 APs in DBS, only using Passing Bablok regression and 
a comparison of clinical interpretation. Despite the lack of Bland Altman analysis, these authors 
concluded that DBS can be used in routine clinical practice. However, our study demonstrates that 
Bland Altman might yield a large bias despite good correlation based on regression analysis. In 
general, this underlines the importance of Bland Altman analysis in clinical validation studies and 
warrants interpretation of studies without such analysis with great caution.
In this study, we used a hematocrit correction formula to assess best agreement between DBS and 
venous samples. For pipamperone, results did not improve with hematocrit correction, in contrast 
to the other compounds. This might be explained by a lower affinity of pipamperone to red blood 
cells, thus indicating that the DBS concentrations of pipamperone could be less influenced by 
hematocrit. Unfortunately, very little is known about pharmacokinetic properties of pipamperone, 
despite being on the market for several decades. To our knowledge, only two other clinical 
validation studies of DBS analysis for APs have been published, and neither of them reported 
using hematocrit correction.11 A clinical validation study on Ziprasidone used a blood-to-plasma 
concentration ratio correction factor to derive estimated plasma concentrations,18 while Patteet et 
al. did not report any conversion of DBS concentrations.10
The findings of this study are in contrast with the successful analytical validation of this DBS method 
that has been performed previously.12 In this previous analytical validation, venous blood spotted 
on DBS paper showed good agreement with plasma samples. The discrepancy between the 
analytical and clinical validation might be explained by several factors. Firstly, with real-time DBS 
sampling, contamination with interstitial fluid and dermal flora takes place. These factors might 
have contributed significantly in our cohort. Inpatients using antipsychotics often express motoric 
restlessness and anxiety, which sometimes impairs adequate cleaning of the finger, or resampling 
in case of a limited blood flow from the fingerprick. The latter might require pressuring the finger, 
which might enhance hemolysis and contamination with more interstitial fluid. Secondly, the 
distribution phase of antipsychotics might be quite long, which means large differences between 
venous and capillary concentrations may occur. These factors might have complicated our clinical 
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Although not all clinical validation criteria have been met, the DBS assay for determining these 
antipsychotics could still be used in clinical practice, for example, as a medication adherence 
tool. In our study, antipsychotic drug concentrations could be determined in all analyzed DBS 
and plasma samples. Given this result, we can conclude that the sensitivity of DBS for qualitatively 
determining antipsychotic drugs is 100%. At the same time, antipsychotic drugs could not be 
quantified in the blanco samples that were measured during DBS analysis. Therefore, this shows 
that the DBS method can accurately measure if antipsychotic drugs have been taken by the patient. 
This might be of great value in daily clinical practice, as medication adherence for antipsychotic 
therapy has shown to be rather low.19 Especially for patients that are difficult to reach, for example, 
because of isolated living circumstances by certain patients with schizophrenia, DBS might offer 
an easily applied measure to determine adherence at home.
Besides application as an adherence tool, our DBS method can also be useful for pharmacokinetic 
research purposes in vulnerable populations. For example, for children using antipsychotics, venous 
sampling can be very traumatic. A fingerprick is less invasive and of shorter sampling duration, 
which might increase willingness to participate in trials where repeated sampling is required. 
Furthermore, pharmacokinetic modeling programs, such as NONMEM, enable correction for a 
certain bias by considering extra variance of the DBS measurements. Different error models can 
be used to describe the effect of plasma samples versus DBS samples, in which the latter has a 
larger uncertainty.
This study has several limitations. Firstly, fewer than 40 samples were obtained per drug, despite 
the recommendation to include this number of samples in certain guidelines.20 The main reason for 
lower number of samples was that eligible patients were often anxious, suspicious, or incompetent 
to give consent in case of a psychosis or delirium, which made them unsuitable for inclusion. 
However, other clinical validation studies have shown that it is possible to draw conclusions from 
smaller sample size.21, 22 Furthermore, agreement between the two methods did not improve with 
larger patient numbers compared to earlier interim analyses with smaller sample sizes. This suggests 
that further enlargement of our sample sizes would not have improved the results. Secondly, 
another limitation is that somatically ill patients were also included, while the target population for 
at-home sampling consists of outpatient psychiatric patients who are, in general, not physically ill. 
Nevertheless, a stratification based on department type was made, which did not, however, show 
better agreement in the non-somatically ill patients. Thirdly, antipsychotic concentrations were in a 
relatively low range compared to the therapeutic reference range. Especially for risperidone, this 
led to a significant share of the samples being below the LLOQ. This might be explained by the 
fact that the therapeutic ranges are mainly based on treatment of patients with schizophrenia, in 
which higher dosages and other outcome measures are used, than for patients with, for example, 
behavioral problems. In our sample, only 11% of the patients used antipsychotics for schizophrenia. 
However, the samples with values below the LLOQ did show a similar agreement as the samples 
in the validated quantification range. Therefore, our method should be valid for populations with 
reduced dosing schedules, such as patients with delirium or in children. Lastly, in our study, we 
measured hematocrit in the venous sample, while this value possibly differs from the hematocrit 
measured in capillary blood. However, simultaneous measurement of hematocrit by DBS was not 
possible in our laboratory at the time of analysis.
This study also has several strengths. First of all, this is the first study that performed a complete 
clinical validation of a DBS method for risperidone, aripiprazole, and pipamperone using Bland 
Altman plots. For pipamperone, this was the first study to report the clinical validation of DBS 
sampling. Secondly, we performed a solid clinical validation according to current international 
guidelines, using typical patients in a real-life clinical setting. In this way, we have been able to 
simulate implementation in real clinical practice. This study can therefore be seen as an exemplary 
clinical validation study of a DBS method. Thirdly, to our knowledge, this is the first study that shows 
a negative performance of DBS sampling during the clinical validation phase. As earlier studies 
might not have been published due to publication bias, this study is of great importance to show 
the reality and drawback of DBS.
C O N C L U S I O N S
Our Dried Blood Spot (DBS) method to determine risperidone, aripiprazole, pipamperone, and 
their major metabolites was not fully clinically valid. This study shows the importance of a clinical 
validation study using Bland Altman plots before clinical implementation. Nevertheless, this DBS 
method could still be useful in clinical practice as a qualitative adherence tool.
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Development, grant 836041011. 
5
Part III:   Alternative sampling - 103102 - Chapter 5
R E F E R E N C E S
1. Halfdanarson O, Zoega H, Aagaard L , et al. International trends in antipsychotic use: a study 
in 16 countries, 2005-2014. Eur Neuropsychopharmacol  27, 1064-76 (2017).
2. Verdoux H, Tournier M and Begaud B. Antipsychotic prescribing trends: a review of pharmaco-
epidemiological studies. Acta Psychiatr Scand  121, 4-10 (2010).
3. Leucht S, Corves C, Arbter D , et al. Second-generation versus first-generation antipsychotic 
drugs for schizophrenia: a meta-analysis. Lancet  373, 31-41 (2009).
4. Laaksonen DE, Lakka HM, Niskanen LK , et al. Metabolic syndrome and development of 
diabetes mellitus: application and validation of recently suggested definitions of the metabolic 
syndrome in a prospective cohort study. Am J Epidemiol  156, 1070-7 (2002).
5. Hiemke C, Bergemann N, Clement HW , et al. Consensus Guidelines for Therapeutic Drug 
Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry  51, 9-62 
(2018).
6. Spina E, Avenoso A, Facciola G , et al. Relationship between plasma risperidone and 
9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. 
Psychopharmacology (Berl)  153, 238-43 (2001).
7. Wang L, Yu L, Zhang AP , et al. Serum prolactin levels, plasma risperidone levels, 
polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. 
J Psychopharmacol  21, 837-42 (2007).
8. Kirschbaum KM, Muller MJ, Malevani J , et al. Serum levels of aripiprazole and 
dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry  9, 212-8 
(2008).
9. Patteet L, Cappelle D, Maudens KE , et al. Advances in detection of antipsychotics in biological 
matrices. Clin Chim Acta  441, 11-22 (2015).
10. Patteet L, Maudens KE, Stove CP , et al. Are capillary DBS applicable for therapeutic drug 
monitoring of common antipsychotics? A proof of concept. Bioanalysis  7, 2119-30 (2015).
11. Martial LC, Aarnoutse RE, Mulder M , et al. Dried Blood Spot sampling in psychiatry: 
Perspectives for improving therapeutic drug monitoring. Eur Neuropsychopharmacol  27, 
205-16 (2017).
12. Tron C, Kloosterboer SM, van der Nagel BCH , et al. Dried blood spots combined with 
ultra-high-performance liquid chromatography-mass spectrometry for the quantification of 
the antipsychotics risperidone, aripiprazole, pipamperone, and their major metabolites. Ther 
Drug Monit  39, 429-40 (2017).
13.  McDade TW. Development and validation of assay protocols for use with dried blood spot 
samples. Am J Hum Biol  26, 1-9 (2014).
14.  Enderle Y, Foerster K and Burhenne J. Clinical feasibility of dried blood spots: Analytics, 
validation, and applications. J Pharm Biomed Anal  130, 231-43 (2016).
15.  Wijma RA, van der Nagel BC, Dierckx B , et al. Identification and quantification of the 
antipsychotics risperidone, aripiprazole, pipamperone and their major metabolites in plasma 
using ultra-high performance liquid chromatography-mass spectrometry. Biomed Chromatogr 
30, 794-801 (2016).
16.  Li W and Tse FL. Dried blood spot sampling in combination with LC-MS/MS for uantitative 
analysis of small molecules. Biomed Chromatogr  24, 49-65 (2010).
17.  Agency EM. Guideline on bioanalytical method validation.   (London, 2011).
18.  Saracino MA, Lazzara G, Prugnoli B and Raggi MA. Rapid assays of clozapine and its 
metabolites in dried blood spots by liquid chromatography and microextraction by packed 
sorbent procedure. J Chromatogr A  1218, 2153-9 (2011).
19.  Lacro JP, Dunn LB, Dolder CR, Leckband SG and Jeste DV. Prevalence of and risk factors for 
medication nonadherence in patients with schizophrenia: a comprehensive review of recent 
literature. J Clin Psychiatry  63, 892-909 (2002).
20.  Budd JR. EP09 Measurement Procedure Comparison and Bias Estimation Using Patient 
Samples. 3rd edn., Vol. 33 (Clinical and Laboratory Standards Institute: Wayne, PA, USA, 
2013).
21.  de Wit D, den Hartigh J, Gelderblom H , et al. Dried blood spot analysis for therapeutic drug 
monitoring of pazopanib. J Clin Pharmacol  55, 1344-50 (2015).
22.  Mastronardi CA, Whittle B, Tunningley R, Neeman T and Paz-Filho G. The use of dried blood 




T H E  F E A S I B I L I T Y 
O F  D R I E D  B L O O D 
S P O T S  I N  C H I L D R E N 
W I T H  B E H A V I O R A L 
P R O B L E M S
Sanne M. Kloosterboer, Estelle van Eijk, 
Monique van Dijk, Gwen C. Dieleman, 
Manon H. J. Hillegers, Teun van Gelder, 
Birgit C. Koch, Bram Dierckx
Therapeutic Drug Monitoring 
2020;42(4):648-51
106 - Chapter 1 Part III:   Alternative sampling - 107
A B S T R A C T 
Background
Minimally invasive sampling methods are important to facilitate therapeutic drug monitoring 
(TDM) and pharmacokinetic research in children with behavioral problems. This study assessed 
the feasibility and pain of dried blood spot (DBS) sampling in this population. 
Methods
Repeated DBS sampling was performed in children with autism spectrum disorder (ASD) and 
severe behavioral problems using antipsychotic drugs, aged between 6 and 18 years. The child, 
guardian, and DBS performer assessed pain using the numeric rating scale (NRS-11) or 5-face 
Faces Pain Scale. The influence of age, sex, and the fingerprick performer on the child’s pain 
intensity was analyzed using linear mixed models. 
Results
Overall, 247 fingerpricks were performed in 70 children. Seven children refused all DBS sampling. 
The median (IQR) NRS-11 pain scores were 2 (3) rated by children, 3 (2.5) by guardians, and 2 
(2) by fingerprick performers. The child’s age and sex, and fingerprick performer had no significant 
influence on pain intensity.
Conclusions
DBS sampling could be performed in most children with ASD and severe behavioral problems. 
However, 1 in 5 children refused one or more DBS fingerpricks owing to distress. The majority 
expressed minimal pain (NRS <4).  Repeated sampling with DBS is feasible in children with ASD 
and severe behavioral problems. 
I N T R O D U C T I O N
As an alternative to invasive venipuncture, dried blood spot (DBS) analysis is well-established 
for drug quantification.1 DBS involves only one fingerprick and is especially suited for pediatric 
populations, in clinical and research settings. DBS can increase sampling tolerability particularly 
in children with behavioral problems. In these children, blood sampling by venipuncture is often 
challenging due to restlessness or aggression; the minimally invasive DBS procedure could 
overcome these challenges and can be performed at home. 
Notably, among children with behavioral problems, DBS sampling is of particular interest in children 
prescribed antipsychotic drugs. These drugs are effective in a wide range of psychiatric disorders 
in childhood2, including behavioral problems in autism spectrum disorder (ASD); however, these 
drugs are associated with serious side-effects. The most important side-effect concerns weight-
gain3, leading to metabolic abnormalities3, diabetes mellitus4, 
cardiovascular diseases5, and possibly even unexpected death6 in children using antipsychotic 
drugs. Therapeutic drug monitoring (TDM) could be an important tool to increase the safety of 
these drugs in children.7, 8
To facilitate TDM research and applicability in children using antipsychotic drugs, a DBS assay 
for the quantification of risperidone, aripiprazole, and pipamperone has been developed.9, 10 
However, the feasibility and burden of DBS in children with severe behavioral problems remains 
unexplored. In the current study, we evaluated the feasibility and pain levels of DBS sampling in 
children with ASD and severe behavioral problems and investigated the influence of sex, age, and 
fingerprick performer on the child’s pain intensity. 
M A T E R I A L S  A N D  M E T H O D S
Study population
Children, aged 6-18 years old, with ASD according to the DSM IV11 or 512 and severe behavioral 
problems were included in an observational study investigating the relationship between 
antipsychotic drug concentrations and effects (Netherlands National Trial Register NTR6050). 
All included children were prescribed risperidone, aripiprazole, or pipamperone, the three most 
commonly used antipsychotic drugs in the Netherlands.13 This study, including the pain assessments, 
was approved by the medical ethics committee of the Erasmus MC (MEC 2016-124). All patients 
and/or their legal representatives provided written informed consent before entering the study.
DBS sampling
Each child received two to three fingerpricks on two separate days, with a minimum of 1 h between 
two fingerpricks to allow random sampling. The fingerpricks were performed with a single-use 
contact-activated lancet (BD Microtainer® 2.0 mm × 1.5 mm), with the first performed by the 
research staff at the clinic. Subsequent fingerpricks were performed by research staff, the guardian, 
or the child itself, at the clinic or home depending upon the patient’s preference. Most children 
6
Part III:   Alternative sampling - 109108 - Chapter 6
underwent a venipuncture the same day. Antipsychotic drug concentrations were determined 
using a previously validated ultra-high performance liquid chromatography-mass spectrometry 
(LC-MS/MS) method for DBS. 9, 10
Pain assessment 
Before performing the fingerprick, the child’s likely response to procedures, coping strategies, 
and possible interventions were discussed with parents and the child. The DBS procedure was 
explained and demonstrated before the performance. Immediately after the fingerprick, the child, 
guardian, and fingerprick performer assessed pain. Children aged 6 years used a 5-face Faces 
Pain Scale (FPS); older children, guardians, and fingerprick performers used the 11-point numeric 
rating scale (NRS-11).14 The FPS demonstrates 5 faces from happy to extremely sad. For children 
with cognitive impairment, the Checklist Pain Behavior (CPG)15, including the NRS-11, was scored 
by the research staff, whereas the guardians only scored the NRS-11. An NRS score of 4 or higher 
and a CPG score of 5 or higher is regarded as an indication for pain-relieving interventions.15, 16 
After each fingerprick, the researcher evaluated the burden for each child based on pain scores, 
assessing whether a subsequent fingerprick could be performed together with the child and the 
guardian. 
Statistical analyses
Groups were compared using the Mann-Whitney U test for continuous data (non-normal data 
distribution) and Fisher’s exact test for categorical data. The interrater reliability of pain scores 
rated by the child, guardian, and research staff were analyzed with the intraclass correlation 
coefficient (ICC) using a two-way mixed model with absolute agreement type. To evaluate the 
influence of the child’s age and sex, as well as fingerprick performer, on the child’s pain, a linear 
mixed model analysis was used with a random intercept. Sampling days were clustered within 
patients. All variables were tested using a univariate model. Variables with p <0.10 were added to 
the multivariate model; variables with p<0.05 in this model were selected for the final model. All 
analyses were performed using SPSS Version 25 (SPSS Inc., Chicago, IL, USA).
R E S U L T S 
Overall, 81 children were eligible for inclusion. Seven children refused all DBS sampling (8.6%), 
and in nine children (11.1%) not all DBS sampling could be performed as they expected DBS to 
be extremely painful or stressful (figure 1). Children who refused one or more DBS samples were 
significantly younger than those who performed all DBS samples (median age 9.3 versus 10.8 
years, p=0.43). The groups did not significantly differ in terms of sex or mental retardation.
Totally, 253 DBS samples were collected from 70 children, with 21 were female (30%),  and a 
median (IQR) age of 10.7 (5.0) years. Twelve children were diagnosed with cognitive impairment. 
Most DBS fingerpricks were performed by research staff (63.0%), followed by guardians (36.6%), 
and the child (0.4%). DBS samples obtained by guardians were performed at home. Notably, 39 
(15.4%) DBS samples were not of sufficient quality for analysis. 
For 247 DBS samples, 1 or more NRS-11 pain scores were available, including 168 pain scores 
reported by the child, 187 by guardians, and 126 by research staff. The median (IQR) NRS-11 
pain scores were 2 (3) rated by children, 3 (2.5) by guardians, and 2 (2) by research staff. The 
medians and ranges are shown in Figure 2. Furthermore, 61 fingerpricks (36.3%) were rated ≥4 
by the child. Twenty-six CPG scores were available; the median (IQR) score was 3 (1), and 11.5% 
were 5 or higher.
For 147 fingerpricks, both child and guardian NRS-11 pain scores were available. The ICC for 
guardians and children was 0.86 (95% CI 0.81-0.90) and for research staff and children was 
0.79 (95% CI 0.67-0.86), considered excellent and good, respectively.
For 167 NRS-11 scores issued by the child, the age and sex of the child, as well as the nature 
of fingerprick performer, were known. The univariate mixed model analysis showed that none 
of these variables significantly influenced the child’s pain intensity: age of the child (β=-0.087, 
p=0.134), sex of the child (β=0.476, p=0.225) and fingerpick performer (guardian β=0.266, 




Figure 1 DBS sampling fulfilment
* These children expected DBS to be too painful or stressful
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whiskers indicate min-max. NRS-11: 11 point Numeric Rating Scale
D I S C U S S I O N
Repeated DBS sampling was successfully performed in the majority of children with ASD and 
severe behavioral problems. Nevertheless, 1 in 5 children refused one or more DBS fingerpricks 
due to distress. However, most children expressed minimal pain (NRS <4) during DBS sampling. 
Relatively little is known regarding pain in autistic children, although hyper- or hyporeactivity to 
sensory input is a feature of ASD.12 Comparable, reduced, and increased pain thresholds have 
been reported in the literature.17 This is consistent with our study, where both extremely low and 
extremely high pain scores were observed, although most pain scores were lower than the generally 
accepted threshold of 4.  However, pain assessment in children with ASD is challenging, as they 
may express pain differently due to the lack of social responsiveness and language impairment.18 
Unfortunately, pain assessment tools specifically for individuals with ASD have remained largely 
unexplored. 
The tolerability of blood sampling is not only determined by pain, but also by distress and anxiety. 
Children with ASD express higher levels of distress during venipuncture than their non-impaired 
peers.19, 20 DBS sampling may reduce many of these stressors as the sampling preparation phase 
is considerably less complex, allowing sampling by a guardian in the home setting. Hence, most 
children with high levels of distress are expected to prefer DBS sampling over venipuncture, as do 
their normally-developing peers21, 22, but further research is necessary for validation.
Figure 2 Child’s pain associated with DBS sampling rated by child, guardian and research staff In children with behavioral problems, the performance of repeated sampling studies is highly 
challenging. As previously suggested, sparse sampling designs in combination with DBS sampling 
can facilitate pediatric pharmacokinetic research.23, 24 Both the lower burden and acceptance of 
home-sampling improve study recruitment, which is particularly difficult in child- and adolescent 
psychiatry. However, clinical validation remains challenging, e.g. our study showed a larger 
variability in antipsychotic drug concentrations measured with DBS than with venipuncture. As 
advanced pharmacokinetic modeling techniques allow the correction of this variability, the 
advantages of DBS can still outweigh the disadvantages. Currently, this method remains primarily 
useful in research settings; however, further development and study of DBS and TDM could yield 
a clinical, minimally invasive tool that improves the safety of antipsychotic drugs. 
The current study has some limitations. As mentioned earlier, self-reporting of pain might be 
unreliable in children with ASD, leading to an over- or underestimation of pain. However, no pain 
measurement tools are currently available for pain assessment specifically in children with ASD. To 
optimize pain assessment, it was ensured that the DBS sampling performers had prior experience 
in communicating with children with ASD and that the child’s guardians were present. Previous 
research has shown that parent involvement is essential for the interpretation and expression of pain 
in children with ASD.18  A comparison with the pain associated with conventional venipuncture was 
not conducted, limiting the evaluation of the most optimal sampling technique in this population. 
C O N C L U S I O N
This is the first study that evaluated the feasibility of repeated DBS sampling in children with ASD 
and severe behavioral problems, indicating that DBS is a feasible sampling technique in this 
population. Although further research is needed to compare the burden of DBS and venipuncture 
in children with ASD and behavioral problems, DBS can facilitate pharmacokinetic research and 
TDM in these and other pediatric populations where sampling remains challenging. 
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A B S T R A C T
Introduction 
The use of psychotropic drugs in children and adolescents is widespread but associated 
with suboptimal treatment effects. Therapeutic drug monitoring (TDM) can improve safety of 
psychotropic drugs in children and adolescents, but is not routinely performed. A major reason is 
that the relationship between drug concentrations and effects is not well known. 
Areas covered 
This systematic review evaluated studies assessing the relationship between psychotropic drug 
concentrations and clinical outcomes in children and adolescents, including antipsychotics, 
psychostimulants, alpha-agonists, antidepressants and mood-stabilizers. PRISMA guidelines 
were used and a quality assessment of the retrieved studies was performed. 67 eligible 
studies involving 24 psychotropic drugs were identified from 9,298 records. The findings were 
generally heterogeneous and the majority of all retrieved studies was not of sufficient quality. 
For 11 psychotropic drugs a relationship between drug concentrations and side-effects and/or 
effectiveness was evidenced in reasonably reported and executed studies, but these findings were 
barely replicated. 
Expert opinion
In order to better support routine TDM in child- and adolescent psychiatry, future work must 
improve in aspects of study design, execution and reporting to demonstrate drug concentration-
effect relationships. The quality criteria proposed in this work can guide future TDM research. 
Systematic review protocol and registration
PROSPERO CRD42018084159
I N T R O D U C T I O N 
Psychotropic drugs have been proven effective for the treatment of a wide range of psychiatric 
disorders in children and adolescents. As a result, the use of stimulants, antipsychotics, 
antidepressants and mood-stabilizers in youths is widespread. 1-3
However, the use of psychotropic drugs in youth faces several challenges. Some side effects of 
these drugs appear more prevalent in young patients, like metabolic and endocrine abnormalities 
associated with antipsychotic drug use. 4  This also applies to selective serotonin reuptake inhibitors 
(SSRIs), where children seem more vulnerable for restlessness and vomiting.5 At the same time, 
efficacy of some psychotropic drugs may be lower in children than in adults, as demonstrated for 
antidepressants.6
Although the mechanisms behind suboptimal treatment effects in youths are not fully understood, 
both pharmacokinetic and pharmacodynamic changes during childhood might contribute. 
Pharmacokinetic changes that occur during childhood7 may result in over- or underdosing in 
young patients, leading to unanticipated failures of randomized controlled drug trials in child- 
and adolescent psychiatry.8 Also pharmacodynamics might influence suboptimal psychotropic 
treatment effects in children and adolescents, as brain development and target receptor maturation 
are suggested to be related to the failure of many  antidepressants in youths.9 However, age-
specific pharmacokinetic and –dynamic aspects relevant for psychotropic drugs in children and 
adolescents are largely unknown.
Therapeutic Drug Monitoring (TDM), which comprises the quantification of drug concentrations 
in blood or other matrices to optimize individual drug dosing10, incorporates individual 
pharmacokinetic and pharmacodynamic processes. TDM has proven to enhance efficacy and 
safety of many psychotropic drugs in adults and has become routine practice for mood stabilizers 
like lithium, tricyclic antidepressants like amitriptyline, and antipsychotics like clozapine  in adult 
psychiatry10. TDM is especially indicated for patient populations with altering pharmacokinetics 
and pharmacodynamics, such as elderly, pregnant women, children and adolescents, where both 
efficacy and side-effects might be unpredictable.10, 11 As such, TDM may also provide a measure 
for proactive pharmacovigilance in children and adolescents. 12
However, TDM within child- and adolescent psychiatry is generally not routinely performed. A 
major reason is that the relationship between drug concentrations and effects in children and 
adolescents is not well known, and age- or developmental specific therapeutic reference ranges 
are lacking. 13, 14 The objective of this systematic review is to provide an overview of the literature 
investigating the relationship between blood concentrations of psychotropic drugs and clinical 
outcomes in children and adolescents, including stimulants, antipsychotics, antidepressants and 
mood-stabilizers and alpha-agonists, to further investigate the rationale for TDM in this population. 
Based on the findings, the current position of TDM within child- and adolescent psychiatry and 
future research directives are discussed.
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 a The concentration-effect relationships of psychotropic drugs in children and adolescents 
are largely unknown, which hampers the routine application of Therapeutic Drug 
Monitoring (TDM) in this population.
 a Our systematic literature search favors a concentration-effect relationship for 11 
psychotropic drugs in children and adolescents with different indications, but evidence is 
sparse and therapeutic reference ranges are generally not evaluated or reported.
 a Most retrieved studies did not accurately report or execute key aspects of TDM. 
 a Even when therapeutic reference ranges are not well-established, TDM can 
improve psychopharmacotherpay when non-compliance, drug-drug interactions or 
pharmacogenetic polymorphisms are suspected in children and adolescents.
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M E T H O D S 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
reporting guideline for systematic reviews.15 This systematic review is registered under PROSPERO 
number CRD42018084159. 
Information sources
Studies were identified by searching electronic databases and screening reference lists of 
relevant articles. Three databases were systematically searched without restriction of language 
or publication date (Embase.com, Medline Ovid and Cochrane CENTRAL). The last search was 
performed in November 2018. The search strategy can be found in supplementary table 1. 
Eligibility criteria and study selection
Studies reporting the relationship between psychotropic drug concentrations and clinical 
outcomes (i.e. efficacy or safety) in children or adolescents aged up to 18 years were eligible for 
inclusion. The included psychotropic drugs were antipsychotics, psychostimulants, alpha-agonists, 
antidepressants and mood-stabilizers including anti-epileptics used for psychiatric indications. The 
eligibility criteria are presented in table 1. 
Title abstract and full-text screen was independently performed by two reviewers (SK and DV); 
disagreements were resolved by consensus. References of identified studies were checked for 
relevant articles. Also, previous reviews and the international consensus guideline about TDM in 
psychiatry were checked for relevant studies.10, 13, 14
Table 1 In- and exclusion criteria for  selection of relevant articles
Inclusion criteria Exclusion criteria
The study concerns antipsychotics, psychostimulants, 
antidepressants or mood-stabilizers, alpha-agonists
No analysis on relationship between drug levels 
and clinically relevant outcome measures is 
reported
Study is performed in children or adolescents aged 
up to 18 years
Drug under study is used for non-psychiatric 
indications (f.e. epilepsy or enuresis) 
Drug plasma levels are measured and reported Maternal use during pregnancy or lactation
Direct clinical outcome measures are reported, i.e. 
safety or efficacy* 
Non-human subjects
Studies focusing on toxicology / overdoses
Case reports
Conference papers and abstracts
Post-mortem studies 
* biomarkers are not regarded a direct clinical outcome measure
Data collection process
One reviewer (SK) extracted the following data from included studies in a data extraction form: (1) 
characteristics of study participants (including sex, age and diagnoses), (2) study design (including 
duration and dosing strategy), (3) outcome measures, (4) blood sample collection (sampling time, 
relation to steady state) and (5) the results as presented in the study.  A second reviewer (KP) 
checked doubtful items identified by the first reviewer. Disagreements were resolved by discussion 
between reviewers. 
Quality assessment of therapeutic drug monitoring
To ascertain the internal validity of the selected studies, one reviewer (SK) performed a quality 
assessment of the therapeutic drug monitoring component of the selected studies. A second 
reviewer (KP) checked doubtful quality criteria that were identified by the first reviewer during the 
quality assessment. Disagreements were resolved by discussion between reviewers.
Currently available quality assessment tools do not specifically address drug concentration-effect 
studies 16, thus criteria for quality assessment were adapted from a previously published meta-
analysis of Ulrich et al. concerning the concentration-therapeutic effect relationship of haloperidol 
in adults.17 As the current systematic review covers different types of psychotropic drugs with a 
broad range of indications, not all criteria of the total score as used by Ulrich et al. were applicable. 
We therefore used only the hard items of the total score. These items are indicated “sufficient” or 
“insufficient” and presented in table 2. Studies that did not report or did not realize an item were 
rated insufficient. Premedication was registered as study characteristic and not scored. Furthermore, 
“completely insufficient description of study design” was not included as score item, as individual 
items were already rated insufficient when the information could not be found. 
Analytical method for the assay of drug concentration in serum or plasma
The analytical assay for drug quantification should be selective, able to discriminate the 
measured drug from other similar drugs and metabolites, and sensitive, accurately quantifying 
drug concentration.10 Accurate analytical methods have become available relatively recently.18 
Examples of selective and sensitive methods include chromatographic methods, including High 
Performance Liquid Chromatography (HPLC) and Liquid Chromatography-Mass Spectrometry 
(LC-MS). Older analytical methods like (radio) immunoassay often present high variability in 
drug quantification. Analytical methods for drug quantification must be validated to demonstrate 
reliability and reproducibility.  The quality assessment of the analytical method was checked per 
study by a laboratory based hospital pharmacist (BK). 
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Table 2 Criteria for quality assessment of the selected studies
Quality criteria Sufficient score Comments
1. Analytical method for the 
assay of drug concentration 
in serum or plasma
 a Validated analytical method 
2. Blood sample collection  a Steady state plasma or serum 
concentrations
 a Sampling time and drug intake 
described
3. Patient selection  a Representative sample for study 
outcome
 a Psychiatric classifications and 
associated classification system is 
reported
With a heterogeneous 
sample, a sub 
analysis per relevant 
category should be 
provided
4. Measurement of illness 
severity and registration of 
therapeutic improvement or 
worsening
 a Adequate quantification of outcome 
measure (rating with a structured 
scale)
 a A baseline assessment of the 
outcome measure is provided
 a Adequate calculation of change in 
outcome measure
 a Sufficient time to rate effect
Retrospectively scored 
change is rated 
insufficient
5. Comedication  a No drug that influences 
pharmacokinetics or 
pharmacodynamics of the drug 
under study is taken simultaneously, 
or:
 a A sub analysis/correction is 
provided
6. Number of patients  a At least 10 patients are included 
and used for analysis
Blood sample collection
Steady state is achieved when a drug is given in a constant dose and schedule for at least 4-6 
half-lives.10 During steady state, overall bioavailability is in equilibrium with elimination, such that 
the drug concentration reflects the dosage given. Sampling should therefore be performed during 
steady state of the drug and its metabolites. An exception is when population pharmacokinetic-
pharmacodynamic modelling is performed, which can correct for non-steady state concentrations. 
Furthermore, the concentration of a drug rises quickly after drug intake and declines afterwards 
as a function of time. An accurate assessment of the time interval between sampling relative to 
the drug intake is crucial for correct interpretation of the drug concentration. In clinical practice, 
sampling of the trough concentration is often the standard procedure. The trough concentration is 
the concentration at the end of a dosing interval, taken immediately before the subsequent dose. 
The concentration time curve in the final period of the dose interval is relatively flat, and therefore 
the exact sampling time is less critical. For normal release methylphenidate formulations, steady 
state sampling is not relevant due to its short half-life, and thus this item was not weighed in scoring. 
Patient selection
A representative sample is important for the generalizability of results (external validity). If a 
heterogeneous patient group is selected, and there is concern that different relationships exist 
between drug plasma concentrations and (side-) effects, sub-group analysis should be performed, 
bearing in mind that adequate power is achieved. Furthermore, psychiatric classifications within 
the sample and the associated classification system should be reported, as concentration reference 
ranges are disorder-specific.
Measurement of illness severity and registration of therapeutic improvement or worsening
For the analysis of the relationship between drug concentrations and effect, it is important to assess 
the effect that is likely to be attributable to the drug. Therefore, a baseline assessment of the severity 
of the outcome measure, prior to drug treatment, is essential. The change from baseline should 
be used for analyses rather than a point measurement during treatment. Preferably a validated 
rating scale should be used to determine outcome measures. Lastly, a sufficient time to rate effect 
should be considered. For example with antipsychotics, a delay of at least one week after start of 
treatment is expected to observe a clinical effect.17
Comedication 
Comedication can influence the effect of a drug trough pharmacokinetic and pharmacodynamic 
interactions. In particular, pharmacodynamic interactions might confound the observed clinical 
effects. Co-medication should be taken into account and corrected for when necessary, where 
possible trough strategies such as stratification or multivariate methods. 
Number of patients 
Power calculations are challenging in observational studies, and in the setting of observational 
studies in TDM. Ulrich et al 17, suggest a minimum of 10 patients, which was rated a sufficient 
number within our quality assessment.
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R E S U L T S
Study selection
Figure 1 shows the process by which articles were identified. Screening of title and abstract 
identified 311 primary studies. Full-text was not available for 43 of these. 
Sixty-seven studies were included after full-text screen, representing 24 psychotropic drugs: two 
stimulants, one alpha-agonist, six SSRI’s, five tricyclic antidepressants, one other antidepressant, 
seven antipsychotics and two mood stabilizers.
Of the selected studies, 35.8% evaluated efficacy measures, 32.8% evaluated side-effect 
measures and 31.3% evaluated both. A substantial proportion of studies was performed prior 
to 1995 (n=23, 34.3%).  Most studies were performed in the United States (n=42, 62.7%), and 
25.3% of studies was performed in Europe. 
Figure 1 Flowchart
Records identified through database 
searching Embase.com, Medline Ovid, 
Cochrane CENTRAL 
   
Additional records identified 
through cross reference 
checking 
 
Records after duplicates removed 
(n = 7722) 
Records screened 
(n =  7722) 
Records excluded 
(n =7411) 
Full-text articles assessed for 
eligibility 
(n =311) 
Full-text articles excluded: total 248 
 
- Study not performed in children or 
adolescents: 103 
- Relationship between drug levels and 
clinically relevant outcome measures  not 
assessed: 86 
- Medication not taken for psychiatric 
indication (epilepsy/migraine/apnea): 
13 
- Toxicology/overdoses: 1 

























Twenty-one studies met all 6 quality criteria (31.3%), while 47 studies did not meet quality criteria 
in full (one study described two trials, and fulfilled all criteria for one trial19). Five criteria were met 
in 25 studies (37.3%). 
The most frequently missed criterion was comedication and blood sample collection. Comedication 
was rated as insufficient in 25 studies (37.3%); it was unreported in 9 studies (13.4%) and was not 
addressed in analyses in 16 studies (22.4%). Blood sample collection was insufficient in 24 studies 
(35.8%), where either sampling in steady state was not performed, or time point of sampling 
relative to the drug intake was not described. Measurement of illness severity and registration of 
therapeutic improvement or worsening was rated as insufficient in 20 studies (29.9%), principally 
as baseline measurement was not performed. The analytical method was scored insufficient in 
10 studies (14.9%), the method was judged non-selective or non-sensitive in 3 studies, and the 
analytical method was not reported in 7 studies. 
The characteristics, results and quality assessment of the studies are presented in table 3.
The studies meeting all quality criteria involved 15 psychotropic drugs. A concentration-efficacy 
relationship was found for six drugs (citalopram20, fluoxetine20, nortriptyline21, buproprion22, 
quetiapine23, lithium24), a concentration-side-effects relationship was found for three 
(venlafaxine20, desipramine25, ziprasidone26), and a relationship with both efficacy and side-
effects for two (methylphenidate 19, 27-29, imipramine 30-32). The indications for use of these drugs 
included major depression, conduct disorder, bipolar disorder, attention-deficit disorder with or 
without hyperactivity and Tourette syndrome or chronic tic disorder (table 3). In 7 of the studies 
meeting all quality criteria, therapeutic reference ranges or concentrations for optimal treatment 
were reported 21-24, 29-31. 
The 47 studies that did not meet all quality criteria involved 20 psychotropic drugs, for which 
concentration-effect relationships were reported for 13. These concerned 8 additional drugs 
compared to the studies judged high-quality studies: one with a concentration-efficacy 
relationship (atomoxetine 33), six with a concentration-side-effect relationship (fluvoxamine 34, 
sertraline35, clomipramine36, haloperido37, olanzapine38, 39, risperidone39-43) and one with both 
(clozapine44-46). In 9 of the studies with lower quality, suggested therapeutic reference ranges or 
optimal concentrations were reported36, 37, 46-52. 
For 5 of the 24 psychotropic drugs that were retrieved with our search, no relationship between 
concentration and clinical outcomes was found in either high-quality studies or lower-quality 
studies (dexamphetamine, paroxetine, imipramine, loxapine, valproic acid). 
Overall, findings were highly heterogeneous. Most studies were not primarily designed to assess 
the relationship between drug concentrations and effects. Furthermore, most of the studies were 
not replicated and for most drugs and outcomes, only one study was available.
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C O N C L U S I O N S
This systematic review presents published evidence for the relationship between drug 
concentration and clinical outcomes of psychotropic drugs in children and adolescents. We 
found a minority of therapeutic drug monitoring studies were reasonably reported and executed. 
Among these, concentration-effect relationships were evidenced for methylphenidate, citalopram, 
fluoxetine, venlafaxine, desipramine, imipramine, nortriptyline, bupropion, quetiapine, 
ziprasidone and lithium, for various indications in children and adolescents. However, findings 
were often heterogeneous, barely replicated and therapeutic reference ranges were not often 
provided. Moreover, interpretation of data from retrieved studies was primarily complicated by 
inappropriately conducted or inadequately reported sampling.
E X P E R T  O P I N I O N 
Considering the relevance of a drug concentration-effect relationship in the clinical 
context 
Although for a wide range of psychotropic drugs some evidence was found for a concentration-
effect relationship, its relevance in clinical practice depends on several drug-related and clinical 
factors53, including the time-course of the observed effects.
For instance, the relationship between systemic methylphenidate concentrations and efficacy in 
children and adolescents with Attention Deficit Hyperactivity Disorder was frequently reported, 
but might be of questionable relevance. Among 160 children and adolescents across three 
reasonably reported and executed trials, a higher methylphenidate concentration was associated 
with improved performance, though different instruments were used across the studies 29, 54, 55. 
Most studies judged of lower quality reported similar findings, with one exception 56; however, 
the length of the follow-up period was unclear in this work, thus the relationship might have been 
underestimated. These findings suggest that this stimulant might be a candidate for TDM in children 
and adolescents, although routine application should be carefully considered 53. As improvement 
in attention is readily assessable by parents and teachers 57, it is questionable that concentration 
measurement would further inform clinical decision-making. 
TDM may be more informative for psychotropic drugs with delayed therapeutic or side-effects, 
such as antidepressants or antipsychotic drugs. TDM would ideally provide important information 
on adequacy of therapy in an early phase, thereby preventing sub-therapeutic treatment and long-
term side-effects. Given growing concerns about antipsychotic-induced metabolic abnormalities 
in children and adolescents 58, these drugs could be an important target for TDM. Unfortunately, 
no relationship was found in two studies evaluating the relationship between antipsychotic 
concentrations and metabolic outcomes such as weight, glucose and fatty acids in children 
and adolescents.59, 60 However, these studies did not perform baseline measurements and the 
relationship may be underestimated. Others report associations between higher dose and weight 
gain 61, 62, thus a relationship with systemic concentrations is suspected. 
Another aspect that should be considered when assessing the relevance of a drug concentration-
effect relationship, is the margin between effective and toxic drug concentrations. If this margin 
is very narrow, as for example for lithium, it is important to closely monitor drug concentrations 
to prevent intoxications. For this reason, routine TDM is recommended for lithium in children and 
adolescents.63 At the same time, for drugs with a very wide window, as generally applies to SSRIs, 
TDM is expected to be less useful in routine care, but may be useful to objectify non adherence. 
Furthermore, the drug concentrations after a given dosage should be difficult to predict. This is 
referred to as a high inter-individual pharmacokinetic variation, and means that drug concentrations 
differ largely between patients after administration of equal dosages. Another aspect that should 
be considered for the clinical application of TDM, is that a rapid and reliable method for analysis 
of the drug should be available. Lastly, before TDM is routinely applied, it should be demonstrated 
that TDM improves patient outcomes and is cost-effective in clinical practice. 
Research recommendations to support TDM in child- and adolescent psychiatry
A proven drug concentration-effect relationship is the first step to provide a rationale for TDM, but 
this was only sparsely evidenced for most psychotropic drugs in children and adolescents. In order 
to better demonstrate drug concentration-effect relationships in this field, future work must improve 
in aspects of study design, execution and reporting. Many studies failed to perform standardized 
sampling, including sampling with respect to steady state and administration time.  Therefore there 
is a need for an accepted tool for the appraisal of drug concentration-effect studies. 10, 16 The 
assessment criteria proposed by this report could serve as a starting point, hopefully reducing the 
heterogeneity observed to date, and permitting meta-analyses. 
Besides the need for more adequate sampling protocols, also study designs should be 
considered for their feasibility and appropriateness to demonstrate a drug concentration-effect 
relationship. Pharmacokinetic and –dynamic research in children with psychiatric morbidities 
is challenging and is liable to ethical constrains. As such, observational study designs may 
provide initial estimates towards defining reference ranges for this patient group. However, 
results should be interpreted in the light of their limitations. Flexible dosing schemes might lead 
to an underestimation of the concentration-effect relationship due to the placebo effect that is 
common for psychotropic drugs. Lower dosages, and thus lower drug concentrations, are likely 
used in placebo-responders, weakening association estimates.64 Furthermore, observational 
studies often permit dosage changes and comedication, thereby altering concentrations of the 
index drug and complicating analyses with respect to outcomes. In particular within child- and 
adolescent psychiatry, psychotropic comedication is very common and should be considered.65 
Also, non-pharmacological interventions such as behavioral interventions are commonly part of 
multimodal treatment, possibly influencing therapeutic outcomes.  Results of observational work 
can nevertheless be very valuable, especially when aspects of therapeutic drug monitoring are 
well-reported and well-executed. It may be argued that if dose effect relationships are apparent in 
the setting of observational study designs, the effect would be more pronounced in a randomized 
controlled trial that involves titration to concentrations associated with efficacy. 
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However, before TDM is routinely applied in clinical practice, preferably its effect on patient 
outcomes is evaluated. Ideally, to demonstrate that TDM can improve clinical outcomes, 
randomized controlled trials would be used to evaluate TDM as an intervention, comparing 
clinician directed dosing with dose adjustment based on drug monitoring, or comparing different 
target concentrations. 10 Relevant outcomes would include response, side-effects and cost-
effectiveness. An excellent example of such a trial investigating effects and side-effects is the 
randomization to one of three target concentrations for clozapine in adults 66, however no such 
RCTs have been performed for psychotropic drugs in children and adolescents. This is partly due 
to difficulties in performing such trials within child- and adolescent psychiatry. 67 However, in 
general, such RCTs are very rare in the field of TDM and are therefore not always required before 
its implementation in clinical practice.
Current position of TDM within child- and adolescent psychiatry
Almost no studies reported therapeutic reference ranges for psychotropic drugs in children 
and adolescents. Unfortunately, ranges cannot be simply extrapolated from adults, as both 
pharmacokinetic and pharmacodynamic processes differ considerably. This is the result of 
developmental changes in body composition, target receptor maturation and organ ripening7, 
generally leading to lower psychotropic drug concentrations in children and adolescents than 
recommended therapeutic reference ranges in adults. 12 Also, psychotropic drugs may be used 
for other indications in children and adolescents than in adults, and in other dosages, such as 
antipsychotic drugs (behavioral problems versus psychosis). 
The absence of established reference ranges prevents routine application of TDM on a population 
level. An exception applies to lithium, for which routine TDM is recommended based on a known 
narrow therapeutic range in adults, which is also applied in children and adolescents.63 Within our 
systematic review, one well-documented and executed study found a drug concentration-effect 
relationship in pediatric patients with bipolar I disorder24, but studies that systematically investigate 
the added value and optimal concentrations of lithium in clinical practice are lacking. For other 
psychotropic drugs, despite the unavailability of clear-cut concentration effect-relationships, TDM 
can be of added value on an individual level when non-compliance is suspected or, drug-drug 
interactions or pharmacogenetic polymorphisms, for example in cytochrome 2D6, are foreseen in 
children and adolescents using psychotropic drugs. A drug concentration measurement can identify 
unexpected concentrations, as for many antipsychotic drugs expected concentrations based on 
a given dosage in steady state are known. 68 These are called pharmacokinetic reference ranges 
and can optimize antipsychotic pharmacotherapy by guiding dose- or comedication adjustments. 
In this way, TDM can prevent over- or underdosing, and improve psychotropic pharmacological 
treatment in children and adolescents. As long-term safety data of psychotropic drugs in this 
population are generally lacking and these drugs are frequently prescribed off-label, TDM can 
provide an important tool to improve psychopharmacotherapy in children and adolescents. 
L I M I T A T I O N S 
The results of this systematic review should be interpreted in the light of its limitations. Firstly, 
among quality assessment criteria, unreported elements were judged insufficient. However, older 
work might be have reported data on methodological aspects more concisely, thus might have 
been assessed too strictly. As such, five studies were rated insufficient for the item comedication. 
Secondly, a substantial number of articles was not available full text, primarily reflecting older 
work. However, based on title and abstract screen, these are not expected to have influenced our 
conclusions. Thirdly, the older publications also concerned drugs that are currently not widely used 
in children and adolescents anymore, such as tricyclic antidepressants. Fourthly,, publication bias 
is a possibility that due to heterogeneity we were unable to evaluate, and this may have bias our 
findings toward positive results. Lastly, the scope of the current review was very broad and aimed 
at providing an overview of the current literature, which limits a more profound discussion of the 
individual drugs. 
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S U P P L E M E N T A R Y  D A T A
Supplementary table 1 search strategy
embase.com
(‘drug monitoring ‘/de OR ‘drug blood level’/mj/de OR ‘pharmacokinetics’/mj/de OR ‘pharmacodynamics’/
mj/de OR ‘anticonvulsive agent’/mj/de OR ‘mood stabilizer’/mj/de OR ((therapeut* NEAR/3 (drug) NEAR/3 
monitor*)):ab,ti OR (((antidepress* OR anti-depress* OR anticonvulsi* OR anti-convulsi* OR antiepileptic* OR anti-
epileptic* OR neuroleptic*  OR antipsychot* OR anti-psychot* OR ‘mood stabilizer*’ OR stimulant* OR psychostimulant* 
OR psychotropic* OR Hydroxyzin* OR Buspiron* OR melatonin  OR ramelteon  OR desipramin*  OR imipramin* OR 
clomipramin*  OR trimipramin*  OR amitriptylin*  OR nortriptylin*  OR doxepin  OR fluoxetin*  OR citalopram  OR 
paroxetin*  OR sertralin*  OR fluvoxamin*  OR escitalopram OR moclobemide  OR mianserin  OR trazodon*  OR 
mirtazapin*  OR bupropion  OR venlafaxin*  OR duloxetin*  OR dexamfetamin*  OR methylphenidate*  OR modafinil  
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promazin*  OR fluphenazin*  OR perphenazin*  OR haloperidol  OR melperon*  OR pipamperon*  OR sertindole  OR 
ziprasidon*  OR lurasidon*  OR flupentixol  OR chlorprothixene  OR zuclopenthixol  OR pimozide  OR penfluridol  OR 
clozapin*  OR olanzapin*  OR quetiapin*  OR sulpiride  OR tiapride  OR amisulpride  OR lithium  OR risperidon*  OR 
aripiprazole  OR paliperidon*  OR clonidin*  OR valproic-acid OR carbamazepin* OR lamotrigin* OR oxcarbazepin* 
OR topiramate* ) AND (blood OR plasma* OR serum) NEAR/6  (level* OR concentrat*)) OR ((antidepress* OR anti-
depress* OR neuroleptic*  OR anticonvulsi* OR anti-convulsi* OR antiepileptic* OR anti-epileptic* OR antipsychot* 
OR anti-psychot* OR ‘mood stabilizer*’ OR stimulant* OR psychostimulant* OR psychotropic* OR Hydroxyzin* OR 
Buspiron* OR melatonin  OR ramelteon  OR desipramin*  OR imipramin* OR clomipramin*  OR trimipramin*  OR 
amitriptylin*  OR nortriptylin*  OR doxepin  OR fluoxetin*  OR citalopram  OR paroxetin*  OR sertralin*  OR fluvoxamin*  
OR escitalopram OR moclobemide  OR mianserin  OR trazodon*  OR mirtazapin*  OR bupropion  OR venlafaxin*  OR 
duloxetin*  OR dexamfetamin*  OR methylphenidate*  OR modafinil  OR atomoxetin*  OR dexmethylphenidate*  OR 
lisdexamfetamin*  OR chlorpromazin*  OR levomepromazin*  OR promazin*  OR fluphenazin*  OR perphenazin*  
OR haloperidol  OR melperon*  OR pipamperon*  OR sertindole  OR ziprasidon*  OR lurasidon*  OR flupentixol  OR 
chlorprothixene  OR zuclopenthixol  OR pimozide  OR penfluridol  OR clozapin*  OR olanzapin*  OR quetiapin*  OR 
sulpiride  OR tiapride  OR amisulpride  OR lithium  OR risperidon*  OR aripiprazole  OR paliperidon*  OR clonidin*  OR 
valproic-acid OR carbamazepin* OR lamotrigin* OR oxcarbazepin* OR topiramate*) AND  (pharmacokinetic* OR 
pharmacodynamic*))):ab,ti)  AND (‘antidepressant agent’/exp OR ‘neuroleptic agent’/exp OR ‘central stimulant agent’/
exp OR ‘psychostimulant agent’/exp OR ‘psychotropic agent’/de OR ‘child psychiatry’/exp OR Psychopharmacology/
de OR (antidepress* OR anti-depress* OR neuroleptic*  OR antipsychot* OR anti-psychot* OR stimulant* OR 
psychostimulant* OR psychotropic* OR (stimulat* NEAR/3 (agent* OR drug*)) OR ((child* OR youth OR adolescen* 
OR pediatr* OR paediatr*  ) NEAR/3 (psychiatr*)) OR Psychopharmacol*):ab,ti)  AND (child/exp OR adolescent/
exp OR adolescence/exp OR pediatrics/exp OR childhood/exp OR ‘child development’/de OR ‘child growth’/de OR 
‘child health’/de OR ‘child health care’/exp OR ‘child care’/exp OR ‘childhood disease’/exp OR ‘pediatric ward’/de 
OR ‘pediatric hospital’/de OR ‘child psychiatry’/exp OR (adolescen* OR infan* OR newborn* OR (new NEXT/1 born*) 
OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR minors OR 
underag* OR (under NEXT/1 (age* OR aging)) OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR 
prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* OR preschool* OR highschool*):ab,ti)  NOT 
([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim) AND [english]/lim 
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(Drug Monitoring/ OR *pharmacokinetics/ OR *Anticonvulsants/ OR ((therapeut* ADJ3 (drug) ADJ3 monitor*)).
ab,ti. OR (((antidepress* OR anti-depress* OR anticonvulsi* OR anti-convulsi* OR antiepileptic* OR anti-epileptic* 
OR neuroleptic*  OR antipsychot* OR anti-psychot* OR mood stabilizer* OR stimulant* OR psychostimulant* OR 
psychotropic* OR Hydroxyzin* OR Buspiron* OR melatonin  OR ramelteon  OR desipramin*  OR imipramin* OR 
clomipramin*  OR trimipramin*  OR amitriptylin*  OR nortriptylin*  OR doxepin  OR fluoxetin*  OR citalopram  OR 
paroxetin*  OR sertralin*  OR fluvoxamin*  OR escitalopram OR moclobemide  OR mianserin  OR trazodon*  OR 
mirtazapin*  OR bupropion  OR venlafaxin*  OR duloxetin*  OR dexamfetamin*  OR methylphenidate*  OR modafinil  
OR atomoxetin*  OR dexmethylphenidate*  OR lisdexamfetamin*  OR chlorpromazin*  OR levomepromazin*  OR 
promazin*  OR fluphenazin*  OR perphenazin*  OR haloperidol  OR melperon*  OR pipamperon*  OR sertindole  OR 
ziprasidon*  OR lurasidon*  OR flupentixol  OR chlorprothixene  OR zuclopenthixol  OR pimozide  OR penfluridol  OR 
clozapin*  OR olanzapin*  OR quetiapin*  OR sulpiride  OR tiapride  OR amisulpride  OR lithium  OR risperidon*  OR 
aripiprazole  OR paliperidon*  OR clonidin*  OR valproic-acid OR carbamazepin* OR lamotrigin* OR oxcarbazepin* 
OR topiramate* ) AND (blood OR plasma* OR serum) ADJ6  (level* OR concentrat*)) OR ((antidepress* OR anti-
depress* OR neuroleptic*  OR anticonvulsi* OR anti-convulsi* OR antiepileptic* OR anti-epileptic* OR antipsychot* OR 
anti-psychot* OR mood stabilizer* OR stimulant* OR psychostimulant* OR psychotropic* OR Hydroxyzin* OR Buspiron* 
OR melatonin  OR ramelteon  OR desipramin*  OR imipramin* OR clomipramin*  OR trimipramin*  OR amitriptylin*  OR 
nortriptylin*  OR doxepin  OR fluoxetin*  OR citalopram  OR paroxetin*  OR sertralin*  OR fluvoxamin*  OR escitalopram 
OR moclobemide  OR mianserin  OR trazodon*  OR mirtazapin*  OR bupropion  OR venlafaxin*  OR duloxetin*  OR 
dexamfetamin*  OR methylphenidate*  OR modafinil  OR atomoxetin*  OR dexmethylphenidate*  OR lisdexamfetamin*  
OR chlorpromazin*  OR levomepromazin*  OR promazin*  OR fluphenazin*  OR perphenazin*  OR haloperidol  OR 
melperon*  OR pipamperon*  OR sertindole  OR ziprasidon*  OR lurasidon*  OR flupentixol  OR chlorprothixene  OR 
zuclopenthixol  OR pimozide  OR penfluridol  OR clozapin*  OR olanzapin*  OR quetiapin*  OR sulpiride  OR tiapride  
OR amisulpride  OR lithium  OR risperidon*  OR aripiprazole  OR paliperidon*  OR clonidin*  OR valproic-acid OR 
carbamazepin* OR lamotrigin* OR oxcarbazepin* OR topiramate*) AND  (pharmacokinetic* OR pharmacodynamic*))).
ab,ti.)  AND (exp Antidepressive Agents/ OR exp Antipsychotic Agents/ OR exp Psychotropic Drugs/ OR child 
psychiatry/ OR Psychopharmacology/ OR (antidepress* OR anti-depress* OR neuroleptic*  OR antipsychot* OR anti-
psychot* OR stimulant* OR psychostimulant* OR psychotropic* OR (stimulat* ADJ3 (agent* OR drug*)) OR ((child* OR 
youth OR adolescen* OR pediatr* OR paediatr*  ) ADJ3 (psychiatr*)) OR Psychopharmacol*).ab,ti.)  AND (exp Child/ 
OR exp Infant/ OR exp Adolescent/ OR exp “Pediatrics”/ OR “Hospitals, Pediatric”/ OR (adolescen* OR infan* OR 
newborn* OR (new ADJ born*) OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR 
boy* OR girl* OR minors OR underag* OR (under ADJ (age* OR aging)) OR juvenil* OR youth* OR kindergar* OR 
puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* OR preschool* OR 
highschool*).ab,ti.)  NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt. AND english.la. 
Cochrane CENTRAL
(((therapeut* NEAR/3 (drug) NEAR/3 monitor*)):ab,ti OR (((antidepress* OR anti-depress* OR anticonvulsi* OR anti-
convulsi* OR antiepileptic* OR anti-epileptic* OR neuroleptic* OR antipsychot* OR anti-psychot* OR ‘mood stabilizer*’ 
OR stimulant* OR psychostimulant* OR psychotropic* OR Hydroxyzin* OR Buspiron* OR melatonin OR ramelteon 
OR desipramin* OR imipramin* OR clomipramin* OR trimipramin* OR amitriptylin* OR nortriptylin* OR doxepin OR 
fluoxetin* OR citalopram OR paroxetin* OR sertralin* OR fluvoxamin* OR escitalopram OR moclobemide OR mianserin 
OR trazodon* OR mirtazapin* OR bupropion OR venlafaxin* OR duloxetin* OR dexamfetamin* OR methylphenidate* 
OR modafinil OR atomoxetin* OR dexmethylphenidate* OR lisdexamfetamin* OR chlorpromazin* OR levomepromazin* 
OR promazin* OR fluphenazin* OR perphenazin* OR haloperidol OR melperon* OR pipamperon* OR sertindole 
OR ziprasidon* OR lurasidon* OR flupentixol OR chlorprothixene OR zuclopenthixol OR pimozide OR penfluridol 
OR clozapin* OR olanzapin* OR quetiapin* OR sulpiride OR tiapride OR amisulpride OR lithium OR risperidon* OR 
aripiprazole OR paliperidon* OR clonidin* OR valproic-acid OR carbamazepin* OR lamotrigin* OR oxcarbazepin* OR 
topiramate*) AND (blood OR plasma* OR serum) NEAR/6 (level* OR concentrat*)) OR ((antidepress* OR anti-depress* 
OR neuroleptic* OR anticonvulsi* OR anti-convulsi* OR antiepileptic* OR anti-epileptic* OR antipsychot* OR anti-
psychot* OR ‘mood stabilizer*’ OR stimulant* OR psychostimulant* OR psychotropic* OR Hydroxyzin* OR Buspiron* 
OR melatonin OR ramelteon OR desipramin* OR imipramin* OR clomipramin* OR trimipramin* OR amitriptylin* OR 
nortriptylin* OR doxepin OR fluoxetin* OR citalopram OR paroxetin* OR sertralin* OR fluvoxamin* OR escitalopram 
OR moclobemide OR mianserin OR trazodon* OR mirtazapin* OR bupropion OR venlafaxin* OR duloxetin* OR 
dexamfetamin* OR methylphenidate* OR modafinil OR atomoxetin* OR dexmethylphenidate* OR lisdexamfetamin* OR 
chlorpromazin* OR levomepromazin* OR promazin* OR fluphenazin* OR perphenazin* OR haloperidol OR melperon* 
OR pipamperon* OR sertindole OR ziprasidon* OR lurasidon* OR flupentixol OR chlorprothixene OR zuclopenthixol OR 
pimozide OR penfluridol OR clozapin* OR olanzapin* OR quetiapin* OR sulpiride OR tiapride OR amisulpride OR lithium 
OR risperidon* OR aripiprazole OR paliperidon* OR clonidin* OR valproic-acid OR carbamazepin* OR lamotrigin* 
OR oxcarbazepin* OR topiramate*) AND (pharmacokinetic* OR pharmacodynamic*))):ab,ti) AND ((antidepress* OR 
anti-depress* OR neuroleptic* OR antipsychot* OR anti-psychot* OR stimulant* OR psychostimulant* OR psychotropic* 
OR (stimulat* NEAR/3 (agent* OR drug*)) OR ((child* OR youth OR adolescen* OR pediatr* OR paediatr*) NEAR/3 
(psychiatr*)) OR Psychopharmacol*):ab,ti) AND ((adolescen* OR infan* OR newborn* OR (new NEXT/1 born*) 
OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR minors OR 
underag* OR (under NEXT/1 (age* OR aging)) OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR 
prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* OR preschool* OR highschool*):ab,ti) 
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A B S T R A C T 
Background 
Pipamperone is a frequently prescribed antipsychotic drug in children and adolescents in the 
Netherlands, Belgium and Germany. However, pediatric pharmacokinetics and the relationship 
with side-effects and efficacy are unknown. Currently divergent pediatric dosing recommendations 
exist. 
Objectives 
To describe the population pharmacokinetics of pipamperone in children and adolescents; to 
correlate measured and predicted pipamperone trough concentrations and predicted 24h area 
under the curves with effectiveness, extrapyramidal symptoms and sedation; to propose dose 
recommendations based on simulations. 
Methods 
Pipamperone concentrations were collected from Dutch pediatric patients in a prospective 
naturalistic trial (n=8), and German pediatric patients in a therapeutic drug monitoring (TDM) 
service (n=22). A total of 70 pipamperone concentrations were used to develop a population 
pharmacokinetic model with non-linear mixed-effects modeling (NONMEM®). Additionally, an 
additional random sample of 21 German patients with 33 pipamperone concentrations from the 
same TDM service was used for external validation. Pharmacokinetic parameters were related 
to clinical improvement, sedation, and extrapyramidal symptoms. Simulations were performed to 
determine optimal dosages. 
Results
 In a one-compartment model the apparent volume of distribution was 416 L/70kg and the 
apparent clearance was 22.1 L/h/70 kg. Allometric scaling was used to correct for differences 
in bodyweight. The model was successfully externally validated. The median [25th-75th 
percentile] measured pipamperone trough concentrations were numerically higher in responders 
(98.0 µg/L [56.0-180.5]) than in non-responders (58.0 µg/L [14.9-105.5]), although non-
significant (p=0.14). A twice daily 0.6 mg/kg dosage was better than a fixed dosage to attain the 
concentration range observed in responders.
Conclusion 
Our findings suggest that pipamperone therapeutic reference ranges may be lower for children 
with behavioral problems than recommended for adults with psychotic symptoms (100-400 
µg/L). When dosing pipamperone in children and adolescents, bodyweight should be taken into 
account. 
I N T R O D U C T I O N
Pipamperone is one of the most frequently prescribed antipsychotic to children and adolescents 
in the Netherlands, Germany and Belgium.1-3 Between 2005 and 2015, 18% of all antipsychotics 
prescribed to children and adolescents in the Netherlands concerned pipamperone, with similar 
but slightly lower prescription rates in Germany and Belgium.1-3 These prescription rates have been 
fairly constant for the past decades. 
Pipamperone, being introduced in 1961 as Dipiperon® by Janssen Pharmaceutica, is considered 
a low-potency antipsychotic due to the relatively low affinity for the D2 receptor. The antagonism 
of the serotonin 5-HT2 and  adrenergic alpha1 receptor is more pronounced 4, which explains its 
sedative effect, which is partly the result of relative hypoperfusion in the brain.5, 6 For this reason, 
pipamperone has not only been explored for its antipsychotic properties 7, but also as a hypnotic 
in patients with sleep disorders, showing good efficacy.8 
However, in children and adolescents pipamperone is particularly prescribed for behavioral 
problems, like other antipsychotics in this population.2, 9, 10 Severe behavioral problems in youths 
represent the main symptoms of conduct disorder, or may occur within other psychiatric disorders 
such as autism spectrum disorder, attention-deficit/hyperactivity disorder, or mental retardation. 
Pipamperone may be a preferred antipsychotic for these indications, mainly because of the 
calming effects and the availability of oral liquid dosage formulation, enabling flexible dosing.11, 
12 However, despite the extensive practical experience in children and adolescents, the evidence 
for efficacy of pipamperone is very limited. Although two small open label studies from the 1970s 
showed positive results for the treatment of behavioral problems in children and adolescents, 
randomized controlled trials are lacking.13, 14 For this reason, prescribing pipamperone to youths is 
currently considered off-label or restricted to use with particular consideration of the benefit-risk 
ratio, depending on the country.15, 16 Indications for use as mentioned in the summary of product 
characteristics within the Netherlands, Germany and Belgium include psychomotor agitation and 
behavioral problems, with as major clinical contra-indication depression of the central nervous 
system.4, 15, 17 
Side-effects of pipamperone mainly concern sedation and extrapyramidal symptoms.4, 18 Prolactin 
elevation has also been reported, and is associated with galactorrhea and amenorrhea.4 Although 
weight gain and metabolic changes have become the major concern for atypical antipsychotic 
use in children and adolescents19, these side-effects have not been described in literature for 
pipamperone. However, as antipsychotic-induced weight gain is believed to be partly attributed 
to the serotonin system20, the 5-HT2 antagonism of pipamperone is likely to induce weight gain 
as well. 
While data on efficacy and side-effects are scarce, publicly available pharmacokinetic data of 
pipamperone in children and adolescents are completely missing. In adults some pharmacokinetic 
studies have been performed, showing a maximum plasma concentration after 1-2 hours 
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and an elimination half-life of 12-30 hours.4, 21, 22 However, in children and adolescents both 
pharmacokinetics and pharmacodynamics are expected to be considerably different, as some 
consensus based-dosing guidelines advise to lower the starting dose in this population by 95% 
compared to recommended doses in adults, resulting in 2 mg instead of 40 mg.16 
The aim of this study was to describe the population pharmacokinetics of pipamperone in children 
and adolescents. Furthermore, the relationships of pharmacokinetic parameters of pipamperone 
with both clinical improvement and side-effects, including sedation and extrapyramidal symptoms 
in children and adolescents were explored. These data will provide a more solid basis for 
pipamperone dose recommendations in this vulnerable patient population.
M E T H O D S
Study population
The study population consisted of two samples. The first sample included children and adolescents 
who were prospectively enrolled in a Dutch multicenter observational trial (SPACe, NTR6050). 
Inclusion criteria were: age 6 to 18 years, documented clinical diagnosis of autism spectrum 
disorder according to DSM 423 or DSM 524 and comorbid behavioral problems and treatment 
with pipamperone. Exclusion criteria were: diabetes type I or II, congenital or acquired syndrome 
associated with changes in appetite, body weight or lipid profile (e.g. Prader Willi), treatment with 
another antipsychotic within the last 6 months or known Long QT syndrome. Eligible patients were 
treated in an inpatient or outpatient setting in one of the 7 participating centers in the south-west 
region of the Netherlands (2 academic tertiary care centers and 5 psychiatric secondary care 
centers). Subjects were prescribed flexible pipamperone dosages once or twice daily, as part of 
routine clinical care and prescribed by the treating physician. Pipamperone was prescribed as 
tablet formulation or oral solution. Patients were recruited between August 2016 and May 2018. 
All patients and/or their legal representatives gave written informed consent before entering the 
study. The study was approved by the medical ethics committee of the Erasmus Medical Centre, 
the Netherlands (number MEC 2016-124). 
The second sample consisted of children and adolescents of whom pipamperone concentrations 
had been measured as part of the routine Therapeutic Drug Monitoring (TDM) service of the 
department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the 
University Hospital of Wuerzburg, Germany. Subjects were treated at this clinic or at associated 
clinics for child and adolescent psychiatry within the competence network of TDM in child and 
adolescent psychiatry, which is described elsewhere.25 Patients were prescribed flexible dosages 
of pipamperone as tablets or oral solution, being administered one up to five times daily. The 
pipamperone samples were collected between June 2008 and February 2015 in patients with 
various psychiatric diagnoses. The medical ethics committee of the University of Wuerzburg 
approved the study (study number 27/04) and waived informed consent, as drug concentrations 
were measured as part of routine care. 
Both studies were conducted in accordance with the Declaration of Helsinki.
Pipamperone concentrations
In the Dutch trial, a total of 6 pipamperone drug concentrations per subject were collected at 
random time points on 2 separate days during a 6 month follow-up with 3 to 6 months in between 
sampling. The time between 2 samples was at least 1 hour. Samples were collected with venipuncture 
and the Dried Blood Spot (DBS) method. The time of sampling, time of last pipamperone intake, 
the pipamperone dosages and comedication during follow-up were recorded. Both samples in 
steady state and in non-steady state were collected. The Dutch samples were analyzed using 
previously validated ultra-high performance liquid chromatography-mass spectrometry (LC-MS) 
methods for plasma and DBS.26-28 The lower limit of quantification was 1.5 µg/L. The accuracy of 
the quality-control samples was well below a limit of relative standard deviation of 15% and the 
intra- and inter-assay imprecision was less than 15% during the study period. 
Within the German TDM service, samples were collected with venipuncture in the morning before 
the first pipamperone dosage of that day (trough concentrations)21 The pipamperone dosage 
and administration time (morning, midday, evening or night) was reported on the request form. 
Only concentrations measured in steady state were included for analyses, as for non-steady state 
samples previous dosages were not known. The German samples were analyzed with a validated 
serum high-performance liquid chromatography-ultraviolet method (HPLC-UV) for plasma. The 
lower limit of quantification was 8 µg/L. The method was linear in a range of 2 µg/L – 1050 µg/L 
(r2 = 0.99952). Concentrations below the LLOQ were excluded, as for these no quantification of 
the plasma concentration was provided.
Assessment of clinical outcomes
In the Dutch trial, measures of clinical effectiveness and side-effects were collected at baseline 
and prospectively during the 6 month follow-up (at 6 months and for a subset of patients at 1 and 
3 months). Clinical effectiveness was measured by the Clinical Global Impression Scale (CGI).29 
This scale describes the severity of psychopathology (CGI-S) and its improvement (CGI-I) by 7 
categories, rated by the treating physician. The CGI-S describes the severity of illness relative to 
the physicians experience with patients with the same diagnosis: 0 = not assessable; 1 = normal; 2 
= borderline; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = extremely ill. The 
CGI-I rates the improvement in comparison to the original medication-naive state of symptoms: 0 
= not assessable, 1 = very much better, 2 = much better, 3 = moderately better, 4 = unchanged, 5 
= minimally worse, 6 = much worse. Extrapyramidal symptoms were measured with the Abnormal 
Involuntary Movement Scale (filled in by treating physician or researcher)29 and sleepiness with 
the Epworth Sleepiness Scale (filled in by parents).30 Biochemical laboratory check-ups were 
performed at baseline, after 6 months and for a subset of children at 3 months, and included 
renal function, liver function, fasting glucose, HbA1c, prolactin, cholesterol, fatty acids and 
albumin. During follow-up, medication adherence was measured with questionnaires (Medication 
Adherence Rating Scale MARS-531, filled in by parents, and a visual analog scale, filled in by 
parents and treating physician) and during the last month of follow-up with an electronical 
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monitoring system (MEMS©).32 Weight and height was measured at baseline, at time of blood 
sampling and for a subset of children after 1 month of follow-up. 
At the German TDM service, the following information was reported at the request form at time of 
sampling: renal dysfunction, hepatic dysfunction, smoking status, current infection, comedication, 
CGI-S, CGI-I and side-effects with the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale 
(UKU-scale).33 The UKU scale rates the severity of the side-effects with the following categories: 0 
= no side effects; 1 =mild, 2 = moderate and 3 = severe side effects. The nature of the side-effects 
was also recorded and classified as follows: sedation, dermatological, tension, salivation (more/
less), accommodation disorder, polydipsia, delirium, extrapyramidal symptoms, cardiovascular, 
gastrointestinal, urogenital, other. 
Population pharmacokinetic modelling 
Pharmacokinetic analysis was performed by non-linear mixed-effects modelling using NONMEM® 
version 7.4.2 (FOCE+I; ICON Development Solutions, Ellicott City, MD, USA) and PsN® Version 
4.7.0. Pirana® software version 2.9.7 was used as an interface between NONMEM® and R 
(version 3.4.4). 
Base model development
One and two compartment models were considered with first order absorption with and without 
lagtime. Typical values for volume of distribution (V) and clearance (CL) were estimated as 
ratios, as bioavailability could not be quantified (V/F and CL/F). As the absorption rate constant 
(ka) could not be estimated, ka was fixed at 2 h-1, based on previous literature.21 For each 
pharmacokinetic parameter inter-patient variability (IPV) was evaluated and shrinkage was 
calculated for all parameters for which IPV was established. A shrinkage value below 25% was 
considered acceptable.34 Allometric scaling was used to account for the influence of bodyweight 
on pharmacokinetic parameters, which was explored with a fixed exponent 0.75 for CL/F and 
1 for V/F, and with exponents estimated by the model. Residual variability was modelled as 
a separated additive and proportional error for the analytical method (LC-MS versus HPLC-
UV) and sampling method (DBS versus venepuncture). Model selection was based on minimum 
objective function values (OFVs), parameter precision, error estimates, shrinkage values, and 
visual inspection of the goodness-of-fit plots.
Covariate model development
The following covariates were considered as potential model covariates: sex, age, body mass 
index (BMI), weight, comedication, psychiatric disorder, somatic comorbidities, smoking, renal 
function, liver function, pipamperone dose and dose/kg. For the Dutch patients, also albumin, 
hematocrit and medication adherence were known and evaluated as covariates. The correlation 
between the covariates and IPV was first evaluated graphically. Subsequently, covariates with 
a visual relationship with IPV were individually added to the model. Continual covariates were 
described using an exponential function and categorical covariates using a proportional function. 
The forward inclusion-backward elimination method was used.35 Covariates that significantly 
improved the model with the univariate analysis (p<0.05), were selected for multivariate analysis. 
During the backward elimination process, covariates that improved the model at a level of p<0.001 
were selected. 
Internal model evaluation 
Two methods were used for the internal validation of the model. Firstly, a bootstrap analysis 
was performed.36 One thousand bootstrap datasets were randomly resampled from the original 
dataset with replacement. The validity of the model was evaluated by comparing the bootstrap 
estimates and their 95% confidence intervals with the values generated by the original dataset. 
Secondly, the model was evaluated with the visual predictive check (VPC), using a set of 1000 
simulated datasets to compare the observed concentrations with the distribution of the simulated 
concentrations.37 
External model evaluation 
An additional dataset of another group of  German patients from the same TDM service was 
used for external validation of the final model. Goodness-of-fit plots and a normalized prediction 
distribution errors (NPDE) analysis (n=1000) were used to evaluate the external validity.38 
Pharmacodynamic analyses
The medians with 25th-75th percentiles of measured trough concentrations were correlated to 
CGI-I, extrapyramidal symptoms (EPS) and sedation. As trough pipamperone concentrations 
were not available for all Dutch patients, individual trough concentrations were also predicted 
for all patients, next to 24 hour areas under the concentration-time curve (AUCs24h). These 
pharmacokinetic parameters were also correlated to CGI-I, EPS and sedation. A subject 
was considered a responder when the CGI-I was rated “very much better”, “much better” or 
“moderately better”, and a non-responder when another score was given (except from “not 
assessable”). EPS were scored positive when at least two times “mild” or one time “moderate” 
in the first seven items had been filled in on the AIMS (Dutch patients), or when “EPS” was filled 
in as a side-effect on the application form (German patients). Sedation was considered as a 
score ≥1 on the Epworth Sleepiness Scale (Dutch patients) or as “sedation” being filled in as 
side-effect on the application form (German patients). The pipamperone trough concentration, 
predicted trough concentration and predicted AUC24h at the time of first response or side-
effect (EPS and sedation) was used for the analyses. In this analysis efficacy was accepted as an 
endpoint regardless of the time interval since initiation of treatment (but within the study period). 
If no response or side-effect was observed, the highest concentration during follow-up was used. 
Laboratory findings were compared with age- (and if applicable sex-) specific reference values 
as being used in the Erasmus MC Rotterdam in July 2019.39 The Mann-Whitney U test was used to 
compare trough concentrations and AUC24h between groups. The Fisher’s Exact test was used to 
compare proportions. A p-value <0.05 was considered significant. Graphpad Prism 5 (GraphPad 
Software, La Jolla California USA) was used for the analyses. 
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Predictions 
Pipamperone concentrations using a twice daily 30 mg dosing regimen were predicted for a patient 
of 25, 50 and 75 kg during a 12 hour time interval. After graphical inspection, a mg/kg dosage 
was chosen for optimal attainment of the concentration range that was found to be associated 
with response based on pharmacodynamic analyses. This mg/kg dosage was evaluated with 
additional predictions for a patient of 25, 50 and 75 kg. The population predictions were used as 
mean with a 95% confidence interval based on 1000 simulations of individual predictions. 
R E S U L T S 
Thirty patients with 70 measured pipamperone concentrations were included in the model building 
group (Dutch patients n=8 and German patients n=22). Two German samples were below the 
LLOQ and were not included. The pipamperone concentrations were collected in the entire 
absorption and elimination phase, as can be seen in figure 1. Subsequently, 21 extra patients 
with 33 measured pipamperone concentrations were included in the external validation group 
(German patients). The baseline characteristics of the included patients are presented in table 
1. Most patients were diagnosed with autism spectrum disorder, attention deficit/hyperactivity 
disorder or mental retardation. The median (range) measured pipamperone concentration 
was 66.5 µg/L (0.21-1068) in the model building group and 88 µg/L (16-337) in the model 
validation group. 
In the model building group, n=1 sample was below the LLOQ (Dutch sample). In the model 
validation group, no samples below the LLOQ were included. 
Indications for a pipamperone concentration measurement in the German TDM service were known 
for n=60 samples (90.9 % of total n=66 German samples). Most pipamperone concentrations 
were measured because of non-effectiveness (n=16, 26.7%) or dosage change (n=16, 26.7%). 
Other indications included drug-drug interaction (n=13, 21.7%), start of therapy (n=10, 16.7%) 
adherence (n=8, 13.3%) or side-effects (n=5, 8.3%); more than one reason could apply. 
Figure 1 Measured pipamperone concentrations used for model development versus time after dose.
Table 1 Patient characteristics 
Model building group (n=30) Model validation group (n=21)
Male (n) 21 (70%) 13 (61.9%)
Age (years) 13.0 (5.6-17.7) 14.9 (7.2-20.6)
Body weight (kg) 50.4 (24.8-100.4) 47.4 (24.0-118.0)
Height (cm) 152 (123-180) 155 (122-186)
Body mass index (kg m-2) 20.41 (14.3-37.2) 19.0 (12.2-43.3)
Body mass index Z-score 0.98 (-2.57-3.49) 0.38 (-4.49-4.25)











































No of pipamperone samples per patient









Clinical Global Impression Scale (CGI) score 5 (4-7) 5 (4-7)
Patient characteristics at time of first pipamperone concentration measurement. Presented as median and range 
for continuous variables. 
The model building group consisted of patients from a Dutch multicenter observational trial and patients from a 
German TDM service. The model validation group consisted of patients from the same German TDM service. 
CGI: Clinical Global Impression Scale; 1 = normal; 2 = borderline; 3 = mildly ill; 4 = moderately ill; 5 = markedly 
ill; 6 = severely ill; 7 = extremely ill. CGI was missing for n=2 in the model building group and n=2 in model 
validation group.
* includes methylphenidate, amphetamine, atomoxetine 
** unknown for n=1 patient in model building group
*** includes DBS concentrations before conversion to estimated plasma concentrations. 
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Pipamperone concentrations were collected 
during the absorption and elimination phase. 
The presented DBS concentrations are 
measured concentrations before conversion 
to estimated plasma concentrations. Four 
samples are not shown for readability 
of the figure (x=182, y=0.21; x=118.63, 
y=2.69; x=121.4, y=4.82; x=12.25, 
y=1068). DBS: dried blood spot; HPLC-UV: 
high-performance liquid chromatography-
ultraviolet; LCMS: ultra-high performance 
liquid chromatography-mass spectrometry
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Pharmacokinetic analyses 
Base model
The data were best described using a one-compartment model. This model was further improved 
by including an IPV on clearance. The residual error was described by a combined error model 
with an extra additional error for HPLC-UV concentrations. As the conversion of DBS concentrations 
to plasma concentrations based on the previously conducted clinical validation study28 showed a 
trend towards under-estimation of the predicted concentrations by the model, a model-based 
conversion was calculated which showed better predictions. The GOF plots of the final model are 
presented in figure 2, and the parameter estimates of the final model are presented in table 2. 
Figure 2 (2a – 2d) Goodness of Fit Plots – final model
Table 2 Parameter estimates final model
Parameter Estimate  
(RSE %) [shrinkage]
Bootstrap median  
(90th percentile)
Ka1 (l/h) 2 2








Additional error (µg/L) 0.21 (1) 0.21 (0.11-10.5)
Proportional error 0.39 (19) [7%] 0.33 (0.15-0.46)
Additional error HPLC-UV 
(µg/L)
26.6 (40) [7%] 25.6 (8.5-39.1)
DBS correction: y = ax + b
a (µg/L) 0.33 (8) 0.31 (0.19-0.40)
b (µg/L) 3.90 (15) 3.87 (3.42-14.84)
1 fixed; 2 Allometric scaling with exponent 1 for V and 0.75 for CL; 3 IPV: inter-patient variability. 90th percentile 
based on bootstrap with n=772 successful runs. 
Ka: absorption rate constant; V: volume of distribution; CL: clearance; IPV: inter-patient variability; HPLC-UV: 
high-performance liquid chromatography-ultraviolet ; DBS: dried blood spot 
Covariate analysis 
After graphical analysis, the univariate analysis resulted in 3 significant covariates for the IIV on 
clearance (bodyweight, creatinine, BMI). These covariates were added to the base model for 
multivariate analysis. No covariates remained significant after backward elimination except from 
bodyweight, which was best described using fixed exponents with allometric scaling. 
Evaluation of the final model
The model-based parameter estimates were similar to the values computed from the bootstrap 
analysis, indicating the stability of the model (see table 2). The extra additional error for HPLC-
UV concentrations was 26.6 (µg/L). The VPC showed a good predictive performance (figure not 
shown). 
The model was successfully externally validated, as is shown by the goodness-of-fit plots and 
NPDE. The goodness-of-fit-plots show that the model adequately describes the observed 
concentrations (figure S1), and the NPDE show a normal distribution of the normalized errors 






























































Population concentration prediction (µg/L) 
DBS: dried blood spot; HPLC-UV: high-performance liquid chromatography-ultraviolet; 
LCMS: ultra-high performance liquid chromatography-mass spectrometry
Figure 2a Final model: measured 
concentrations versus population predictions
Figure 2c Final model: the correlation of 
conditional weighted residuals (CWRES) with 
time. 
One outlier is not presented for readability 
of the figure (x=529.7, y=1068). 
One outlier not shown for readability of the figure 
(time 38232.00, CWRES 0.244350).
Figure 2b Final model: measured concentrations 
versus individual predictions. 
Figure 2d Final model: the correlation of 
conditional weighted residuals (CWRES) with 
population predicted concentrations. 
One outlier is not presented for readability 
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Pharmacodynamic analyses
Effectiveness 
For a total of 35 patients CGI improvement scores were reported; 28 (80%) of them was rated 
as responder, and 7 as non-responder (20%). Psychotropic comedication was common in both 
responders (68%) as non-responders (57%), but non-significantly different (p=0.67).  
For 29 of these patients, both CGI improvement scores and measured pipamperone trough 
concentrations were available. The median [25th percentile-75th percentile] pipamperone trough 
concentration was higher in responders (98.0 µg/L [56.0-180.5], n=24) than in non-responders 
(58.0 µg/L [14.91-105.5], n=5), but this difference was non-significant (p=0.14). See figure 3a. 
For the total sample of patients with a CGI improvement score (n=35), pipamperone trough 
concentrations were also predicted based on the pharmacokinetic model. The median [25th 
percentile-75th percentile] predicted trough concentration for responders was higher than in 
non-responders: 80.0 µg/L [63.0-136.6] versus 51.3 µg/L [43.4-78.8], with a trend towards 
significance (p=0.07). See figure 3b. The predicted median AUC24h in responders (3448.0 
µg*h/L) was also higher than in non-responders (1811.0 µg*h/L), p= 0.05. 
Figure 3 (3a – 3b) Pipamperone trough concentrations and clinical improvement
When patients with ADHD and concurrent ADHD comedication (methylphenidate, amphetamine 
or atomoxetine) were excluded from the analyses, the results remained the same. The median [25th 
percentile-75th percentile] pipamperone trough concentration was higher in responders (113.5 
µg/L [62.0-180.5], n=20) than in non-responders (58.0 µg/L [14.91-105.5], n=5), p=0.10, as 
was the predicted trough concentration (83.5 µg/L [66.5-136.6], n=24,  versus 51.3 µg/L [43.4-
78.8], n=7), p<0.05, and the AUC24h (3486 µg*h/L versus 1811 µg*h/L), p<0.05. 
Extrapyramidal symptoms 
In 4 patients extrapyramidal symptoms (EPS) were observed (8% of 50 patients with EPS scores). 
All these 4 patients came from the Dutch sample. For 2 of these patients, and 44 of the patients 
without EPS, measured trough concentrations were available. The median [25th percentile-75th 
percentile] pipamperone trough concentration was lower in patients with EPS (25.74 µg/L [8.6-
42.9]) than in patients without EPS (109.5 µg/L (62.0-174.5). Predicted pipamperone trough 
concentrations (median [25th percentile-75th percentile]) were also lower in patients with EPS 
(46.4 µg/L [22.2-77.1], n=4) than in patients without (99.6 µg/L [57.7-166.8], n=46), p=0.06. 
The AUC24h was significantly lower in patients with EPS (1583.0 µg*h/L) than in patients without 
EPS (3633.0 µg*h/L), p=0.03. 
Sedation
Sedation scores were available for 50 patients; 9 of them had sedation at least once. For 46 
of these patients, measured trough concentrations were available. The median [25th percentile-
75th percentile] pipamperone trough concentration was 77.0 µg/L [36.7-132.5] in patients with 
sedation (n=6) versus 114.0 µg/L [59.0-174.5] in patients without sedation (n=40), p=0.32. The 
median [25th percentile-75th percentile] predicted trough concentration was also non-significantly 
lower in patients with sedation (61.9 µg/L [38.1-88.9], n=9) than patients without sedation 
(103.8 µg/L [59.9-166.9], n=41), p=0.08. The AUC24h was significantly lower in patients with 
sedation than patients without sedation (2050 versus 3852 µg*h/L, p=0.02). All patients using 
benzodiazepines as comedication were not rated as having sedation. 
Biochemical laboratory parameters 
A total of 15 biochemical laboratory measurements was available for n=8 patients (all Dutch 
patients). The median duration (range) of pipamperone use of these patients was 34 months (1-54). 
During pipamperone treatment, the median (range) prolactin level was 0.3 Units/L (0.03-0.46); 
2 patients had decreased levels (both did not have prior treatment with another antipsychotic 
drug), while no patients had elevated prolactin levels. The median (range) total cholesterol level 
was 4.2 mmol/L (3.5-5.1); no patients had elevated total cholesterol levels. The median (range) 
triglyceride level was 0.71 mmol/L (0.38-2.06); one patient had elevated triglyceride levels 
(no baseline levels known). Fasting glucose and HbA1c were normal in all patients; the median 
(range) glucose level was 4.7 mmol/L (4.2-5.6); the median (range) HbA1c level was 32.5 

























































Figure 3a Measured trough concentrations 
versus response based on the Clinical Global 
Impression Scale.
Figure 3b Predicted trough concentrations 
versus response based on the Clinical Global 
Impression Scale.
Data available for n=29 subjects. In responders, the 
measured trough concentration at time of first response 
was used. In non-responders, the highest measured 
trough concentration during follow-up was used. 
Whiskers indicate 10th-90th percentile. 
Data available for n=35 subjects. In responders, the 
predicted trough concentration at time of first response 
was used. In non-responders, the highest predicted 
trough concentration during follow-up was used. 
Whiskers indicate 10th-90th percentile.
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Predictions
Predicted concentrations with 95% confidence intervals using a twice daily 30 mg dosing scheme 
in steady state for a patient of 25kg, 50kg and 75 kg are shown in figure 4a. The mean (95% 
confidence intervals) of the predicted pipamperone trough concentrations (population prediction) 
after a 30 mg dose were 163.2 (67.3-268.9) µg/L for a patient of 25 kg, 103.9 (49.0-167.2) 
µg/L for a patient of 50 kg and 79.3 (38.4-124.4) µg/L for a patient of 75 kg. The same 
predictions were performed with a 0.6 mg/kg dosage in a twice daily dosing scheme, showing 
less variability in pipamperone concentrations and better attainment of the pipamperone trough 
concentration range that was found to be associated with response (figure 4b). The mean (95% 
confidence intervals) of the predicted pipamperone trough concentrations (population prediction) 
after a 0.6 mg/kg dosage were 81.6 (33.6-134.5) µg/L for a patient of 25 kg, 103.9 (49.0-
167.2) µg/L for a patient of 50 kg and 119.0 (57.6-186.7) µg/L for a patient of 75 kg. 
D I S C U S S I O N 
This is the first study that describes the population pharmacokinetics of pipamperone in children 
and adolescents, and investigates the relationships between pipamperone concentrations, 
effectiveness and side-effects in this young population. 
The pediatric pipamperone pharmacokinetics in this study are comparable to adult values found in 
a previously published study by Potgieter et al..21 This study found a mean maximum concentration 
of 263-266 µg/L after a 120 mg dose for three pipamperone products in healthy volunteers 
(mean weight 76.8 kg), corresponding to a calculated mean volume of distribution of 451-456 
L assuming a bioavailability of 100%. In our pediatric study sample, the mean apparent volume 
of distribution was estimated 416 L/70 kg. Both in our sample and in the study by Potgieter et al., 
a high variability was found. Strikingly, another study performed in adults found relatively low 
pipamperone concentrations after a 40 mg dose, corresponding to a more than twofold larger 
calculated volume of distribution of 908 L.22 Possibly, the bodyweight of the subjects in this latter 
study was higher, but patient characteristics were not provided. It could also be hypothesized that 
non-linear pharmacokinetics underlie these differences; this however, was not seen in our sample. 
Although well-established reference ranges are lacking for pipamperone, the Consensus 
Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology recommends a 
therapeutic range between 100-400 µg/L for adults with psychotic symptoms.40 In the absence of 
studies correlating pipamperone concentrations to clinical effects, this range is based on expected 
concentrations at an approved dose and derived from the previously mentioned pharmacokinetic 
study by Potgieter et al.21
However, ideally, reference ranges are defined by well documented concentration-effect 
relationships in the relevant population.40 Recently it has been suggested that the Q1-Q3 (25th-
75th percentile) range of psychotropic drug concentrations in responders would be the most optimal 
way to define preliminary therapeutic ranges based on observationally collected data.41 In our 
study, this would result in a suggested pipamperone reference range for children and adolescents 
of 56.0-180.5 µg/L. Although the indications for use were mostly unknown, it is expected that 
the main indication concerned behavioral problems associated with autism spectrum disorders, 
attention-deficit/hyperactivity disorder and mental retardation, given the major share of these 
diagnoses in our sample. This range is substantially lower than the suggested range in adults, 
which might be partly explained by different indications for use, as psychotic symptoms and 
aggressive behavior are associated with different pathomechanisms. This however, needs further 
confirmation for pipamperone. Furthermore, the therapeutic reference range for children might 
be different from the optimal range in adolescents due to developmental pharmacodynamics 
changes, which should be investigated in larger prospective trials. 





























Figure 4a Fixed 30 mg dose Figure 4b 0.6 mg/kg dose
Curves represent population predictions with 95% 
confidence intervals using a twice daily 30 mg 
pipamperone dosing scheme in steady state for a child 
of 25, 50 and 75 kg.
Curves represent population predictions with 95% 
confidence intervals using a twice daily 0.6 mg/kg 
pipamperone dosing scheme in steady state for a child 
of 25 kg (15 mg), 50 kg (30 mg) and 75 kg (45 mg). 
Figure 4 Simulations
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within our sample, several dose recommendations for children and adolescents could be made. 
Firstly, a twice daily dosing scheme should be sufficient based on the relatively long mean 
elimination half-life (13h), as has also been found for adults  (12-30h).4, 21 However, current 
guidelines are not uniform with respect to dosing intervals; while in Germany a dosing interval 
of 3 times per day is advised 15, the Dutch guideline states 1-2 times a day.16 Secondly, a mg/
kg dosage seems more appropriate than a fixed dosage, as weight was found to significantly 
influence the pharmacokinetics. Based on our simulations, a twice daily 0.6 mg/kg dosage seems 
appropriate to attain the concentration range that was associated with response. However, given 
the large variability between patients, some patients might have adequate response with lower 
dosages, while others need higher dosages. This calls for careful pipamperone dosage titration.  
Strikingly, children and adolescents with side-effects had lower pipamperone concentrations than 
subjects without side-effects in our study. This is remarkable, as previous studies have found that a 
higher D2 receptor occupancy, as a result of higher antipsychotic drug concentrations, is associated 
with an increased risk for extrapyramidal symptoms 42. Certain children and adolescents might 
be more susceptible to side-effects based on their pharmacodynamic profile, which makes them 
prone to side-effects even at low pipamperone concentrations, preventing further dosage increase. 
It might be hypothesized that this is the case for younger children, as these have been found to 
be more vulnerable for other side-effects associated with antipsychotic use as well.43 However, 
patients with extrapyramidal symptoms were not generally younger than patients without in our 
sample; neither did patients with extrapyramidal symptoms have other psychopathology than 
generally in the sample. Possibly, certain genetic variances underlie the elevated risk, as certain 
polymorphisms in the dopamine and serotonin receptor have been suggested to be a risk factor 
for antipsychotic-induced side-effects in adults.44 Another explanation is that part of the side-
effects may be due to the nocebo-effect, as with off-label use patients and legal representatives 
are informed about potential effects and side effects in a very detailed manner. More likely 
however, is that side-effects have been over-estimated in the Dutch patients, while underestimated 
in the German patients in our study. While the Dutch patients were enrolled in a clinical trial with 
structured screening and reporting of side-effects, it is expected that in the daily practice of the 
German TDM service relatively less side-effects were reported. As the pipamperone dosages and 
concentrations were higher in the German sample, this might have led to the finding that higher 
concentrations are associated with less side-effects. 
In this study, the Dried Blood Spot (DBS) method was used as pharmacokinetic sampling method 
next to conventional venipuncture. DBS only involves one fingerprick for drug concentration 
measurement and can be performed in the home-setting, which makes it a promising, less invasive 
method for pharmacokinetic sampling in children. The development of a DBS assay requires a 
thorough validation process before implementation, including the assessment of agreement 
between DBS samples and simultaneously collected plasma samples in a real-life, clinical 
setting.45 During this previously performed clinical validation study for pipamperone, the best 
agreement was found by dividing DBS samples by 0.158 (corresponding to a recovery of ca 
16% in DBS).28 However, in our model this conversion of the DBS samples initially led to a clear 
underestimation of the predicted plasma concentrations. This proportional bias was resolved by 
a new conversion of DBS concentrations to estimated plasma concentrations, being estimated 
by the model: DBS/0.33 +3.90 (see table 2). However, this finding questions the validity of the 
clinical validation process in our pediatric population. After consultation with the medical ethics 
committee the clinical validation was performed in adults due to ethical concerns. However, 
several factors may differentially impact DBS recovery of pipamperone in children versus adults. 
This could include the amount of interstitial fluid that is collected during the fingerprick, which may 
be more in adults. Also, sampling in children may require more pressuring on the finger to collect a 
full blood spot, and this may have caused hemolysis. Our findings show that results cannot simply 
be generalized across age groups and performing a clinical validation study in the intended target 
group should hence be considered. At the same time, in the clinical validation study a suboptimal 
agreement was already observed, which was confirmed by the findings in our population. 
The results of this study must be considered in the context of its limitations. The pipamperone 
concentrations were collected in an observational setting with flexible dosing schemes in 
clinical practice. As has been suggested earlier, this study design is suboptimal to demonstrate 
concentration-effect relationship.41, 46 Placebo-responders, who generally represent a substantial 
share of the patients in psychiatry, are likely to receive lower dosages, while non-responders 
might receive higher dosages. Also, dosages might be lowered when side-effects are observed. 
Therefore, the observed relationships between clinical effects and pipamperone concentrations 
could be biased. Furthermore, the analyses were performed with two different datasets. The 
data was collected in two countries, with different clinical and laboratory assessment methods, 
different inclusion criteria and prospectively versus retrospectively collected data. The data in 
Dutch patients was collected in a screening-based way, with questionnaires and screening-tools 
being applied at fixed time points, while in German patients improvement was retrospectively 
scored and side-effects were only reported at time of sampling. Possibly, this might have led to 
an overestimation of side-effects in the Dutch patients and an underestimation in the German 
patients. As the pharmacodynamic data on response was mainly retrospectively scored and 
collected in patients with various indications for use, this data did not allow for a more extensive 
exposure-response analysis. Despite combining the two datasets, the total number of patients was 
relatively low, and the relatively sparse amount of non-trough pipamperone concentrations might 
have limited the pharmacokinetic model development. As pipamperone is relatively lipophilic, it is 
expected to distribute to peripheral tissues. However, our data was possibly too sparse to support 
a two-compartment model, although a one-compartment model reflected the observed data best. 
Furthermore, different matrices and analytical methods were used to determine pipamperone 
concentrations, further increasing variability despite the corrections within the error-model for 
these influences. Lastly, the influence of metabolizing enzymes such as the cytochrome P450 could 
not be tested. Although the metabolism of pipamperone is assumed to take place in the liver, it is 
unknown which cytochrome P450 enzyme(s) are involved.40
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C O N C L U S I O N
This study presents the pharmacokinetics and pharmacodynamics of pipamperone in children 
and adolescents, based on concentrations measured in a real-life, clinical setting. Based on 
our findings, we recommend a twice daily dosing scheme for pipamperone in this population. 
Furthermore, bodyweight should be taken into account when dosing pipamperone in children and 
adolescents. Although more research is needed for the routine application of therapeutic drug 
monitoring in children and adolescents, we suggest considerably lower reference ranges than 
suggested for adults. 
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DBS: dried blood spot; HPLC-UV: high-performance liquid chromatography-ultraviolet; 
LCMS: ultra-high performance liquid chromatography-mass spectrometry
Figure S1a External validation: measured 
concentrations versus population predictions.
Figure S1c External validation: the correlation 
of conditional weighted residuals (CWRES) with 
time
Figure S1b External validation: measured 
concentrations versus individual predictions.
Figure S1d External validation: the correlation 
of conditional weighted residuals with population 
predicted concentrations
S U P P L E M E N T A R Y  D A T A
Figure S1  Goodness Of Fit plots – external validation
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Figure S2  Normalized prediction distribution errors (npde) of external validation
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A B S T R A C T 
Aim
Risperidone is the most commonly prescribed antipsychotic drug to children and adolescents 
worldwide, but is associated with serious side-effects, including weight gain. This study assessed 
the relationship of risperidone and 9-hydroxyrisperidone trough concentrations, maximum 
concentrations and 24-h area-under-the curves with BMI z-scores in children and adolescents with 
autism spectrum disorder (ASD) and behavioral problems. Secondary outcomes were metabolic, 
endocrine, extrapyramidal and cardiac side-effects and effectiveness. 
Methods 
Forty-two children and adolescents (32 males) aged 6-18 years were included in a 24 week 
prospective observational trial. Drug plasma concentrations, side-effects and effectiveness were 
measured at several time points during follow-up. Relevant pharmacokinetic covariates, including 
medication adherence and CYP2D6, CYP3A4, CYP3A5 and P-glycoprotein (ABCB1) genotypes, 
were measured. Non-linear mixed-effects modeling (NONMEM®) was used for a population 
pharmacokinetic analysis with 205 risperidone and 205 9-hydroxyrisperidone concentrations. 
Subsequently, model-based trough concentrations, maximum concentrations and 24-h area-
under-the curves were analyzed to predict outcomes using generalized and linear mixed-effects 
models.
Results
A risperidone two-compartment model combined with a 9-hydroxyrisperidone one-compartment 
model best described the measured concentrations. Off all pharmacokinetic parameters, higher 
risperidone sum trough concentrations best predicted higher BMI z-scores during follow-up 
(p<0.001). Higher sum trough concentrations also predicted more sedation (p<0.05), higher 
prolactin levels (<0.001), and more effectiveness measured with ABC-irritability score (p<0.01). 
Conclusion
Our results indicate a therapeutic window exists, which suggests that therapeutic drug monitoring 
of risperidone might increase safety and effectiveness in children and adolescents with ASD and 
behavioral problems.
I N T R O D U C T I O N
Risperidone is the most frequently prescribed antipsychotic drug to children and adolescents 
worldwide, with a prevalence ranging from 1.1 to 6.6 per 1000 youths across different countries.1, 
2 In this population risperidone is used for a broad range of mental health disorders, including 
disruptive behavioral disorders, schizophrenia and bipolar disorder. An important and increasing 
indication concerns irritability associated with autism spectrum disorder (ASD), with almost one 
in 9 youth with ASD using risperidone.3 For these and other indications, the short-term efficacy of 
risperidone is well-established and supported by numerous randomized controlled trials.4, 5 
However, there are growing concerns about the side-effects of risperidone in children and 
adolescents. Weight gain is the most important adverse effect, which is more pronounced in 
youths than in adults.6 Children and adolescents gain several kilograms during the first weeks 
of risperidone treatment.7 This results in serious long term health risks, including metabolic 
abnormalities and diabetes mellitus.8, 9 
Other common side-effects of risperidone include extrapyramidal symptoms (EPS), prolactin 
elevation and sedation.10 During long term risperidone treatment, up to one in three youths 
experience mild to moderate EPS, and more than half demonstrate prolactin elevations, possibly 
leading to gynecomastia, galactorrhea and sexual dysfunction.11, 12 Risperidone-induced sedation 
is significantly more prevalent in young patients than in adults.13 Lastly, risperidone can increase the 
corrected QT (QTc) interval, although clinically relevant QTc prolongation is rare.14 
Several studies have shown that the risk of most of these side-effects, including weight gain, 
increases with higher risperidone dosages in children and adolescents.9, 11, 15, 16 However, the 
relationship between individual exposure, reflected in risperidone plasma concentrations, and 
side effects remains unclear. A few studies have shown a correlation between prolactin elevation 
and plasma concentrations of risperidone or its active metabolite 9-hydroxyrisperidone in youths 
16-20, but the relationship with weight gain and other side-effects is unknown. This hampers the use 
of therapeutic drug monitoring to improve safety in this population.
Also the concentration-effectiveness relationship of risperidone in children and adolescents has yet 
to be determined. One study showed no correlation between total plasma risperidone and 9-OH-
risperidone concentrations and clinical response in a prospective cohort of children with ASD.21 
However, in that study, both trough and non-trough risperidone concentrations were analyzed 
together, which prevents correct interpretation. Another study neither found a concentration-
effectiveness relationship in a sample of children and adolescents with different indications for 
risperidone use, but this study had limitations due to the naturalistic and retrospective study design.22 
Here we study for the first time the relationship between risperidone and 9-hydroxyrisperidone 
plasma concentrations, weight gain, other side-effects, and effectiveness in a prospective cohort 
of children and adolescents with ASD. The primary aim is to investigate the relationship between 
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model-based individual pharmacokinetic parameters and body mass index (BMI) z-scores. For 
this purpose, trough concentrations, maximum concentrations and 24-h area-under-the curves are 
analyzed. Secondary, the relationships between the most relevant pharmacokinetic parameter and 
EPS, sedation, metabolic abnormalities, prolactin elevation, QTc-prolongation and effectiveness 
are investigated. The influence of a large number of demographic and biochemical characteristics 
including the cytochrome P450 enzymes CYP2D6, CYP3A4, CYP3A5 and P-glycoprotein 
(ABCB1) genotypes is taken into account.
The findings of this study can indicate whether there is a therapeutic window and rationale for 
therapeutic drug monitoring of risperidone to improve safety and effectiveness in children and 
adolescents.
M E T H O D S
Study population 
Children aged 6-18 years with the diagnosis of ASD according to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) IV 23 or 5 24 and using or starting risperidone for irritability 
were eligible for inclusion in this 24-week observational prospective multicenter cohort study 
(Netherlands Trial Register 6050). Exclusion criteria were diabetes type I or II, congenital or 
acquired syndromes associated with changes in appetite, body weight or lipid profile (e.g. Prader 
Willi), treatment with another antipsychotic drug within the last 6 months or known Long QT 
syndrome. Patients were treated in one of the 7 participating centers in the south-west region of the 
Netherlands (2 academic tertiary care centers and 5 psychiatric secondary care centers). They 
were prescribed risperidone as tablet formulation or oral solution in flexible dosing schemes by 
their treating physician according to standard clinical care. Patients were recruited between August 
2016 and October 2018. All patients and/or their legal representatives gave written informed 
consent before entering the study. The study was approved by the medical ethics committee of the 
Erasmus Medical Center, the Netherlands (number MEC 2016-124). The study has been carried 
out in accordance with the Declaration of Helsinki and the regulations on medical research with 
human subjects the Netherlands.
Drug concentration measurement
Three blood samples were repeatedly collected for risperidone and 9-hydroxyrisperidone 
quantification on two separate days. For patients who initiated risperidone treatment at the start 
of the study, blood samples were withdrawn at 12 and 24 weeks follow-up. For patients who 
already used risperidone at the start of the study, blood samples were collected at the start of 
the study and at 24 weeks follow-up. Blood samples were collected using venipuncture or Dried 
Blood Spot (DBS) method at random time points, with at least one hour between two samples. DBS 
sampling has experienced renewed interest in bioanalysis, as it requires only a simple finger prick 
and less blood than a venipuncture. DBS is regarded less painful and stressful for the patient than 
conventional blood sampling, and can be collected in a home environment, which increases the 
feasibility of repeated sampling in children.25 Time of sampling, time of risperidone intake in the 
prior 24 hours, risperidone dose and comedication were reported during sampling. Risperidone 
and 9-hydroxyrisperidone plasma concentrations were measured with previously validated 
ultra-high performance liquid chromatography-mass spectrometry (LC-MS/MS) methods for 
plasma and DBS.26-28 The lower limit of quantification (LLOQ) for risperidone was 1 µg/L and for 
9-hydroxyrisperidone 0.7 µg/L for plasma and DBS samples. The lower limit of detection (LOD) 
for plasma risperidone samples was 0.02 µg/L and for plasma 9-hydroxyrisperidone 0.22 µg/L; 
for the DBS risperidone samples 0.9 µg/L and for the DBS 9-hydroxyrisperidone samples 0.5 
µg/L. 
DBS concentrations were converted to estimated plasma concentrations (EPC) using the following 
formulas with correction for hematocrit (ht), based on a previously performed clinical validation 
study 28:
In this study hematocrit was standardly measured. When the hematocrit value was unknown and 
could not be extrapolated from a previous measurement, the median population value was used. 
Assessment of outcomes
Side-effects and effectiveness were prospectively recorded at start of study and at 24 weeks for 
all patients using and initiating risperidone treatment. 
Patients who initiated risperidone treatment when starting the study had additional assessments of 
side-effects and effectiveness at 4 and 12 weeks. For patients who already used risperidone at the 
start of the study, bodyweight, height, laboratory measurements and comedication since initiation 
of risperidone were retrospectively collected from the patient file.
Side-effects 
Bodyweight and height were measured at each visit. EPS were measured with the Abnormal 
Involuntary Movement Scale (AIMS) 29, filled in by treating physician, nurse or researcher. 
Sedation was assessed with the Epworth Sleepiness Scale 30 and filled in by parents. Laboratory 
indices that were measured were triglycerides, total cholesterol, high-density lipoprotein (HDL)-
cholesterol, low-density lipoproteins (LDL)-cholesterol, glucose, hemoglobin A1C (HbA1C) and 
prolactin. Laboratory indices were measured at the start of the study and at 24-weeks follow-up, 
with an additional measurement at 12 weeks for patients who had initiated risperidone treatment 
at the start of the study. 
QT intervals were measured in triplicate from a twelve-lead ECG as described previously31 at the 
start of the study and after 24 weeks of follow-up. The QT interval was measured at steady state 
heart rates, using preferably lead II, from the beginning of the onset of the QRS complex to the end 
of the T-wave. The measured QT intervals were corrected for heart rate using the Bazett’s formula: 
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The QT times and RR intervals of the first 10 ECG’s were measured by both a researcher and 
experienced pediatric cardiologist who were blinded for study time point. As these measurements 
showed good agreement (<10% difference for all measurements), the researcher individually 
performed the remaining QTc measurements. If there was any doubt, the ECG was also reviewed 
by the pediatric cardiologist. 
Effectiveness 
Effectiveness of risperidone was assessed by parents and the treating physician. Parents filled in the 
Aberrant Behavior Checklist (ABC) 32, a 58-item questionnaire that is sensitive to treatment effects 
in children with ASD. The ABC-irritability subscale (ABC-I) was used as measure for effectiveness; 
this scale reflects irritability symptoms with a maximum of 45 points. Treating physicians filled in 
the Clinical Global Impression Scale (CGI).29 This scale describes the severity of psychopathology 
(CGI-S) and its improvement (CGI-I) by 7 categories, rated by the treating physician. The CGI-S 
describes the severity of illness relative to patients with the same diagnosis in ascending order, with 
1 = normal and 7 = extremely ill. The CGI-I rates the improvement in comparison to the original 
medication-naive state of symptoms: 0 = not assessable, 1 = very much better, 2 = much better, 3 
= moderately better, 4 = unchanged, 5 = minimally worse, 6 = much worse.
Assessment of covariates
Medication adherence was assessed with questionnaires (Medication Adherence Rating Scale 
MARS-533, filled in by parents, and a 100 point visual analog scale (VAS), filled in by parents and 
treating physician) and during the last month of follow-up with an electronical monitoring system 
(MEMS©).34 A VAS score of 100, a MARS score of 25 or a MEMS adherence percentage of 100 
represents optimal adherence on each scale. Comedication was retrieved from medical records 
and from pharmacy records. Comedication for ADHD was recorded for the following drugs which 
are known to influence weight: methylphenidate, amphetamine or atomoxetine.
Parents filled in a study questionnaire at every visit including questions about the child’s diet, physical 
activity, grapefruit-juice use and over the counter self-medication use (including Saint John’s Wort). 
Diet questions involved whether the child had visited a dietician and whether nutritional advice 
was followed. Physical activity questions involved the quantification of the child’s high intensity 
(sports) and low intensity (walking or cycling) activity in hours per week. Familiar cardiometabolic 
risk was assessed after taking the family history at the start of the study as previously defined.35 If 
the family history was unknown, it was considered positive for cardiometabolic risk.
Laboratory measurements 
Renal function (ureum, creatinine), liver function (aspartate aminotransferase (ASAT), alanine 
aminotransferase (ALAT), gamma glutamyl transpeptidase (GGT), alkalic fosfatase (AF), albumin) 
and hematocrit were assessed at baseline and during follow-up. 
All patients were genotyped for the following cytochrome P450 (CYP) enzymes that could 
influence pharmacokinetics: CYP3A4, CYP3A5, CYP2D6 and P-glycoprotein PGP (ABCB1). The 
following single nucleotide polymorphisms were tested: for CYP3A4 *22, for CYP3A5 *3 and 
*6, for CYP2D6 *3, *4, *5, *41 and for ABCB1 (PgP) 3435C>T, using genomic DNA isolated 
from EDTA blood, and analyzed using Taqman 5’ nuclease DME assays (ThemoFisher Scientific). 
All pharmacogenetic testing was performed in the laboratory of the Erasmus MC, Rotterdam, the 
Netherlands. 
Population pharmacokinetic analyses 
Population pharmacokinetic analysis was performed by non-linear mixed-effects modelling using 
NONMEM® version 7.4.2 (FOCE+I; ICON Development Solutions, Ellicott City, MD, USA) 
and PsN® Version 4.7.0. Pirana® software version 2.9.7 was used as an interface between 
NONMEM® and R (version 3.4.4). Concentrations of 9-hydroxyrisperidone were corrected for 
molecular weight of risperidone.
Base model development
One, two and three compartment models were considered to describe the concentration-time 
data based on visual inspection of the goodness-of-fit plots and a review of the literature. 
Typical values for lag-time, first-order absorption rate constant (ka), volume of distribution (V), 
clearance (CL), and inter-compartmental clearance (Q) were estimated. As bioavailability (F) 
could not be quantified, certain parameters were estimated as ratios: CL/F, Q/F, and V/F. Firstly, 
risperidone data was described and subsequently 9-hydroxyrisperidone data was added. For 
each pharmacokinetic parameter inter-patient variability (IPV) was evaluated and shrinkage was 
calculated for all parameters for which IPV was established. A shrinkage value below 25% was 
considered acceptable.36 Allometric scaling was used to account for the influence of bodyweight 
on pharmacokinetic parameters, which was explored with a fixed exponent (0.75 for CL and Q, 
and 1 for V), and with exponents estimated by the model. Residual variability was described with 
a combined (additive and proportional) error model, with extra errors for sampling method (DBS 
versus venipuncture) and concentrations below LLOQ. Concentrations measured below the LOD 
were set on half the value of the LOD in combination with an extra additional error of half the value 
of the LOD. Components of the error model estimated to approach zero were removed. Model 
selection criteria were a decrease in the NONMEM objective function value (OFV), goodness-of-
fit plots and visual predictive checks (VPC). A decrease in the OFV of 3.84 points was considered 
statistically significant (p<0.05). 
Covariate model development
The following covariates were considered as potential model covariates: sex, age, dose, dose 
per kilogram, bodyweight, height, BMI, CYP3A4 genotype, CYP3A5 genotype, CYP2D6 
genotype, PGP genotype, comedication, somatic comorbidities, hematocrit, renal function (ureum, 
creatinine), liver function (ASAT, ALAT, GGT, AF), albumin, medication adherence, grapefruit juice 
use, Saint-John’s Wort use, and smoking. First, the correlation between the covariates and IPV 
was evaluated graphically. Subsequently, covariates with a visual relationship with IPV were 
individually added to the model. Continuous covariates were described using an exponential 
function and categorical covariates using a proportional function. Covariates that significantly 
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improved the model with the univariate analysis (p<0.05), were selected for multivariate analysis. 
The forward inclusion-backward elimination method was used.37 During the backward elimination 
process, covariates that improved the model at a level of p<0.001 were selected. A shark plot was 
generated for each covariate for case-deletion diagnostics.
Internal model evaluation 
Firstly, a bootstrap analysis was performed with 1000 simulations.38 The validity of the model was 
evaluated by comparing the bootstrap estimates and their 90 percentile range with the values 
generated using the original dataset. Secondly, the model was evaluated with a visual predictive 
check (VPC) stratified by compartment, using a set of 1000 simulated datasets to compare the 
observed concentrations with the distribution of the simulated concentrations.39
Pharmacokinetic predictions 
Model-based individual pharmacokinetic predictions were used as trough concentration (Ctrough), 
maximum concentration (Cmax) and 24-hour AUC (AUC24h) were not available for each patient 
because of sparse random sampling within the study. These pharmacokinetic parameters were 
predicted for risperidone and 9-hydroxyrisperidone per subject for the days a BMI z-score was 
known. The Ctrough prior to the first risperidone administration of the day was used. The Cmax was 
calculated for risperidone and was defined as the concentration at 40 minutes after risperidone 
administration, based on visual inspection of concentrations simulated by the final model. In case 
of multiple dosages per day, the highest Cmax on that day was used for the analyses. 
Pharmacodynamic analyses 
Primary outcome
The primary outcome was BMI adjusted for age and weight, the BMI z-score. A BMI z-score of 
≥1 is considered overweight and a BMI z-score ≥2 is considered obesity according to the World 
Health Organization (WHO).40 BMI values were transformed into BMI z-scores based on the 
WHO BMI-for age reference values (5–19 years).41 
Secondary outcomes
The following secondary outcomes were analyzed: EPS, sedation, triglycerides level, total 
cholesterol level, HDL-cholesterol level, LDL-cholesterol level, glucose level, HbA1C level, prolactin 
level, QTc-time, CGI-improvement score and ABC-irritability (ABC-I) score. EPS, sedation and 
CGI-improvement score were considered categorical outcomes. EPS was defined positive if at 
least two times mild or one time moderate was scored with the AIMS. Sedation was defined as 
an ESS total score of 1 or higher. Only children for whom a baseline measurement (before start 
of risperidone treatment) of the concerning outcome was available were included in the analyses. 
Statistical analyses 
Generalized and linear mixed-effects models were used to analyze our longitudinal data. Random-
effects were employed to capture the heterogeneity between the patients. The BMI z-score was 
considered the primary outcome. Each pharmacokinetic parameter of risperidone was separately 
analyzed as predictor versus BMI z-score. Potential relevant covariates (duration of risperidone 
use, sex, age, somatic comorbidities, comedication, IQ, prematurity, physical activity, diet) were 
tested in each model and the best model was selected using backward variable selection. Then, 
the final model among all best models with different pharmacokinetic parameters of risperidone 
was chosen by Akaike information criterion (AIC).42
The secondary analyses were performed with the pharmacokinetic parameter that was selected for 
the final model of the primary outcome. This pharmacokinetic parameter was entered as predictor 
in univariable models, and if significant, relevant covariates were added in a stepwise manner. On 
top of the covariates for the primary analyses, psychiatric comorbidities, psychotropic treatment 
before start of risperidone, non-pharmacological treatment parents and/or child, and familiar 
cardiometabolic risk were checked when relevant.
The correlation between model-based pharmacokinetic parameters was analyzed with Pearson’s 
correlation. Changes in BMI z-scores between baseline and the last visit was assessed with 
the Wilcoxon signed-rank test. The explained variance by the final model was calculated with 
the conditional pseudo-R2. In all analyses a p-value<0.05 was considered significant and all 
analyses were performed in R43 (version 3.4.4). 
R E S U L T S 
Study sample
Forty-two patients were included, of whom 31 initiated risperidone treatment at the time they were 
included in the study and 11 already used risperidone before inclusion in the study. The baseline 
characteristics of the study sample are presented in table 1. The median (interquartile range, 
IQR) follow-up time since start of risperidone therapy was 5.7 (4.8) months. The median (IQR) 
risperidone daily dose at the end of follow up was 1.0 (0.5) mg and 0.02 (0.02) mg/kg. The 
majority of children had one or more comorbid psychiatric disorders besides ASD (64.3%), being 
attention deficit/hyperactivity disorder (ADHD, 52.4%), oppositional defiant disorder (11.9%), 
mood disorder (7.1%), post traumatic stress disorder (4.8%) or anxiety disorder (2.4%).
One-hundred and fifty-four DBS samples and 72 plasma samples were collected. Twenty-one 
DBS samples (13.6%) were of insufficient quality for drug quantification, resulting in a total of 
205 risperidone and 205 9-hydroxyrisperidone concentrations. The median (IQR) measured 
risperidone concentration was 1.72 (6.19) µg/L in plasma and 3.57 (3.55) µg/L in DBS. The 
median (IQR) measured 9-hydroxyrisperidone concentration was 7.02 (6.13) µg/L in plasma and 
6.39 (6.72) µg/L in DBS. Hematocrit was known for 85 DBS measurements in 32 patients, with a 
median (IQR) hematocrit of 0.40 (0.08) L/L.
The medication adherence was generally high: the median (IQR) MEMS adherence percentage 
was 96% (62%), VAS score filled in by treating physician 100 (4), VAS score filled in by parents 
100 (2) and MARS score filled in by parents 24 (1). 
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Table 1 Baseline characteristics 
Characteristic
Male, n (%) 32 (76.2)
Age a (years) 9.7 (5.3)
Bodyweight a (kg) 32.4 (18.3)
Height a (m) 1.42 (0.34)
Body Mass Index a (kg m-2) 16.18 (4.06)
Body Mass Index z-score a -0.32 (1.69)
Ethnicity, n (%) 
Both parents Dutch origin 33 (78.6)
Other b 8 (19.0)
Unknown 1 (2.3)
Laboratory measurements a
Triglycerides (mmol/L) 0.57 (0.42)
Total cholesterol (mmol/L) 4.00 (1.00)
HDL-cholesterol (mmol/L) 1.50 (0.49)
LDL-cholesterol (mmol/L) 2.33 (0.79)
Glucose (mmol/L) 4.90 (0.40)
HbA1C (mmol/mol) 33 (4)
Prolactin (U/L) 0.12 (0.10)
Genotype, n (%) c
CYP2D6
Poor metabolizer 0 (0)
Intermediate metabolizer 27 (64.3)
Normal metabolizer 14 (33.3)
CYP3A4
Poor metabolizer 1 (2.4)
Intermediate metabolizer 6 (14.3)





Poor metabolizer 14 (33.3)
Normal metabolizer 27 (64.3)
Unknown genotype 1 (2.4)
QTc time (ms) a 387 (31)
Clinical Global Impression Scale (CGI-s) score a 5 (2)
Comorbid psychiatric disorders other than ASD, n (%) 27 (64.3)
Comedication ADHD drugs, n (%) d 10 (23.8)
IQ a 100 (40)
Treatment setting, n (%)
Outpatient 37 (88.1)
Inpatient 5 (11.9)
Prior psychotropic treatment, n (%) 25 (59.5)
Physical activity a
High intensity (hours/week) 2.5 (3)
Low intensity (hours/week) 2 (2)
Increased familiar cardiometabolic risk, n (%) e 18 (42.9)
Formulation of risperidone administration, n (%)
Tablet 31 (73.8)
Oral solution 11 (26.2)
All patients were diagnosed with autism spectrum disorder. The values represent start of risperidone treatment unless otherwise 
specified. Values represent total sample of n=42 patients, except for triglycerides (n=29), total cholesterol (n=28), HDL-
cholesterol (n=28), LDL-cholesterol (n=28), glucose (n=30), HbA1C (n=23), prolactin (U/L), CGI (n=29), IQ (n=40), physical 
activity (n=11), QTc (n=25).
ADHD: attention deficit/hyperactivity disorder; CYP: cytochrome P450; HbA1C: hemoglobin A1C;  HDL: high-density 
lipoprotein; LDL: low-density lipoproteins; PGP: P-glycoprotein; QTc: corrected QT
CGI-s: Clinical Global Impression Severity Scale; 1 = normal; 2 = borderline; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 
6 = severely ill; 7 = extremely ill. 
a Presented as median and interquartile range (IQR) for continuous variables
b Seven children had one or two parents of non-European descent. Of these, 5 children had one or two parents with African 
descent. 
c Metabolizing status within the sample was defined as follows: CYP2D6: poor =  2 inactive alleles (e.g. *4/*4); intermediate 
= 1 active and 1 inactive allele (*1/*3, *1/*4, *1/*5) OR 1 inactive and 1 decreased activity allele (*4/*41);  normal = 
2 active alleles (*1/*1) OR 1 active and 1 decreased activity allele (e.g. *1/*41); CP3A4: poor = *22/*22, intermediate 
= *1/*22, normal = *1*1; CYP3A5: expressor = at least 1 active (*1) allele (*1/*3, *1/*6); non-expressor = 2 inactive 
alleles  (*3/*3, *3/*6); ABCB1: poor=3435TT, normal=3435CT, 3435CC.
d Includes methylphenidate, amphetamine, atomoxetine
e As defined by American Academy of Pediatrics 35
Population pharmacokinetic analyses 
Base model
The data was best described using a two-compartment model for risperidone combined with 
a one-compartment model for 9-hydroxyrisperidone. IPV on CL of risperidone and CL of 
9-hydroxyrisperidone significantly improved the model. The residual error was described with 
additional and proportional errors for risperidone and 9-hydroxyrisperidone, concentrations 
below the LOD, concentrations >LOD and <LLOQ, and DBS samples. Pharmacokinetic parameters 
are presented in table 2 and estimates of residual variability are presented in table S1. 
Table 2 Pharmacokinetic parameter estimates of the final model and bootstrap analysis 
Parameter Estimate [shrinkage] Bootstrap median  
(90th percentile)2
tlag (h) 0.42 0.42 (0.40–0.50)
Ka (L/h) 18.6 34.2 (4.0–2587.1)
Vc/F1 (L/70 kg) 107 107.2 (85.5–142.1)
Vp/F1 (L/70 kg) 46.2 426.3 (39.1–9671.2)
Q/F1 (L/h/70 kg) 3.31 4.4 (1.6–14.7)
CL/F1 (L/h/70 kg) 23.9 24.2 (19.5–32.1)
   IPV CL 80% [6%] 82% (66–103)
VC M /F1 (L/70 kg) 111 101.4 (75.2–181.9)
CLM/F1 (L/h/70 kg) 5.19 5.2 (4.6–5.7)
   IPV CLM 28% [12%] 25% (17–34)
St Johns wort and grapefruit juice were not tested as covariates, as no children used these during follow-up.
1Allometric scaling with exponent 1 for V, and 0.75 for CL and Q
2  90th percentile based on bootstrap with n=279 successful runs. 
tlag lag time; Ka: absorption rate constant; V: volume of distribution; CL: clearance; IPV: inter-patient variability; 
M: metabolite, 9-hydroxyrisperidone; P: peripheral; C: Central; RSE: Relative standard error
Covariate analysis 
No covariates remained significant in multivariate analyses after backward elimination except for 
bodyweight, which was best described using fixed exponents with allometric scaling.
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Evaluation of the final model 
The bootstrap analysis yielded similar values as model-based parameter estimates, except from 
a larger estimate for the peripheral V (Vp). The model-based estimate of Vp however was within 
the bootstrap 90th percentile range, indicating the stability of the model. The goodness-of-fit-
plots showed that the model adequately described the observed concentrations (figure S1). The 
VPC showed a good predictive performance, although the lower 90th percentile of the simulated 
concentrations was slightly lower than the measured concentrations (figure S2). 
Pharmacokinetic predictions 
For the time points a BMI z-score was known, 270 model-based individual pharmacokinetic 
predictions for Ctrough, Cmax, and AUC24h of risperidone and 9-hydroxyrisperidone were 
calculated. The correlation between the predicted pharmacokinetic parameters was moderate 
to strong (r>0.5, data not shown), except for risperidone Ctrough and 9-hydroxyrisperidone 
AUC24h, which had a weak correlation (r=0.39). 
Pharmacodynamic analyses 
Primary outcome; BMI z-scores 
Two hundred seventy BMI z-scores were available in 42 patients; for 3 patients no baseline BMI 
z-score was available. The mean BMI z-score increased significantly during follow-up from -0.28 
±1.34 at baseline to 0.26 ±1.24 at end of follow-up (p<0.001). 
A higher risperidone and 9-hydroxyrisperidone exposure significantly predicted higher BMI 
z-scores during follow up for all pharmacokinetic parameters (Ctrough, Cmax, and AUC24h 
p<0.001). Significant covariates in multivariate analyses were risperidone duration of use (months) 
and comedication for ADHD (p<0.05). 
The sum Ctrough most strongly predicted BMI z-scores during follow-up, together with the 
significant covariates: sum Ctrough (β=0.042, p<0.001), duration of use (β=-0.009, p<0.001) 
and ADHD comedication (β=-0.340, p=0.004) with an intercept of -0.040 (p=0.836). The 
relationship between sum Ctrough and BMI z-scores is shown in figure 1 and table 3. 
The explained variance in BMI z-scores of the final model with sum Ctrough was 90.4%, which 
was higher than with risperidone dose at time of measurement (89.3%).
Secondary outcomes 
Sum Ctrough significantly predicted sedation, prolactin levels, and ABC-irritability score with 
correction for relevant covariates. No association was found between Sum Ctrough and EPS, 
triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, glucose, HBA1C, prolactin or QTc 
time, and response based on CGI-improvement score. The results of the effectiveness analyses are 
presented in table 3, the results of the secondary side-effects analyses are presented in table 
S2. 
Table 3 Association between trough concentrations of risperidone + 9-hydroxyrisperidone, BMI 
z-score, and secondary effectiveness outcomes
Variable N (obs) Estimate Standard error p-value 
Primary outcome
BMI z-score 42 (270)
Sum Ctrough 0.042  0.005 <0.001
Duration of use -0.009 0.002 <0.001
Comedication ADHD -0.340 0.116 0.004
Secondary outcomes – effectiveness 
CGI – response 29 (107)
Sum Ctrough 0.300  0.158 0.057
Duration of use 0.445     0.183  0.015
ABC – irritability 42 (121)
Sum Ctrough -0.281    0.093 0.003
Age at start -1.390  0.398 0.001
The median (IQR) predicted sum Ctrough was 10.07 (11.54) μg/L. The influence of diet and physical activity 
could not be analyzed due to too many missing values.
ABC-I: Aberrant Behavior Checklist – irritability score; BMI: Body Mass Index; CGI: Clinical Global Impression 
Scale; obs: number of observations
Legend: BMI: Body Mass Index; sum: risperidone and 9-hydroxyrisperidone 
Figure 1 Sum trough concentration versus BMI z-scores 
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Therapeutic window
Based on the estimated coefficients for BMI z-scores, ABC-I score, and the relevant covariates, a 
plausible therapeutic window for a child 10 years of age, with 3 months of risperidone treatment 
and without ADHD comedication is visualized in figure 2. Assuming a BMI z-score <1 and 
an ABC-I score <11 as relevant cut-offs for treatment success with acceptable weight gain, the 
theoretical therapeutic window of the sum Ctrough would be between 15 and 25 µg/L. 
D I S C U S S I O N 
This study demonstrates that higher risperidone and 9-hydroxyrisperidone plasma concentrations 
are associated with more weight gain, more sedation, higher prolactin levels and increased 
effectiveness in children and adolescents with ASD and behavioral problems. The sum trough 
concentration of risperidone and 9-hydroxyrisperidone was the most predictive pharmacokinetic 
parameter. 
The risperidone and 9-hydroxyrisperidone population pharmacokinetic parameters found in 
this study are comparable to previously described values in children and adolescents.44, 45 After 
adjusting for bodyweight, these pharmacokinetic parameters are similar to adults.45 The effects 
of demographic and biochemical characteristics on risperidone plasma concentrations in youths 
have not been studied extensively. While several studies did not find an influence of sex 44-46, some 
found higher total plasma concentrations in girls than boys 47, and others the opposite.48 Within 
our sample, no influence of sex was found, but our sample mainly consisted of boys. The activity 
of the CYP2D6 enzyme has repeatedly been shown to strongly affect risperidone clearance in 
children and adolescents 44, 45, 49, but was not found as significant covariate due to the absence 
of poor and extensive metabolizers in our study population. The influence of polymorphisms in 
other cytochrome P450 enzymes CYP3A4, CYP3A5 and the transport protein PGP on risperidone 
Figure 2 Example of theoretical therapeutic window 
Legend: The relationship between BMI z-scores, ABC-I scores and sum Ctrough for a child being 10 years old, 
with 3 months of risperidone treatment and without ADHD comedication. The grey are indicates a theoretical 
therapeutic window (15-25 μg/L), for a BMI z-score < 1 and a ABC-I score <11. 
BMI: Body Mass Index, ABC-I: Aberrant Behavior Checklist – irritability scale; Sum Ctrough: sum of trough 
concentrations of risperidone and 9-hydroxyrisperidone
concentrations has not been previously studied in children and adolescents, despite evidence for 
this influence in adults.50, 51 Our study is the first to examine these polymorphisms for risperidone 
in youths, but did not find any significant effect of polymorphisms in these genes on risperidone 
pharmacokinetics. 
Higher risperidone and 9-hydroxyrisperidone concentrations predicted higher BMI z-scores 
during risperidone treatment in children and adolescents. The sum trough concentration of 
risperidone and 9-hydroxyrisperidone, also referred to as the “active moiety”, was found to 
be the most predictive pharmacokinetic parameter. This confirms the recommendation in current 
therapeutic drug monitoring guidelines52, but was not self-evident, as for other drugs, including 
antibiotic drugs, it is known that maximum concentrations or area-under-the curves can predict 
outcomes better than trough concentrations.53 Two other studies have investigated the relationship 
between both risperidone and 9-hydroxyrisperidone concentrations and BMI z-scores in children 
and adolescents. One of these two studies did find higher risperidone metabolite and sum 
concentrations in children and adolescents with higher BMI z-scores 48, the other did not find any 
association.54 However, both studies had a cross-sectional design without baseline measurement, 
and were not able to take weight gain into account. In adults, to date no studies have investigated 
the relationship between risperidone plasma concentrations and weight gain.55
The analysis of the relationship between risperidone plasma concentrations and weight 
gain is complicated, as this relationship is bidirectional. Risperidone exposure may influence 
bodyweight in a pharmacodynamic way, but bodyweight also moderates risperidone exposure 
by pharmacokinetic processes. Higher body weight is expected to result in lower risperidone 
concentrations with an unaltered dose, as volume of distribution and clearance increase with 
bodyweight as a result of allometric scaling. Therefore, the pharmacodynamic explanation of the 
relationship is favored, as in our study higher concentrations were found with higher bodyweights. 
Still, it is unknown how well the established allometric scaling exponents fit pediatric populations 
with overweight.56 For risperidone, a relatively lipophilic drug, the volume of distribution is likely to 
increase with increasing fat mass, but for 9-hydroxyrisperidone, the more hydrophilic metabolite, 
this is more unlikely. Further research is needed to clarify the relationship between measured 
risperidone concentrations, rather than predicted concentrations, and overweight in pediatric 
patients. 
Higher risperidone sum trough concentrations were also related to more sedation, prolactin 
elevation and effectiveness in our sample. In adults, the risperidone exposure-response relationship 
has been studied almost exclusively in schizophrenia patients, yielding conflicting results. While 
some studies found a higher risperidone plasma concentrations predicting better response, others 
found the opposite.55 The positive correlation with extrapyramidal symptoms is better established, 
although different plasma thresholds are reported, including >40 µg/L 57, >180 µg/L 58 or > 
74 µg/L 55. As a result, a therapeutic reference range of risperidone in adults has not yet been 
clearly established, but is proposed as 20-60 µg/L for schizophrenia by the AGNP consensus 
guideline.52
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For children and adolescents, no therapeutic reference range is known, although it is suggested that 
optimal risperidone concentrations in children with impulsive-aggressive symptoms are lower than 
in adults with schizophrenia.22 Our findings confirm this, and show that optimal concentrations 
might depend on the child’s age at start of risperidone therapy, duration of treatment and 
comedication with ADHD drugs. When accounting for these variables, a therapeutic window 
of risperidone in children and adolescents with autism and behavioral problems seems to exist. 
For example for a child of 10 years old, after 3 months of risperidone treatment without ADHD 
comedication, the theoretical therapeutic range would be 15-25 µg/L, when a BMI z-score 
<1 and ABC irritability score <11 are considered as optimal treatment outcomes. This response 
corresponds to a 25% reduction in ABC irritability score, which has been previously defined as 
clinically relevant.59 
Although this study demonstrates a rationale to explore the added value of therapeutic drug 
monitoring in this population, more research is needed to better define the therapeutic reference 
range of risperidone in these youths. Future studies should assess measured rather than predicted 
sum trough concentrations, and focus on their predictive value in an early treatment phase for 
weight gain during later follow-up. Eventually, a randomized controlled trial should evaluate the 
added value of risperidone titration towards optimal concentrations versus treatment as usual. 
These efforts should be made before therapeutic drug monitoring of risperidone in youths can be 
routinely used as standard care. 
The findings of this study should be interpreted in the light of its limitations. First, the study had a 
sparse sampling design with different sampling methods, including venous sampling and dried 
blood spot sampling. This design was chosen to minimalize the patient’s burden and increase the 
study feasibility, as has been previously advised for pediatric pharmacokinetic trials.25 This however 
resulted in a higher variability in measured and predicted pharmacokinetic concentrations, further 
enhanced by the relatively large share of the measured risperidone concentrations below the 
LOD. We have reduced these variabilities in the analyses with the development of an extensive 
pharmacokinetic residual error model, although this resulted in less accuracy in the estimation of 
Vp/F. Second, the analysis of the relationship between risperidone exposure and effects was done 
with model-based concentrations rather than the measured concentrations themselves. Although 
this is suboptimal compared to really measured exposure, the model-based concentrations showed 
a good fit with measured concentrations. Moreover, this allowed for an analysis of not only trough 
concentrations, but also peak concentrations and AUC24h. Third, due to a limited sample size, 
relatively few patients had high risperidone sum trough concentrations. These patients had a quite 
large impact on the regression analyses. However, the mg/kg doses and characteristics of these 
patients were within the range of the total sample, thus reflecting average patients. Fourth, the 
sample size was not powered for the secondary outcomes, thus possibly leading to non-significant 
results. Fifth, this study has the typical limitations of naturalistic study designs in analyzing the 
exposure-response relationship60, as placebo-responders and patients with side-effects are likely 
to receive lower dosages, while non-responders are likely to receive higher dosages. This might 
have led to an over- or underestimation of the exposure-response relationship. Lastly, although 
a large panel of pharmacogenetic polymorphisms was tested for its pharmacokinetic influence, 
candidate genes that might be relevant for pharmacodynamic outcomes were currently not tested; 
these however are of interest for future research.61
This is the first study that prospectively investigated the relationship between risperidone 
pharmacokinetic parameters, side-effects and effectiveness in children and adolescents with 
autism spectrum disorder and severe behavioral problems. The finding that the risperidone sum 
trough concentration predicts both weight gain, other side effects and response, indicates that 
therapeutic drug monitoring might improve safety and efficacy of risperidone treatment in this 
vulnerable population. 
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What is already known about this subject:
 a Risperidone treatment in children and adolescents is associated with serious side-effects, 
most importantly weight gain. 
 a  The risk of side-effects increases with higher dosages, but the relationship of concentrations 
of risperidone and its active metabolite 9-hydroxyrisperidone with side-effects is unknown. 
What this study adds:
 a In children and adolescents with Autism Spectrum Disorder (ASD), weight gain can 
be predicted by model-based risperidone sum trough concentrations. The sum trough 
concentration is a better predictor than the maximum concentration or the 24h area under 
the curve.
 a  Higher risperidone sum trough concentrations predict higher BMI z-scores, but also more 
sedation, higher prolactin levels, and, interestingly, more effectiveness.
 a  Our findings indicate that a therapeutic window for effectiveness with acceptable weight 
gain in children and adolescents with ASD seems to exist, but more research is needed to 
establish the therapeutic reference range in this vulnerable population. 
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S U P P L E M E N T A R Y  D A T A
Table S1 Residual variability of the final model and bootstrap analysis
Estimate Estimate  Bootstrap median  (90th percentile)
Risperidone 
εadd (µg/L) =
< LOD risperidone plasma2 0.01 0.01
< LOD risperidone DBS2 0.73 0.73
<LLOQ >LOD risperidone 0.21 0.20 (0.08-0.30)
εprop =
Risperidone 0.27 0.26 (0.19–0.32)
Risperidone DBS 0.27 0.26 (0.12–0.38)
<LLOQ >LOD risperidone 0.37 0.37 (0.18–0.51)
9-hydroxyrisperidone 
εadd (µg/L) =
9-hydroxyrisperidone 0.94 0.80 (0.33-1.08)
9-hydroxyrisperidone DBS 0.26 0.30 (0.05–0.54)
< LOD 9-hydroxyrisperidone plasma2 0.11 0.11
< LOD 9-hydroxyrisperidone DBS2 0.42 0.42
εprop =
9-hydroxyrisperidone 0.31 (58%) 0.32 (0.29–0.35)
Residual variability was described according to the following formula: Cobs=Cpred*εprop + εadd
Shrinkage was 11% for the combined additional error and 12% for the combined proportional error.
For risperidone, 5 plasma concentrations and 74 DBS concentrations were below the LOD, and 26 plasma and 
1 DBS sample below the LLOQ but above the LOD. For 9-hydroxyrisperidone, 1 DBS sample was below the 
LOD. 
2 fixed value
Obs: observed, pred: predicted, prop: proportional, add: additional, LLOQ: lower limit of quantification, LOD: 
lower limit of detection; RSE: Relative standard error
Bootstrap with n=279 successful runs.
Table S2 Association between trough concentrations of risperidone + 9-hydroxyrisperidone and 
secondary side-effect outcomes 
Variable N (obs) Estimate Standard error p-value 
EPS 42 (136)
Sum Ctrough -0.385  0.203 0.058
Sedation 41 (117)
Sum Ctrough 0.296    0.127 0.019
Triglycerides (mmol/L) 41 (103)












Sum Ctrough -0.003  0.006 0.567    
Glucose (mmol/L) 42 (103)
Sum Ctrough 0.003 0.005 0.562   
HbA1C (mmol/mol) 40 (87)
Sum Ctrough -0.015    0.026 0.571   
Prolactin (U/L) 41 (93)
Sum Ctrough 0.027   0.007 <0.001
Age at start 0.054 0.018 0.004
QTc time (ms) 25 (52)
Sum Ctrough 0.464  0.345 0.187    
EPS: extrapyramidal symptoms; HbA1C: hemoglobin A1C;  HDL: high-density lipoprotein; LDL: low-density 
lipoproteins; obs: observations; QTc: corrected QT
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Figure S1 Goodness of fit plots of final model
Figure S1a measured concentrations versus individual predictions risperidone 
Figure S1b measured concentrations versus individual predictions 9-hydroxy-risperidone 
Figure S2 Visual Predictive Check (VPC)
Legend: left figure shows VPC of risperidone, right figure shows VPC of 9-hydroxyrisperidone
9
PART V
G E N E R A L 
D I S C U S S I O N , 
S U M M A R Y ,  A N D 
A P P E N D I C E S
CHAPTER 10
G E N E R A L  D I S C U S S I O N 
Part V:   General discussion, summary, and appendices - 203202 - Chapter 10
Autism spectrum disorder (ASD) is characterized by the impairment in two symptom domains: 
social communication and restricted and repetitive behaviours.1 In addition, secondary 
characteristics such as emotional and behavioral problems are extremely common in children and 
adolescents with ASD.2 Antipsychotic drugs are proven effective to treat these comorbid problems, 
but antipsychotic drugs also entail severe side effects, especially in the young. 
This thesis aims to improve the safety of antipsychotic drugs in children and adolescents by using 
an individualized approach, focusing on antipsychotic drug concentration measurement. Within 
this last chapter, the findings are discussed in a broader perspective and recommendations for 
both clinical practice and future research are provided.
M A I N  F I N D I N G S
 a The large extent of antipsychotic drug use
Since the introduction of atypical antipsychotic drugs, their use in children and adolescents has 
increased significantly.3 Our study in chapter 2 showed that this trend has continued to rise, 
with a prevalence of  9.8 per 1000 youths in 2009, before stabilizing.4 Dutch practitioners, 
including general practitioners, seem to prescribe antipsychotic drugs more commonly to youths 
than practitioners in other countries.5 Among other reasons, this relatively high prescription rate in 
the Netherlands is explained by a considerably long duration of antipsychotic drug use, with one 
in eight children in whom antipsychotic drugs are initiated using it for at least 4 years (chapter 
2). This is particularly worrying as the long-term efficacy of antipsychotic drugs in children and 
adolescents is not sufficiently established6, and the risk for side-effects increases with a longer 
duration of use.7-9 
 a Weight gain is most pronounced in the first weeks of antipsychotic treatment
Side effects of antipsychotic drugs in children and adolescents are common, and especially the 
metabolic side effects can lead to serious long term health risks. Our study in chapter 3 has shown 
that the antipsychotic-induced weight gain is most pronounced in the first 15 weeks, with a less 
steep increase afterwards. Several monitoring guidelines for antipsychotic-related side effects 
in children and adolescents have been developed in response to the growing concerns about 
side-effects in the young population.10-12 The most frequently used Accare-guideline presents an 
intensified monitoring schedule for children with an increased familial cardiovascular risk, non-
Caucasian descent and a higher BMI at start, but the evidence on which this guideline is based is 
sparse and highly heterogeneous. Our study in chapter 3 aimed to provide more evidence on 
predictors of excessive weight gain. In this study we found that a higher baseline BMI, adjusted 
for sex and age and depicted as the z-score, was associated with a higher BMI z-score during 
antipsychotic treatment. Moreover, we found that concomitant stimulant use can reduce weight 
gain during follow-up, and that prior antipsychotic use is associated with less weight gain during 
the first 15 weeks. Ethnicity was associated with antipsychotic-induced weight gain in our study. 
 a Psychotropic drug concentrations and clinical outcomes in children and 
adolescents
Although the monitoring of side-effects is important to increase the safety of antipsychotic drugs 
in children and adolescents, the prevention of side-effects is even more crucial. For many drugs, 
Therapeutic Drug Monitoring (TDM), which comprises the measurements of drug concentrations 
to optimize pharmacotherapy, has proven to be an excellent tool to prevent side-effects and 
suboptimal effectiveness.13 By titrating dosages towards concentration ranges that are associated 
with minimal side-effects and maximal effectiveness, patient outcomes can be improved 
significantly. As such, TDM is widely applied within adult psychiatry and beyond.13 
However, at this moment, TDM is rarely performed within child- and adolescent psychiatry. An 
important requirement for TDM is that a relationship between drug concentrations and clinical 
outcomes exists, but our systematic review in chapter 7 reveals that this relationship is largely 
unexplored for psychotropic drugs in children and adolescents, including for antipsychotic drugs. 
The evidence that exists is sparse and highly heterogeneous. Most studies fail to report on the key 
aspects of well- performed TDM research, such as sampling under steady state circumstances, 
which complicates the interpretation of the reported concentrations. Moreover, therapeutic 
reference ranges for all psychotropic drugs are barely provided. This hampers the large scale 
application of TDM as a tool to prevent side-effects of psychotropic drugs, including antipsychotic 
drugs, in the young.
 a Dried Blood Spot sampling as a feasible alternative to venous sampling
Besides established therapeutic reference ranges, also minimally invasive sampling methods are 
important in order to apply TDM routinely within child and adolescent psychiatry. Youths with 
psychiatric disorders and related behavioral problems generally have a lower tolerability for 
venous blood sampling due to distress, anxiety or aggression, which decreases their tolerability for 
venous sampling. In order to investigate the potential of Dried Blood Spot (DBS) sampling within 
child and adolescent psychiatry, part III of this thesis focused on the development, validation and 
feasibility of the DBS method for antipsychotic drug concentration measurement in children and 
adolescents. Despite a successful and extensive laboratory validation in chapter 4, the criteria 
for the clinical validation were not fully met in chapter 5.  As such, the DBS method appeared to 
have a higher variability than venipuncture in quantifying antipsychotic drug concentrations, as 
was shown by a suboptimal agreement between these two methods. DBS however is a feasible 
repeated sampling technique for challenging research in children and adolescents with ASD and 
severe behavioral problems (chapter 6). 
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 a New insights on the concentration-effect relationship for antipsychotic drugs
The main objective of this thesis was to advance the application of TDM of antipsychotic drugs in 
children and adolescents, by providing new insights on the concentration-effect relationships of 
antipsychotic drugs. 
Pipamperone 
For pipamperone no studies on the concentration-effect relationship had been conducted, and 
the pharmacokinetics in youths were unknown. We studied the pharmacokinetics of pipamperone 
in children and adolescents (chapter 8), and found that these are comparable to adult values. 
A relatively long half-life of 13h was found, and optimal pipamperone concentrations in children 
and adolescents with behavioral problems were much lower than for adults with psychosis (56-
180 µg/L versus 100-400 µg/L). 
Risperidone
For risperidone previous concentration-effect studies in children and adolescents were designed 
suboptimally, and mainly focused on correlations with prolactin elevation. To investigate a wider 
range of effects, we have conducted a prospective study in risperidone treated children and 
adolescents with ASD and behavioral problems to analyze the relationship between predicted 
risperidone concentrations, side-effects and effectiveness (chapter 9), within the previously 
mentioned SPACe-trial. Our study showed that higher risperidone sum trough concentrations lead 
to more weight gain, sedation, prolactin elevation and more effectiveness in this population. The 
sum trough concentrations had better predictive value for weight gain than other pharmacokinetic 
parameters. An optimal therapeutic range seems to exist, but should be further confirmed.  
Aripiprazole 
For aripiprazole, another commonly used antipsychotic drug in children and adolescents in 
the Netherlands for ASD and comorbid severe behavioral problems, no studies assessing the 
concentration-response relationship have been performed yet and are highly needed. Unique 
data on this subject have also been collected in the SPACe-trial and are currently analyzed.
C L I N I C A L  I M P L I C A T I O N S
The findings of this thesis have several implications for clinical practice. 
 a Timely discontinuation of antipsychotic drugs
Many children and adolescents use antipsychotic drugs for at least four years, but it is questionable 
whether all patients benefit from prolonged antipsychotic treatment. Therefore a better evaluation 
of timely discontinuation of antipsychotic drugs in this population is called for. To facilitate this, the 
prescription and follow-up of antipsychotic drugs in children and adolescents should be reserved 
to specialists like child- and adolescent psychiatrists. Furthermore, electronic deprescribing 
tools, such as clinical rules incorporated in prescribing systems, may help to identify long use of 
medication and thereby trigger the prescriber to assess the necessity for continued antipsychotic 
drug use. However, these tools are not yet commonly available for antipsychotic drugs in children 
and adolescents.14 
The introduction of the Child and Youth Act (Jeugdwet) in 2015, leading to the transformation of 
child- and adolescents mental health care in the Netherlands15, might further affect prescribing 
trends for the young. Local municipalities are now responsible for the organization of youth 
mental health care in their region, and aim to decrease the number of children and adolescents 
in specialized care by increasing preventive and early intervention support.16 However, instead 
of demedicalizing, the Child and Youth Act could contribute to more psychotropic use in youths. 
As youth mental health care is now organized and provided by local first-line multidisciplinary 
teams (wijkteams) with limited expertise on severe psychopathology and psychopharmacology, 
negative consequences could be suboptimal triage, ineffective treatment and unnecessary crises. 
Future pharmacoepidemiological research should be part of thorough evaluations of the Child 
and Youth Act. At this moment, it is important that child and adolescent psychiatrists engage in 
the public debate on this transformation of youth mental health care. As a field, we must stand 
up for vulnerable youths and advocate adequate triage and timely and optimal care for children 
with psychopathology in every municipality of the Netherlands, thereby preventing unnecessary 
psychotropic drug use, but also under-treatment.
 a Improving side-effect monitoring guidelines 
The Accare guideline17, the most commonly used side-effect monitoring guideline in the 
Netherlands, recommends the first standardized follow-up visit only after 3 months. However, our 
study in chapter 3 has shown that the antipsychotic-induced weight gain is most pronounced 
within the first 15 weeks, with a less steep increase thereafter. This means that the first weeks of 
antipsychotic use are an important determinant of the total weight gain, and should therefore be 
closely monitored. This is supported by other research, which demonstrated that the weight gain 
after one month is predictive of problematic weight gain after 3 months.18 Based on these findings, 
we recommend continuous monitoring including a standardized visit at one month instead of three 
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months after the start of antipsychotic treatment. This enables a timely identification of individuals 
gaining excessive weight, with the possibility of an intervention. Interventions can include exercise 
counseling, dietary interventions or a switch in antipsychotic drug type. To overcome the currently 
divergent approaches and guidelines for the follow-up of youths starting antipsychotic treatment in 
the Netherlands19, this recommendation should be incorporated in one uniform national monitoring 
guideline. 
To further improve clinical side-effect monitoring practices, children and adolescents who are 
particularly at risk to develop weight gain and other side effects should be identified before 
the treatment with an antipsychotic drug, in order to offer an intensified follow-up. Our findings 
support the need for intensified monitoring and proactive diet and exercise counseling of children 
with a high baseline BMI, given the fact that these children are more prone to metabolic laboratory 
abnormalities.20 
 a Optimizing dosing of pipamperone in young patients
Our pharmacokinetic research on pipamperone (chapter 8) has showed that a twice daily 
dosage scheme, adjusted for body weight, was best to reach optimal concentrations in children and 
adolescents. This finding supports an evidence based dosing recommendation for pipamperone 
in the Dutch Kinderformularium, which did not exist up till now.21 Our findings will be incorporated 
in the Kinderformularium. 
 a Therapeutic drug monitoring of antipsychotic drugs in clinical practice 
Our findings in chapters 8 and 9 support a concentration-effect relationship for antipsychotic 
drugs in children and adolescents, thereby providing the most important rationale for TDM. As a 
result the question arises what the current position of TDM is for antipsychotic drugs in children and 
adolescents in daily clinical practice. 
Although some argue that TDM is generally indicated in child- and adolescent psychiatry given the 
large pharmacokinetic and pharmacodynamic variations within this population22-24, its routine use 
should be carefully considered. TDM involves costs and patient burden, which must outweigh the 
benefits. The criteria for rational routine use of TDM25, 26, which are shown in table 1, can help to 
determine the current position of TDM of antipsychotic drugs in child- and adolescent psychiatry. 
As a concentration-effect relationship for pipamperone and risperidone are demonstrated in this 
thesis and discussed before (Crit. 1), the other criteria will be briefly discussed. 
Table 1 Criteria for routine application of TDM – the case for antipsychotic drugs in 
children and adolescents
Crit. 1. There is a clinically significant relationship between drug concentration and 
pharmacological effect. 
Crit. 2. A narrow margin exists between drug concentrations that cause therapeutic 
 and adverse effects. 
Crit. 3. Drug concentrations are unpredictable after a given dosage. 
Crit. 4. The pharmacological effects are not readily assessable. 
Crit. 5. A rapid and reliable method for drug quantification is available. 
Crit. 6. Evidence that clinical outcome is improved by doing TDM
Based on Soldin et al. 200225  and LeMeur et al 2011.26 These criteria are assessed for risperidone and 
pipamperone, the antipsychotic drugs that have been studied in the SPACe trial and are presented in this thesis.  
 = supported by evidence,   = currently unknown, further research needed
Crit. 2 A narrow margin exists between drug concentrations that cause therapeutic and 
adverse effects. 
The measurement of drug concentrations is only of added value if the balance between beneficial 
and harmful drug concentrations is delicate, and small variations in drug plasma concentrations 
can have potential harmful effects. This applies for example to lithium, a drug with a narrow 
therapeutic window, for which TDM is commonly performed. Although our findings indicate that 
a therapeutic window for risperidone and pipamperone exists, the therapeutic reference ranges 
of pipamperone, risperidone and aripiprazole in children and adolescents are not yet sufficiently 
established and need further confirmation. 
Crit. 3 Drug concentrations are unpredictable after a given dosage. 
Only when drug concentrations between individuals vary considerably after administration of an 
equal dosage, the correlation between drug concentrations and effects is likely to be better than 
between the dosage and effects. This variability, known as inter-individual variability, was found 
to be significant for both risperidone and pipamperone in our analyses (chapters 8 and 9), and 
is in line with previous research on antipsychotic drug concentrations in youths.27 This means that 
antipsychotic concentrations are highly variable between patients.  
Besides variability in drug concentrations between patients, also variability within patients may 
occur. This is known as the intra-patient variability and refers to variability in drug concentrations 
within the same patient after administration of an equal dosage, on different occasions. Ideally, 
for TDM within child and adolescent psychiatry, a low intra-patient variability exists, as this makes 
a drug concentration applicable to other time points for the same patient. Within our analyses, 
addition of intra-patient variability did not improve the pharmacokinetic model, implying that 
the intra-patient variability was low enough to extrapolate the pharmacokinetic parameters 
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concentration over time. This further supports the eligibility of TDM for antipsychotics drugs in 
children and adolescents.
Crit. 4  The pharmacological effects are not readily assessable. 
Antipsychotic-induced metabolic adverse events are an illustrative example of delayed effects that 
are not directly assessable, as these effects generally take weeks or even months to develop. This 
means the measurement of a drug concentration can be of added value to predict drug effects. 
For other drugs, for example antihypertensive drugs, the antihypertensive effects are generally 
directly observable and measurable, making them less suitable for routine TDM. The delayed 
effect however also entails challenges for TDM, as the drug concentration measured at the time of 
weight assessment might not be causative for the observed weight at that time. 
Crit. 5  A rapid and reliable method for drug quantification is available. 
The introduction of mass spectrometers and other analytical developments has led to access to 
robust drug-monitoring assays with a short turn-around time. Also, for risperidone, aripiprazole 
and pipamperone, a validated ultra-high performance liquid chromatography-mass spectrometry 
(LC-MS/MS) is available28, enabling quick, selective and sensitive antipsychotic concentration 
measurements in plasma. This thesis demonstrates that also DBS is a rapid and feasible method for 
antipsychotic drug determination (chapters 4, 5 and 6). 
Crit. 6  Evidence that clinical outcome is improved by doing TDM
Evidence-based medicine relies on interventions that improve patient outcomes in robust clinical 
trials. Also TDM of antipsychotic drugs should be proven to decrease weight gain and other 
side-effects significantly in clinical practice before it can be routinely implemented, but such trials 
have not been performed until now. An important reason is that randomized controlled trials are 
logistically hard to perform. 
Crit. 7 Routine TDM of antipsychotic drugs in youths – are we there yet?
After considering the different aspects for a rational routine application of TDM, we can conclude 
that TDM has significant potential to enhance safety of antipsychotic drugs in children and 
adolescents. However, the major drawbacks for its current routine application are that no well-
established therapeutic reference ranges exist yet, and that it is unknown whether TDM in this 
population improves the safety and efficacy outcomes in clinical practice. Therefore, there is 
currently not enough support for standard TDM implementation in clinical practice for all children 
and adolescents using antipsychotic drugs. 
For the individual patient, however, TDM can certainly already improve outcomes. Indications 
for a antipsychotic drug concentration measurement include 1) non-response despite adequate 
dosages 2) excessive side-effects, including weight gain, at low dosages 3) when non-adherence 
is suspected 4) when drug-drug interactions are foreseen. In these cases, a drug concentration 
measurement can identify unexpected concentrations, for example because of Cytochrome 
P450 (CYP) polymorphisms, as for many antipsychotic drugs pharmacokinetic reference ranges 
in children and adolescents are known.29 Especially since off-label use of antipsychotic drugs 
is widespread within child- and adolescent psychiatry30, safety and effectiveness are not well 
established and TDM should be considered a low-threshold tool in this population.
F U T U R E  R E S E A R C H  P E R S P E C T I V E S 
This thesis has contributed to knowledge on different levels of the TDM process for antipsychotic 
drugs in children and adolescents (see figure 1). 
Figure 1 studies in this thesis contributing to knowledge on TDM of antipsychotic drugs in children 
and adolescents
 
Future research on improving the DBS method for antipsychotic drugs
The higher variability in measured DBS concentrations, compared to venous samples, can be 
successfully overcome with sophisticated statistical methods like NONMEM, as is demonstrated in 
chapters 8 and 9. However, we contend that the following efforts may decrease the variance 
between DBS and plasma samples, thereby improving the accuracy of the DBS assay:
 a Lowering the lower limit of quantification (LLOQ). Within the clinical validation process, 
a considerable amount of samples were below the LLOQ, especially for risperidone. 
The measured concentrations were much lower than expected based on adult reference 
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might therefore improve the agreement between DBS and plasma concentrations. 
 a Performing the clinical validation study in children and adolescents. Currently, a clinical 
validation specifically in children and adolescents is not recommended by the international 
guideline for the development and validation of DBS methods31, as the results are 
expected to be comparable to adults and thus an unnecessary burden to minors should 
be prevented. However, it can be hypothesized that the correlation is different in children, 
as with DBS sampling in children less interstitial fluid contamination and more pressuring 
of the finger is involved due to their smaller fingers. As such, different clinical validation 
studies for DBS in children have been previously performed and can be considered for 
antipsychotic drugs as well.32-34
 a Minimizing the hematocrit effect. Hematocrit influences the blood viscosity and therefore 
the spread of a drop, which can lead to higher or lower measured drug concentrations.35 
For risperidone and aripiprazole, a correction for hematocrit was found to improve the 
agreement between venipuncture plasma samples and DBS in our clinical validation 
study, while this was not the case for pipamperone (chapter 5). Although the variation in 
hematocrit is expected to be relatively small in children and adolescents who are treated 
at the outpatient clinic, several approaches can be used to overcome the hematocrit effect, 
such as volumetric application of blood. However, as regular laboratory check-ups are 
indicated for metabolic follow-up in children using antipsychotic drugs, the hematocrit 
can easily and simultaneously be determined. 
Research on therapeutic reference ranges and improvement of clinical outcomes
Following the criteria for rational, routine use of TDM of antipsychotic drugs in children and 
adolescents, future research should focus on establishing therapeutic reference ranges and 
investigating the added value on patient outcomes in clinical practice. 
Therapeutic reference ranges can be based on observational and even retrospective studies, and 
such ranges are commonly used in TDM guidelines.13 However, in an ideal situation, therapeutic 
reference ranges are determined by a prospective study design in which patients are randomized 
to different concentration ranges, to evaluate which group has the best clinical outcomes. Such a 
study has been performed for clozapine36, but is very rare in the field. Ideally, future research 
should confirm the concentration-effect relationship as was found in the SPACe trial in another 
independent sample, preferably analyzing measured instead of pharmacokinetically predicted 
concentrations. For risperidone, such a study should focus on the relationship between the sum trough 
concentration and clinical effects, as this pharmacokinetic parameter had the best correlation with 
weight gain in our study (chapter 9). Obviously, the key aspects for TDM research, as presented 
in this thesis (table 2) and compiled by a multidisciplinary team of international experts, must be 
taken into account. These quality criteria are important to guide and improve future research in this 
field and to facilitate meta-analyses.
Table 2 Key aspects that should be considered when conducting TDM research.
Quality criteria for TDM research
1. Analytical method for the assay of drug concentration in serum or plasma
2. Blood sample collection
3. Patient selection
4. Measurement of illness severity and registration of therapeutic improvement or worsening
5. Comedication
6. Number of patients
For further explanation of these criteria, see chapter 7. 
Subsequently, a randomized controlled trial to demonstrate the added value of TDM in terms of 
patient safety and therapeutic outcomes in clinical practice is ideal. Within this trial, antipsychotic 
drug concentrations should be titrated towards optimal concentrations and compared to treatment 
as usual in terms of efficacy and safety. Such a randomized controlled trial is planned to take 
place as a sequel to the SPACe trial, with as primary endpoint weight gain. 
Performing pharmacokinetic-pharmacodynamic research in a challenging population
Within child and adolescent psychiatry, research on concentration-effect relationships and TDM is 
challenging. Patients often expose emotional and behavioral difficulties, which limits the willingness 
to participate in clinical trials and undergo extra sampling measurements. However, the SPACe 
trial has proven that challenging pharmacokinetic-pharmacodynamic research in this population 
can successfully be performed based on the following success factors. 
 a Using DBS as a minimally invasive sampling method
Blood sampling is highly challenging in children with psychiatric disorders and severe behavioral 
problems. Although DBS yields a higher variability in measured antipsychotic drug concentrations, 
in the SPACe trial the use of DBS has led to an increased willingness to participate. In this way, the 
advantages of DBS outweigh its disadvantage.   Without DBS as alternative sampling method, the 
challenging SPACe recruitment would not have been as successful as it has proven, with 91% of the 
81 included children accepting DBS sampling. However, some of the participants did not tolerate 
repeated DBS sampling as well as others. This stresses an individualized approach to sampling in 
children with ASD; given their heterogeneity, DBS might not be preferred over venipuncture by all.
 a  A flexible, patient-centered approach
During the SPACe trial, the investigator has visited the patients regularly at home for the study 
measurements. This has led to a personal relationship between investigator and study participants, 
leading to less study drop-out. 
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 a  A strong, multicenter network
Seven centers in the south-west region of the Netherlands have participated in the SPACe-trial. 
Such a network not only increases study-enrollment, but also facilitates sharing of new knowledge. 
Furthermore, international collaborations, such as the TDM-KJP network37, are important to 
further facilitate pharmacokinetic-pharmacodynamic research in the field of child and adolescent 
psychiatry. 
Towards safer antipsychotic treatment in children and adolescents – 
that’s in a drop of blood
Antipsychotic drugs can significantly improve the quality of life of children with ASD and severe 
behavioral problems. However, given their serious side-effects, it should be carefully identified for 
which children and adolescents with psychiatric conditions and comorbid behavioral problems 
antipsychotic treatment is truly necessary. For those children for whom antipsychotic therapy is 
required, it should be as brief as possible and closely monitored. 
This thesis shows that a drop of blood may contribute importantly to safer and individualized 
antipsychotic treatment in children and adolescents. It can inform us if a child’s antipsychotic 
concentration is adequate to achieve optimal effectiveness and safety, thereby preventing serious 
side-effects. This means that antipsychotic drug use in children and adolescents might become 
significantly safer by a single drop of blood. 
K E Y  F I N D I N G S 
 a A large share of children and adolescents in the Netherlands who are prescribed 
antipsychotic drugs, use these drugs for many years, although the long term safety and 
efficacy is not well established
 a Antipsychotic-induced weight gain in children and adolescents is most pronounced during 
the first 15 weeks of antipsychotic drug treatment
 a DBS has a higher variability than venipuncture in quantifying antipsychotic drug 
concentrations, but is a feasible and suitable technique for repeated sampling in children 
with ASD and severe behavioral problems
 a  Most research on TDM in child and adolescent psychiatry does not meet the key aspects 
of TDM, such as sampling under steady state conditions
 a  The pharmacokinetics of pipamperone in children and adolescents resemble adult values, 
although effective concentration ranges seem to be considerably lower in children with 
behavioral problems than in adults with psychosis
 a Risperidone sum trough concentrations can predict weight gain in children and 
adolescents, and are more predictive than risperidone maximum concentrations or area 
under the curves
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S U M M A R Y 
The aim of this thesis is to improve the safety and effectiveness of antipsychotic drugs in children 
and adolescents, by individualizing antipsychotic drug dosing and monitoring.  
P A R T  I  –  B A C K G R O U N D 
Antipsychotic drugs are commonly prescribed to children and adolescents with severe behavioral 
problems associated with Autism Spectrum Disorder (ASD). For this indication, antipsychotic drugs 
are the cornerstone of multimodal treatment. However, despite its good efficacy, young patients 
frequently experience side effects of these drugs. The most important side-effect concerns weight 
gain, which leads to serious long-term health risks including cardiovascular diseases and diabetes 
mellitus. Higher antipsychotic dosages are associated with more side-effects in children and 
adolescents, which suggests that antipsychotic drug concentrations in the blood mediate safety 
outcomes. Measuring antipsychotic drug concentrations might provide a target to improve safety, 
as this enables the individualization of dosages towards antipsychotic drug concentrations that are 
associated with the most optimal treatment outcomes. 
P A R T  I I  –  C U R R E N T  P R A C T I C E 
In this part, the extent of antipsychotic drug use and the associated weight gain in children and 
adolescents in the Netherlands are explored. The study in Chapter 2 investigates the prescription 
trends of antipsychotic drugs in patients aged 0-19 years in the Netherlands between 2005 and 
2015. This study finds that prescription rates have increased from 7 to almost 10 per 1000 Dutch 
youths in the general population from 2005 to 2009. Since then, antipsychotic drug prescriptions 
for children and adolescents have stabilized and slightly decreased, but they have still been 
substantial. Risperidone, aripiprazole and pipamperone are the most frequently prescribed 
antipsychotic drugs. Strikingly, one in eight youths who has been prescribed an antipsychotic drug 
uses it for at least four years, while good evidence for long-term efficacy is lacking in the literature. 
The study in Chapter 3 examines the pattern and risk factors of antipsychotic-induced weight 
gain in 144 Dutch children and adolescents, and finds that weight gain is most pronounced during 
the first 15 weeks of treatment. A higher dose equivalent is associated with more weight gain 
during these weeks, but when corrected for other variables, only a higher baseline bodyweight, 
the absence of stimulant use and no previous antipsychotic treatment predicts more weight gain 
during different time frames of follow-up. These findings stress a close monitoring of side effects in 
the first weeks of use, especially for those children who are already overweight when starting an 
antipsychotic drug. 
N E D E R L A N D S E  S A M E N V A T T I N G
Het doel van dit proefschrift is het vergroten van de veiligheid en effectiviteit van antipsychotica in 
kinderen en adolescenten door het individualiseren van doseringen van deze geneesmiddelen.
D E E L  I  –  A C H T E R G R O N D
Antipsychotica worden regelmatig voorgeschreven aan kinderen en adolescenten met een autisme 
spectrum stoornis (ASS) en ernstige gedragsproblemen. Voor deze indicatie zijn antipsychotica 
de hoeksteen van de multidisciplinaire behandeling. Helaas hebben juist minderjarigen vaak 
bijwerkingen van antipsychotica.  De belangrijkste bijwerking is gewichtstoename, wat kan leiden 
tot ernstige gezondheidsrisico’s op de lange termijn, zoals hart- en vaatziekten en diabetes mellitus. 
Hogere doseringen van antipsychotica zijn geassocieerd met meer bijwerkingen bij  kinderen 
en adolescenten, wat veronderstelt dat er een correlatie is tussen de geneesmiddelconcentraties 
in het bloed en de bijwerkingen die optreden. Het meten van deze geneesmiddelconcentraties 
kan een aangrijpingspunt zijn om de veiligheid van antipsychotica te vergroten. Immers, 
antipsychoticadoseringen kunnen op deze manier getitreerd worden naar concentraties met de 
beste behandeluitkomsten en de minste bijwerkingen. 
D E E L  I I  –  D E  H U I D I G E  P R A K T I J K
In dit deel van het proefschrift wordt bekeken wat de huidige omvang van antipsychotica 
gebruik en de bijbehorende gewichtstoename in kinderen en adolescenten in Nederland is. In 
hoofdstuk 2 worden de voorschrijftrends van antipsychotica aan patiënten tussen de 0 en 19 
jaar in Nederland tussen 2005 en 2015 onderzocht. In deze studie wordt beschreven dat het 
aantal antipsychotica voorschriften fors toenam tussen 2005 en 2009, van gemiddeld 7 naar 
bijna 10 per 1000 minderjarigen die op enig moment een antipsychoticum gebruikte. Hoewel 
het aantal antipsychoticavoorschriften vanaf dat moment stabiliseerde en daarna zelfs een lichte 
daling liet zien, was deze nog steeds aanzienlijk. Risperidon, aripiprazol en pipamperon worden 
het meest voorgeschreven. Opvallend was dat één op de acht kinderen die een antipsychoticum 
voorgeschreven krijgt, dit middel voor minstens 4 jaar blijft doorgebruiken, terwijl de lange termijn 
effectiviteit niet goed onderbouwd is. In hoofdstuk 3 worden het verloop en de risicofactoren voor 
antipsychotica-geïnduceerde gewichtstoename in 144 Nederlandse kinderen en adolescenten 
onderzocht. Er wordt geconcludeerd dat gewichtstoename het meest uitgesproken is in de eerste 
15 weken van gebruik. Een hogere dosisequivalent is geassocieerd met meer gewichtstoename 
tijdens deze eerste weken, maar na correctie voor andere variabelen, zijn alleen een hoger 
uitgangsgewicht, het niet gebruiken van stimulantia en geen eerder antipsychotica gebruik 
voorspellend voor een gewichtstoename na verschillende gebruikersduren. Deze bevindingen 
onderstrepen het belang van een geïntensiveerde monitoring van bijwerkingen in de eerste weken 
van gebruik, vooral voor kinderen die al overgewicht hebben bij start van een antipsychoticum. 
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P A R T  I I I  –  A L T E R N A T I V E  S A M P L I N G 
This part focuses on investigating a minimally invasive way to measure antipsychotic drug 
concentrations in children and adolescents with severe behavioral problems; the Dried Blood Spot 
(DBS) method. This method enables the quantification of drugs in a single drop of blood, collected 
on a filter paper by a finger prick in a home setting. Three studies are conducted to investigate 
the reliability and feasibility of this method in our population. First, a DBS assay is developed 
to measure risperidone, aripiprazole, pipamperone and their major active metabolites with 
Liquid Chromatography–Mass Spectrometry (LC-MS/MS). Chapter 4 describes the successful 
validation of this DBS assay in the laboratory. In this study, accuracy and imprecision are well within 
the acceptance criteria of conventional guidelines for bioanalytical method validation. After the 
development, the DBS assay is tested in a real-life clinical setting and compared to simultaneously 
taken venous samples, which is reported in the study in chapter 5. Strikingly, the performance 
of the DBS assay in a clinical setting is worse than in the laboratory setting, and does not meet 
all the acceptance criteria. This results in a higher variability of antipsychotic drug concentrations 
when measured with DBS than with venipuncture. Lastly, the feasibility of DBS sampling in children 
with ASD and severe behavioral problems is studied in chapter 6. DBS sampling is successfully 
performed in most of these children, although 1 in 5 children refuses one or more DBS fingerpricks 
due to distress.
D E E L  I I I  –  A L T E R N A T I E V E  B L O E D A F N A M E 
Deel III van het proefschrift richt zich op het onderzoeken van een nieuwe manier om antipsychotica 
concentraties te meten in het bloed van kinderen en adolescenten met ernstige gedragsproblemen: 
de Dried Blood Spot (DBS) methode. Deze methode maakt het mogelijk om antipsychotica 
concentraties te meten in slechts één druppel bloed, verkregen met een vingerprik dat thuis 
kan worden uitgevoerd. Drie studies worden verricht om de betrouwbaarheid en haalbaarheid 
van de DBS methode te onderzoeken in deze specifieke doelgroep. Allereerst wordt een DBS 
methode ontwikkeld om risperidon, aripiprazol, pipamperon en de actieve metabolieten te meten 
met vloeistofchromatografie gecombineerd met tandem-massaspectrometrie (LC-MS/MS). 
Hoofdstuk 4 beschrijft de succesvolle validatie van deze DBS methode in ons laboratorium. In 
deze studie vallen nauwkeurigheid en precisie ruim binnen de acceptatiecriteria van conventionele 
richtlijnen voor validatie van bioanalytische methoden. In de studie in hoofdstuk 5 wordt deze 
DBS methode getest in een klinische setting en vergeleken met gelijktijdig afgenomen veneuze 
monsters. Opvallend is dat de DBS methode in deze klinische setting minder betrouwbaar is dan 
in de laboratoriumomgeving en niet aan alle acceptatiecriteria voldoet. De variatie in gemeten 
antipsychotica concentraties is groter met de DBS methode dan met de venapunctie. Ten slotte 
wordt de haalbaarheid van DBS-afname bij kinderen met ASS en ernstige gedragsproblemen 
onderzocht in hoofdstuk 6. DBS wordt met succes uitgevoerd bij de meeste kinderen, hoewel 1 
op de 5 kinderen een of meer DBS-vingerprikken weigert vanwege angst.
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P A R T  I V  –  A N T I P S Y C H O T I C  D R U G 
C O N C E N T R A T I O N S  A N D  C L I N I C A L  O U T C O M E S
Part IV investigates the relationship between antipsychotic drug concentrations and clinical 
outcomes in children and adolescents. Previous studies that have assessed the relationship 
between psychotropic drug concentrations and clinical outcomes are systematically reviewed and 
discussed in chapter 7. Based on this review, it is concluded that there is a lack of well-reported 
and well-executed therapeutic drug monitoring studies in this population. For pipamperone, no 
such studies had been conducted at all. In chapter 8, the pharmacokinetics of pipamperone are 
described and externally validated using non-linear mixed effect modelling (NONMEM®), based 
on measured concentrations in 51 children and adolescents from the Netherlands and Germany. 
It is found that pipamperone can best be dosed twice daily, with adjustment for bodyweight. 
Interestingly, pipamperone pharmacokinetic parameters are related to clinical improvement and 
side effects, showing that responders have considerably higher pipamperone concentrations than 
non-responders. In chapter 9, the relationship between risperidone plasma concentrations and 
side effects and efficacy is analyzed in a Dutch prospective observational study. In this study, 
risperidone concentrations, side effects and effectiveness are repeatedly measured in children and 
adolescents with ASD and severe behavioral problems. Different pharmacokinetic parameters 
are described using NONMEM® and correlated with clinical outcomes. We find that higher 
risperidone trough concentrations predict higher bodyweight, more sedation, higher prolactin 
levels and strikingly, also more effectiveness. The results of this study indicate that a therapeutic 
window for risperidone in this population might exist. 
P A R T  V  –  G E N E R A L  D I S C U S S I O N
Chapter 10 discusses the findings of the studies presented in this thesis in a broader context. 
The implications and advances for safer and individualized antipsychotic therapy in children and 
adolescents based on this thesis are discussed. In this final chapter, the findings on the relationship 
between antipsychotic drug concentrations and clinical outcomes are put in a larger perspective, 
by assessing the criteria for routine application of therapeutic drug monitoring (TDM). Also, 
recommendations for clinical practice and future research are made. 
 
D E E L  I V  –  A N T I P S Y C H O T I C A  C O N C E N T R A T I E S 
E N  K L I N I S C H E  U I T K O M S T E N
In deel IV van dit proefschrift wordt de relatie tussen antipsychotica concentraties en klinische 
uitkomsten bij kinderen en adolescenten onderzocht. Eerdere studies die deze relatie hebben 
onderzocht voor psychiatrische medicatie werden systematisch beoordeeld en besproken 
in hoofdstuk 7. Op basis van deze systematic review concluderen we dat er een gebrek is 
aan goed gerapporteerde en goed uitgevoerde therapeutic drug monitoring (TDM) studies in 
deze populatie. Voor pipamperon bleken dergelijke onderzoeken helemaal niet te bestaan. In 
hoofdstuk 8 wordt de farmacokinetiek van pipamperon beschreven en extern gevalideerd 
met behulp van niet-lineaire mixed-effect modellering (NONMEM®), gebaseerd op gemeten 
concentraties bij 51 kinderen en adolescenten uit Nederland en Duitsland. In deze studie wordt 
gevonden dat pipamperon het beste twee keer per dag kan worden gedoseerd, aangepast op 
het lichaamsgewicht. Interessant genoeg zijn de farmacokinetische parameters van pipamperon 
gecorreleerd aan klinische verbetering en bijwerkingen: kinderen met goed effect van pipamperon 
hebben aanzienlijk hogere pipamperonconcentraties dan kinderen die geen baat hebben bij deze 
medicatie. In hoofdstuk 9 wordt de relatie tussen de plasmaconcentraties van risperidon en de 
bijwerkingen en effectiviteit geanalyseerd in de Nederlandse prospectieve observationele studie 
“SPACe”, onder kinderen en adolescenten met ASS en ernstige gedragsproblemen. Verschillende 
farmacokinetische parameters worden beschreven middels NONMEM® en gecorreleerd aan 
klinische uitkomsten. Er wordt gevonden dat hogere dalconcentraties van risperidon voorspellend 
zijn voor een grotere gewichtstoename, maar ook meer sedatie, hogere prolactinespiegels en 
meer effectiviteit. De resultaten van deze studie geven aan dat er mogelijk een therapeutisch 
venster voor optimale concentraties van risperidon in deze populatie bestaat. 
D E E L  V  -  A L G E M E N E  D I S C U S S I E
In hoofdstuk 10 worden de bevindingen van de studies in dit proefschrift in een bredere 
context geplaatst. De implicaties voor veiligere en geïndividualiseerde antipsychotische therapie 
bij kinderen en adolescenten op basis van dit proefschrift worden besproken. In dit laatste 
hoofdstuk wordt gebruik gemaakt van de criteria voor routinematige toepassing van therapeutic 
drug monitoring. Ook worden aanbevelingen gedaan voor de klinische praktijk en toekomstig 
onderzoek.
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ABC   Aberrant Behavioral Checklist
ADD   Attention Deficit Disorder
ADHD   Attention-Deficit/Hyperactivity Disorder
AF   Alkalic fosfatase
AIMS   Abnormal Involuntary Movement Scale 
ALAT   Alanine aminotransferase
AP   Antipsychotic 
ASAT   Aspartate aminotransferase 
ASD   Autism Spectrum Disorder
AUC   Area under the concentration-time curve
BP    Blood pressure
C   Central 
Ctrough   Trough concentration
Cmax   Maximum concentration
CABRS    Conners Abbreviated Rating Scale
CAPTRS   Conner’s Abbreviated Parent Teacher Rating Scale
CDI    Children’s Depression Inventory
CDRS-R   Children’s Depression Rating Scale – revised
C-GAS    Childrens Global Assessment Scale
CGI-I    Clinical Global Impression improvement Scale
CGI-S    Clinical Global Impression severity Scale
CI   Confidence Interval
CL   Clearance 
CPRS    Comprehensive Psychopathological Rating Scale
CTRS    Conner’s Teaching Rating Scale
CWRES   Conditional weighted residuals 
CY-BOCS   Childrens’ Yale-Brown Obsessive Compulsive Scale
CYP   Cytochrome P450
DOTES    Dose Record and Treatment Emergent Symptom Scale
DSM   Diagnostic and Statistical Manual of Mental Disorders 
BMI   Body-mass-index
BPRS    Brief Psychiatric Rating Scale
DBS   Dried Blood Spot
EC50    Half maximal effective concentration, the concentration of a drug  
   which induces a response halfway between the baseline and maximum
ECG    Electrocardiogram
EMA   European Medicines Agency
EPS   Extrapyramidal symptoms 
L I S T  O F  A B B R E V I A T I O N S ER    Extended release formulation
ESS   Epworth Sleepiness Scale 
F   Bioavailability 
FDA   US Food and DrugsAdministration
GAF    Global Assessment of Functioning
GH    Growth hormone
GGT   Gamma glutamyl transpeptidase
HbA1c   Hemoglobin A1c
HDL   High-density lipoprotein
HDRS    Hamilton Depression Rating Scale
HPLC-UV  High performance liquid chromatography-ultraviolet
HR    Heart rate
IPV   Inter-patient variability 
Ka   Absorption rate constant 
K-SADS   Kiddie Schedule for Affective Disorders and Schizophrenia
K-SADS-P   Kiddie Schedule for Affective Disorders and Schizophrenia - 
   Present Episode
LDL   Low-density lipoprotein
LFTs    Liver function tests
LLOQ   Lower limit of quantification
LOD   Lower limit of detection
LOI-CV    Leyton Obsessional Inventory-Child version
NONMEM  Nonlinear mixed effects modelling
M   Metabolite 
MARS   Medication Adherence Rating Scale
MDD    Major Depressive Disorder
MEMS   Medication Event Monitoring System
MFFT    Matching Familiar Figures Test
M-MAT    McLean Motion Attention Test
M-SADS  Abbreviated Kiddie Schedule for Affective Disorders 
   and Schizophrenia (K-SADS), just covering affective symptoms
NIMH    National Institute of Mental Health
NR    Normal release
Obs   Number of observations 
OCD    Obsessive-compulsive disorder
OCRS    Obsessive-Compulsive Rating Scale
ODD    Oppositional defiant disorder
P   Peripheral  
PERMP    Permanent Product Measure of Performance
PGP   P-glycoprotein 
PLT    Platelet
PRISMA   Preferred reporting items for systematic reviews and meta-analyses
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PRL    Prolactin
Q   Intercompartmental clearance 
QC   Quality control
QTc   Corrected QTc 
RCMAS   Revised Children’s Manifest Anxiety Scale
sCR    Serum creatinine
RSE   Relative standard error 
SEFCA    Side Effects Form for Children and Adolescents
SPACe   Safety and Pharmacokinetics of Antipsychotics in Children
SD   Standard Deviation
SERS    Side Effects Rating Scale
SKAMP    Swanson, Kotkin, Agler, M-Flynn and Pelham Scale
SNAP    Swanson, Nolan, and Pelham Questionnaire
SRT    Scanning Reaction Time, part of  three computer tests
tlag   Lag time
TC    Total cholesterol
TDM   Therapeutic Drug Monitoring
TG    Triglycerides
TSH    Thyroid stimulating hormone
UHPLC-MS/MS  Ultra–High-Performance Liquid Chromatography–Mass Spectrometry 
UKU    Udvalg for Klinske Undersogelser
ULOQ   Upper limit of qualification
V   Volume of distribution
VAS   Visual Analogue Scale 
WBC   White blood cell counts
WHO   World Health Organization
WWPAS   Werry-Weiss Peters Activity Scale
YGTSS    Yale Global Tic Severity Scale
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B E H I N D  T H E  S C E N E S D A N K W O O R D
Onderzoek lijkt alleen over cijfers te gaan, maar niets in minder waar: het is mensenwerk 
van begin tot eind. Zonder de inzet van een heleboel belangrijke mensen was al dit 
onderzoek nooit wat geworden. Graag wil ik de kans nemen om jullie hier te bedanken. 
Allereerst: alle kinderen en hun ouders die mee hebben gedaan aan het SPACe onderzoek. 
Ik vind het ontzettend bijzonder dat jullie, terwijl jullie wereld op zijn kop stond, bereid zijn geweest 
om uren aan vragenlijsten, talloze vingerprikken en andere extra metingen te volbrengen. Bedankt 
voor de openhartige gesprekken en vele koppen thee aan jullie keukentafels; het ging over zoveel 
meer dan de onderzoeksmetingen, en het heeft me waardevolle inzichten gegeven in het leven 
met autisme die ik nooit uit een boek had kunnen opdoen.
Prof. dr. van Gelder, beste Teun. Als promotor stond je deur altijd open om even stoom af te 
blazen, voor wijze raad, of voor gewoon een gezellig praatje. Ik heb veel geleerd van je scherpe 
blik als klinisch farmacoloog. Naast de onderzoekbesprekingen was eigenlijk overal voor in, 
of het nou de trappenloop, de Tour de Rotterdam of karaoke was. Bedankt voor je oprechte 
betrokkenheid. 
Prof. dr. Hillegers, beste Manon. Jouw visie op de kinder- en jeugdpsychiatrie is inspirerend. 
Met ogenschijnlijk simpele vragen kom je meteen tot de kern. Dit heeft me vaak aan het denken 
gezet, niet alleen wat betreft het onderzoek, maar zeker ook wat betreft mijn eigen ambities. Veel 
dank daarvoor. 
Prof. dr. Verhulst, beste Frank, tot je met pensioen ging was ook jij mijn promotor. In de eerste 
fase van het onderzoek was je doorgewinterde kennis van de deelnemende centra in de regio 
onmisbaar.  
Dr. Koch, beste Birgit. Jouw energie en optimisme zijn echt ongekend. Je verliest de grote lijn in 
het onderzoek niet uit het oog en weet snel creatieve oplossingen te vinden voor hobbels op de 
weg. Bovendien benader je alles met een gezonde dosis humor; een verademing als ik me weer 
eens kon verliezen in details. Je hebt me gestimuleerd om me ook ver buiten het onderzoek te 
ontwikkelen; bedankt voor je onvoorwaardelijke steun en vertrouwen. 
Dr. Dierckx, beste Bram. Bedankt voor je scherpe, analytische blik en eerlijkheid. Ik heb veel 
geleerd van onze discussies over statistische resultaten, maar ook over de Vlaamse politiek, de 
GGZ, en wat al niet meer. Als het op onderzoek aankomt, sta je echt voor wat je doet. Het is 
dankzij jou dat ik ook voor de psychiatrie gekozen heb. Ik hoop dat je wat mindert met je cola-
consumptie, zodat we nog lang kunnen samenwerken. 
Dr. de Winter, beste Brenda. Je bent misschien wel de slimste persoon die ik ken. Je weet 
werkelijk alles van NONMEM en hebt ook nog eens de gave om het heel geduldig, keer op 
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keer, uit te leggen. Hoewel er soms wat frustratie richting een vastlopende computer ging, stond je 
vooral altijd klaar om te helpen. Daarnaast is geen borrel compleet zonder jou. 
Dr. Dieleman, beste Gwen, ook jij was vanaf het begin bij het project betrokken. Op de 
polikliniek wist je alle includerende artsen goed bij de les te houden als de inclusie inzakte. Mede 
dankzij jou is de SPACe studie ook in het Sophia Kinderziekenhuis een succes geworden.
Veel dank aan de leden van de leescommissie – prof. dr. de Wildt, prof. dr. Hoekstra en 
prof. dr. van den Broek voor het beoordelen van dit proefschrift. Beste Walter, als opleider 
vind ik het extra bijzonder dat je op deze manier ook bij mijn onderzoek betrokken bent. 
Naast het Erasmus MC zijn de studies in dit proefschrift ook op vele andere plekken uitgevoerd. 
De hulp van een heleboel mensen was hierbij onmisbaar. 
Drs. Dekker, beste Annet. Dankzij jou hadden we bij Middin binnen no time een groot aantal 
patiënten en hun vertegenwoordigers gemobiliseerd om mee te doen aan de DBS validatie studie. 
Voor  de pipamperon inclusie was dat echt onze redding.
De SPACe studie had wel zeven deelnemende centra, een aardige logistieke uitdaging. De lokale 
hoofdonderzoekers waren op al die plekken onmisbaar om alles in goede banen te leiden. Veel 
dank aan dr. van Daalen, dr. Reichart, dr. Rieken en drs. Ouwehand, dr. Kouijzer, 
drs. De Kroon en dr. Ester. Daarnaast ook aan dr. Atanasios Maras en prof. dr. Robert 
Vermeiren voor het mogelijk maken van de SPACe studie op jullie locaties. Uiteraard veel dank 
aan alle includerende artsen die op de (poli-)klinieken de SPACe kinderen hebben vervolgd; 
alle genomen extra tijd en moeite (naast de overvolle poli agenda’s) kan ik enorm waarderen. 
Naast artsen hebben ook een aantal verpleegkundigen een belangrijke bijdrage geleverd. Op de 
polikliniek in het Sophia Kinderziekenhuis hebben Roelie van Zon en Henriette Rijpkema 
een heleboel vingerprikjes uitgevoerd, metingen gedaan, en data ingevoerd. Bij GGZ Breburg 
heeft Jeske van de Velden veel op zich genomen (en is zelfs mee gegaan op huisbezoek!). 
Voor de studie logistiek in het Sophia Kinderziekenhuis waren Monique Knol en Q Andriessen 
onmisbaar. Dank allemaal, jullie enthousiasme voor de studie gaf me veel energie. 
Achter de schermen moesten een heleboel vingerprikjes geanalyseerd worden. Alle analisten 
van het farmacologisch laboratorium in het Erasmus MC hebben honderden DBS kaartjes 
verwerkt. Heel veel dank voor jullie geduld met al die nét niet goed ingevulde aanvraagformulieren. 
Één analist heeft in het bijzonder een enorme berg werk verzet: lieve Soma Bahmany, met jouw 
precisie en rust had ik dat aan geen beter persoon kunnen toevertrouwen. Ruud Huisman, als 
jij aan mijn bureau stond wist ik dat ik er ergens een rommeltje van had gemaakt, maar gelukkig 
hield jij altijd een oogje in het zeil.  
Al vroeg in mijn promotietraject reisde ik af naar Groningen, waar we dankbaar gebruik mochten 
maken van de IADB.nl database. Dr. Nynke Schuiling-Veninga, we werden meteen met 
open armen ontvangen, bedankt voor het faciliteren van ons onderzoek en de fijne samenwerking. 
Jens Bos, ondanks de afstand was jij altijd bereikbaar voor ondersteuning bij data-extracties. 
Op statistisch gebied heb ik dankbaar gebruik gemaakt van de hulp van dr. Jan van der Ende 
en dr. Kazem Nasserinejad. Ik heb ook een aantal studenten mogen begeleiden: Linda Al-
Hassany, Esmé van Eijk en Casper van Esch. Het was erg leuk om jullie te zien groeien als 
onderzoekers. Daarnaast was voor jullie hulp bij de praktische uitvoer van de studie onmisbaar. 
Linda, het avontuur waar we bij Middin samen in terecht kwam zal ik niet snel vergeten; zonder 
jou had ik het niet overleefd. 
Ook over de grens hebben een aantal mensen een belangrijke bijdrage geleverd aan dit 
proefschrift. Herr prof. dr. Romanos, vielen Dank dass Sie mich auf Ihrer Abteilung so herzlich 
Wilkommen geheissen haben. Liebe Frau dr. Egberts, Karin, da dein Niederländisch um ein 
Vielfaches besser ist als mein Deutsch, werde ich dir auf Niederländisch schreiben. Dankzij jou 
was mijn tijd in Würzburg onvergetelijk. Je warme onthaal en enthousiasme maakte dat ik me 
meteen welkom voelde. Ons onderzoek heeft veel raakvlakken, ik kom graag nog eens terug 
want ik hoop echt dat we zullen blijven samenwerken. Sehr geehrter Herr prof. dr. Gerlach, 
auch vielen Dank für Ihre Begleitung.
Alle co-auteurs die ik nog niet genoemd heb, ook aan jullie dank voor de input voor de 
manuscripten. 
Naar goed voorbeeld wil ook ik  mijn auto bedanken. Met 6977 gedeclareerde kilometers had 
ik het nooit zonder je gered. 
Lieve collega’s van de apotheek. Ik kan het iedere arts aanraden om een aantal jaar in 
de apotheek te werken, en dan in het bijzonder de ziekenhuisapotheek van het Erasmus MC. 
Ik heb veel geleerd van jullie andere perspectief en scherpe inzichten. Al vlogen de regeltjes en 
richtlijnen me soms om de oren, er was vooral heel veel tijd voor gezelligheid. De skivakanties 
waren hierbij zeker een hoogtepunt.
Lieve mede-onderzoekers van de apotheek, zonder jullie was mijn onderzoekstijd toch 
wel echt een heel stuk minder leuk geweest. Oud Na-206, Florine, Annette, Linda, Louise, 
Rehana, Suzanne en Femke, van werken kwam het niet perse maar dankzij jullie was ik 
in ieder geval op de hoogte van de Tour de France en Wie is de Mol. Janique (JJ), Laura, 
Dimokrat en Laura, met jullie overleefde ik de jungle van de kantoortuin, hetzij op een wat 
lager geluidsniveau. Tijdens de vele nutteloze rondjes lopen konden we gelukkig alsnog de 
laatste roddels uitwisselen, stomme grappen maken of Surinaams dan wel donuts halen. Usha, 
als “moeder” van de groep hield je altijd het hoofd koel, dankzij jou kon ik me een weg banen in 
het oerwoud van de AVG. Lieve Floor, jouw passie voor onderwijs werkt echt aanstekelijk. Je was 
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een geweldige partner in crime voor de Geneesmiddel van de Week Oscars, en ik ben blij dat ik 
je als buurvrouw nog regelmatig tegenkom. Maya, binnen de KJP onderzoeksgroep was jij m’n 
maatje, en een onovertroffen trappenloop-kampioen. 
Lieve dames van de farmafietsclub, naast werk delen we een liefde voor fietsen. Behalve 
de Tour de Rotterdam en Amstel Gold Race, was de Elfstedentocht een absoluut hoogtepunt. 
Annette, als teamcaptain weet je me altijd thuis te brengen en ben ik je erg dankbaar dat ik aan 
jouw zijde nooit verdwaald raak.  Wanneer gaan we weer?
Collega’s van de afdeling psychiatrie, bedankt voor het warme welkom en de tijd die ik 
kon nemen om mijn proefschrift af te ronden. 
Barbara, jou mag ik natuurlijk niet vergeten! Jouw ontwerp van het SPACe logo heeft vele 
taartjes, posters, flyers, PowerPointpresentaties, websites en chocolaatjes gesierd. 
Ik heb een heleboel lieve vrienden die het leven buiten het onderzoek zo leuk maken. Een paar 
mensen wil ik in het bijzonder bedanken. Lieve clubgenoten, ook al zijn onze levens soms 
heel anders, ik ben blij met onze onvoorwaardelijke vriendschap. Lieve Jen en Emma, na ons 
Nieuw-Zeeland avontuur zoeken we ook in Nederland nog regelmatig het groene avontuur op, 
een fijne uitlaatklep. Lieve Lies, bij jou heb ik aan een half woord genoeg en je hebt me vaak 
beter door dan ik mezelf; Ik weet dat we elkaar niet uit het oog zullen verliezen. Lieve Heike, 
Lara en Gab, we kennen elkaar al zo lang, en ik voel me bij bijna niemand zo vertrouwd als bij 
jullie. Na Thailand kan ik niet wachten op alle avonturen die we nog gaan beleven, ook al is dat 
in Friesland, Zeeland of Noordwijk. 
Mijn paranimfen. Lieve Lotte en Rixt, waar jullie begonnen als fijne collega's zijn jullie nu vooral 
goede vriendinnen. Lieve Lot, tijdens mijn onderzoek, maar nu nog steeds, kan ik altijd bij je 
terecht, of dat nou is voor een kop koffie, Disney film of een goed gesprek. Lieve Rixt, ook al zat je 
een paar verdiepingen hoger, je voelde nooit ver weg. Ik word eigenlijk altijd vrolijk als ik je zie. 
Lieve Laura, ik ken je vanaf de allereerste dag dat ik geneeskunde ging studeren, en gelukkig 
ben ik je nooit uit het oog verloren. Ook al kan je er door de coronamaatregelen waarschijnlijk 
niet fysiek aanwezig zijn, je bent er gevoelsmatig helemaal bij.
Lieve schoonfamilie, bedankt voor het warme nest. Jullie zijn echt familie voor me geworden. 
Tom, een bijzonder woord van dank voor jou, omdat ik nu eindelijk weet hoe ik Würzburg moet 
uitspreken.
Lieve broer en zus. Lieve Marit, ook al zijn we heel anders, ik zie steeds meer hoe erg we op 
elkaar lijken. Ik ben ontzettend blij met zo’n lieve, trouwe zus als jij. Lieve Koen, ik vind het 
bijzonder hoe we vaak met dezelfde thema’s in ons leven bezig zijn, hoewel we zo’n ander leven 
leiden. Je bent een mooi mens. Lieve Pieter en Anne, ook jullie horen er voor mij meer dan bij. 
Lieve pap en mam. Ik kan me nog goed herinneren dat ik jullie opzocht na mijn sollicitatiegesprek 
voor dit promotietraject in de stromende regen op de camping. Jullie wisten m’n gedachten te 
structureren en me te steunen in mijn keuze, zoals jullie zo vaak hebben gedaan. Jullie hebben me 
alle kansen gegeven in het leven om te groeien en mezelf te ontwikkelen tot wie ik nu ben. Jullie 
trots en liefde is hartverwarmend.
Liefste Ruben. Alle ups en downs van het promotieonderzoek heb jij van heel dichtbij mee 
gemaakt. Ondertussen kan je alle geneesmiddelnamen van mijn studie moeiteloos oplepelen. Als 
ik door de bomen even het bos niet meer zag, kan je relativeren als geen ander en zette je me 
met beide benen op de grond. Maar meer nog laat je me zweven en zien wat het leven zo mooi 
maakt: ik ben bij niemand liever dan bij jou. 
Sanne 
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Ik ben meer
Ik ben meer dan alleen mijn naam 
ik heb een hoofd waarin verlangen woont 
een eigen wil heb ik, twee oren en een 
mond. 
 
Maar hoe vertel ik duidelijk: kijk, dit ben ik? 
En hoe beluister ik nu wie die ander is. 
 
Ik heb als iedereen een kostbaar hoofd 
met dromerijen over hoe en wie en mij 
en dat ik word erkend: ja, dat ben jij.
Hester Knibbe
stadsdichter Rotterdam 2015 - 2016
Antipsychotic drugs are effective for a 
wide range of disorders in children 
and adolescents. Unfortunately, these 
drugs are associated with serious 
side-effects in this population, 
including weight gain. The aim of 
this thesis is to improve the safety 
and effectiveness of antipsychotic 
drugs in children and 
adolescents, by individualizing 
antipsychotic drug dosing and 
monitoring. 
